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Dysfunction of the blood brain barrier (BBB), the specialized complex of cells situated at the
central nervous system (CNS) microvasculature has been associated with numerous
neuroinflammatory disorders like multiple sclerosis (MS) and its animal model, experimental
autoimmune encephalomyelitis (EAE). BBB known to restrict passage of soluble and cellular
elements between the blood and CNS is breached. The mechanism by which auto-reactive T
cells cross the normally “impermeable” BBB, invade the initially naive CNS, and cause
neuroinflammation, remains unclear. Recent studies suggest an initial route by which these cells
first gain entry from circulating blood through the choroid plexus (CP). The permeable
fenestrated capillaries of CP allow these sentinal T cells into the cerebrospinal fluid (CSF) across
the surrounding tight junction expressing choroidal epithelium also known as the blood-CSFbarrier (BCSFB). Once into the CSF, these cells travel to the subarachnoid space (SAS) that
surrounds the CNS parenchyma. Here, T cells are known to encounter their cognate antigen and
set off a cytokine storm that propagates inflammation. The effects are first observed within the
SAS in the meningeal vessels followed by activation of parenchymal inflammation. However,
several critical questions in this scenario remain. First, how do these T cells cross the epithelium
of the CP to enter the CSF? Does this involve changes in the tight junctional integrity between
adjacent epithelial cells to allow leukocyte diapedesis? Second, once they enter the CSF, do these
cells select a segment within the SAS to ignite the inflammatory sequence? Given the ascending
inflammation within spinal cord segments in developing EAE (caudal to rostral), regional blood
vessels in meninges and parenchyma might display unique vulnerabilities depending upon the
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segment of the spinal column in which they reside. Third, what links the inflammatory signals in
the SAS to neuroinflammation in the parenchyma? Results obtained from this work show
evidence towards the hypothesis that the ascending course of EAE is due to initial penetration of
sentinal T cells through a structurally compromised CP choroidal epithelium, followed by a
spinal segment-dependent relay of inflammatory signals between meningeal and parenchymal
vessels.
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Publications and contributions to Thesis project:
1. Chapter II: Choroid Plexus in evolving EAE: This work focuses on the regulation of the
Blood-Cerebrospinal Fluid barrier at the level of the Choroid Plexus (CP), in terms of tight
junctions within the epithelial layer of the CP and the functional assessment of permeability
associated with it during evolving EAE induced by immunization with myelin
oligodendrocyte glycoprotein (MOG) peptide35-55 along with adjuvants. This study sheds
light on how the leukocytes navigate across the tight junctions of the choroidal epithelial
layer into circulating Cerebrospinal Fluid (CSF) leading to anatomical changes within this
intricate system. Understanding the changes in the tight junctions between the epithelial cells
of the CP has provided valuable information about the regulation of BCSFB via possible
trans epithelial migration of infiltrating immune cells. BCSFB breach has also been assessed
functionally by permeability studies, thus co-relating the breakdown of tight junctions with
possible increase in the “leakiness” of the barrier.
2. Chapter III: Spinal cord in evolving EAE: Once the immune cells enter the CSF from the
choroid plexus during evolving EAE, do they select a segment within the SAS to ignite the
inflammatory sequence? This work provides the possibility that regional blood vessels in the
meninges and parenchyma might display unique vulnerabilities depending upon the segment
of the spinal column in which they reside. These differences could aid in preferential
accumulation and infiltration of inflammatory cells within the lumbar segment followed by
ascending progression in disease pathology. This work has attempted to address these issues
using 3D confocal microscopy of spinal cord segments, whole spinal cord images and a
systematic and detailed segmental transcriptomic analysis of inflammatory gene expression
patterns of spinal cord meningeal and parenchymal venules.
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3. Chapter IV: CCL2 sources in evolving EAE: This report uses two qRT-PCR-based
approaches to clarify the relative contributions of the parenchymal and vascular
compartments to CNS CCL2 gene expression during evolution of EAE induced by
immunization with myelin oligodendrocyte glycoprotein (MOG) peptide35-55 along with
adjuvants. One approach used a crude separation of CNS parenchymal and microvessel
fractions, based on a common preparative method from homogenized CNS tissue. The other
employed the laser capture microdissection (LCM), to more precisely retrieve separate
BMEC, astrocyte and other parenchymal cell types. Additionally, we assessed CCL2
expression levels following MOG immunization as well as after injection of these adjuvants
alone, to highlight the effects due to MOG immunoreactivity.

•

Appendix-Attached paper 1: This work focuses on the CCL2 synthesis inhibitor bindarit
and it effects on the cells of the neurovascular unit effectively suppressing experimental
autoimmune encephalomyelitis. Bindarit repressed CCL2 expression in cultured murine
astrocytes, microglia and BMEC, and antagonized upregulated expression of CCL2 in both
brain and spinal cord in vivo following LPS administration. Bindarit also significantly
modified the course and severity of clinical EAE, diminished the incidence and onset of
disease, and evidenced signs of disease reversal.

•

Appendix-Attached paper 2: This work allowed us to perfect an experimental technique
coupling Laser Capture Microdissection (LCM) with Taqman Low Density Arrays (TLDA)
plates using expression profiling of brain microvascular endothelial cells. We were able to
report, for the first time, the feasibility of direct cDNA synthesis without RNA isolation in
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mircoarrays. This set the ground work for our following publications using the technique to
show the differential CP epithelial and endothelial expression profile and CP regulation
during EAE.

•

Appendix-Attached paper 3: This work was instrumental to establish the feasibility of
LCM on separate compartments of the intricate system of choroid plexus structure and
coupling it with TLDA analysis. This work put down the ground works, building upon
which, CP epithelial cells were isolated using LCM and probed for tight junctions
expression. This led to experiments towards understanding how these tight junctions were
regulated and BSCFB was maintained during evolving inflammation in EAE.
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CHAPTER I: Introduction
MS and its comprehensive animal model, EAE are widely considered as chronic immune
mediated demyelinating diseases of the CNS (1-5). Breakdown of the BBB and leukocyte
extravasation have been associated with the pathology of these diseases (6, 7). Little is known
however about the initial trigger that activates the healthy, naïve immune system and the resting
vasculature of the CNS within which BBB resides. The spark that initiates the sequence of events
leading to targeted demyelination and subsequent neurodegeneration has been speculative (8, 9).
Reports have highlighted important initial inflammatory events that occur before the breakdown
of the BBB and provide possible leads to the earlier steps necessary for disease (10-13). These
studies suggest that the molecular changes at the level of the BBB are downstream effects of
earlier reported events such as entry of inflammatory T cells via routes other than the BBB.
Evidences point to the CP, cells primarily known to produce CSF (14, 15), as a possible site
where pioneer T cells infiltrate the CNS in MS/EAE.
CP has garnered attention as a critical player in immune reactions of the CNS (13, 1618). It is located within the cerebral ventricles and is composed of a highly vascularized stroma
encapsulated by a “tight” layer of epithelial cells decorated with tight junctions (TJ) (19, 20). CP
stromal capillaries are fenestrated and permit hydrophilic molecules typically excluded by the
BBB (21). This leaky nature of the CP endothelium is known to allow extravasation of T cells
engaged in immunosurveillance. Reboldi et al.(22) reported that CCL20, produced by choroidal
epithelial cells, attracts TH17 cells bearing the cognate receptor CCR6, in circulation within the
capillaries, across the endothelium. However these cells need to cross the blood-CSF barrier
(BCSFB)(6, 23) formed by a tighter epithelium juxtaposed with the “leaky” capillaries in order
to get into the CSF. The CCL20 chemokine gradient doesn’t explain how these cells get past the
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epithelial layer. Reports of adhesion molecules being present in the apical surface of the
epithelial cells rather than the basolateral side further fuels the question of how do T cells get
past the BCSFB (18). Works included within the scope of this thesis contributes to bridge this
gap in knowledge and answer unresolved critical questions lingering in the field.
Is there breach of the BCSFB? Significance of this work lies in understanding how the
leukocytes navigate across the tight junctions of the choroidal epithelial layer. There has been
very limited work in terms of understanding the tight junction regulation of the CP epithelial
layer during naïve as well as pathological scenarios(18, 24, 25). Having established the
importance of the CP, it is as important to understand the anatomical changes within this intricate
system. Understanding the changes in the tight junctions between the epithelial cells of the CP
has provided valuable information about the regulation of BCSFB via possible trans epithelial
migration of infiltrating immune cells. BCSFB breach has also been assessed functionally by
permeability studies, thus co-relating the breakdown of tight junctions with possible increase in
the “leakiness” of the barrier.
In association, the SAS, which is connected to the CP via CSF, is reported to be
another important compartment that supports earlier inflammatory events (10-12). It is within the
SAS, the initial inflammatory T cells are known to encounter their cognate antigen. T cells are
reactivated within the SAS by MHC class II expressing macrophages and DCs presenting myelin
epitopes (26). Reactivated T cells are then known to produce inflammatory cytokines that set off
an inflammatory cascade. The effects are first observed within the SAS in the meningeal vessels
followed by activation of parenchymal inflammation(27). Parenchymal vascular changes in
terms of expression of adhesion molecules and production of cytokines activate the BBB and
allow leukocytes to permeate this normally restrictive BBB (28, 29).
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Once across this barrier and into the CNS parenchyma, these cells then release soluble factors
that initiates destruction of myelinated axons and damage to neurons (4). However, there are
several critical questions within this scheme of events. This work aimed at providing some
answers that will stipulate a holistic picture of immune pathology in EAE.
What links the inflammatory signals in the spinal cord SAS to neuroinflammation in the
parenchyma? Studies have shown that the inflammatory cascade begins in the SAS long before
it is observed in the parenchyma during developing EAE (10, 11, 13). Meningeal vessels within
the SAS are shown to accumulate immune cells and to allow extravasation earlier than the
underlying parenchymal vessels. Why do infiltrating T cells prefer meningeal to parenchymal
vessels to begin infiltration? Is there differential regulation of inflammation within the two
vascular regions and what links them? A detailed immune profile of regional vascular
endothelium within the meninges and underlying parenchyma provided a key in answering these
questions. Major immune players such as adhesion molecules, cytokines, chemokines, statins,
interleukins, T cells activation markers, co-stimulatory molecules, transcription factors and
apoptotic markers were probed to provide a complete immune profile during developing EAE.
Does heterogeneity within the spinal cord segments lead to ascending EAE? Ascending
progression of spinal cord pathology and clinical disease observed in many EAE models has
remained enigmatic (5). The reasons behind the progression of inflammation from the
caudal/lumbar segment to the rostral/cervical segment are yet to be explained. Once the immune
cells enter the CSF from the choroid plexus, do they select a segment within the SAS to ignite
the inflammatory sequence? Our work has shed light on the possibility that regional blood
vessels in the meninges and parenchyma might display unique vulnerabilities depending upon
the segment of the spinal column in which they reside. These differences could aid in preferential
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accumulation and infiltration of inflammatory cells within the lumbar segment followed by
ascending progression in disease pathology. This work has attempted to address these issues
using a systematic and detailed segmental analysis of inflammatory gene expression patterns of
spinal cord meningeal and parenchymal venules.
The significance of this work lies in tackling unresolved questions important to
understand the nascent alternate routes proposed. i.e. the CP and SAS meningeal venules. First,
how do leukocytes navigate across the tight junctions of the tight choroidal epithelial layer and
possibly breach the BCSFB during disease onset? Second, what are the immune gene changes
within the meningeal and underlying parenchymal vessels in the spinal cord segments that could
highlight differences within regional vascular environments and the segmental co-relation
between them? Understanding the earliest events in disease pathology will provide uniquely
sensitive avenues for therapeutic interventions that could halt or delay the progression of the
disease.
This study is novel not just in terms of the unique questions asked but in using new and
challenging technical approaches as well. Quantitative 3D analysis of TJ breakdown and
permeability assessment was used to highlight aspects of CP morphological and functional
changes not resolved before. Previous works in similar accounts (24) have been defined by 2D
qualitative analysis in thin sections, which is restricted to visualization of only a small portion of
the given specimen. Given the tortuosity of the complex of cells within CP, visualizing TJs
embedded within the epithelial cells and the leakage is limited. Focal changes in TJ expression
and functional changes in BCSFB breach was quantified effectively using an encompassing 3D
approach in thicker sections, providing an enhanced perspective of in vivo changes in tight
junctions and permeability within the CP.
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Characterization of immune genes between regional and segmental vasculature was done
with a novel isolation procedure- Laser Capture Microdissection (LCM). With this work we
were able to resolve the differences in meningeal and underlying parenchymal vessels in
terms of their immune gene profile. This work encompassed specialized isolation of vascular
endothelium from meningeal and parenchymal regions within spinal cord segments. This
laboratory has successfully demonstrated that immunohistochemistry-guided laser capture
microdissection (immuno-LCM) can precisely acquire designated cell populations in highly
purified form from their in situ setting (30-34). These lab reports have shown that immunoLCM coupled to qRT-PCR enables highly reproducible, quantitative gene expression profiling
of captured cells. This level of intricate isolation and profiling has not been done before in
comparing meningeal and parenchymal vascular endothelial cells. Tenacious profiling of
immune genes within these vascular types has provided cues for the ascending course of EAE,
which we hypothesized, is due to spinal segment-dependent relay of inflammatory signals
between meningeal and parenchymal vessels.
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CHAPTER II: Choroid plexus in evolving EAE
Alterations in tight junction protein and IgG permeability accompany
leukocyte extravasation across the choroid plexus during neuroinflammation.

1. Abstract
The choroid plexus (CP) is considered a point of leukocyte entry into the central nervous
system (CNS) during normal immune surveillance and developing neuroinflammatory disease.
However, structural or functional alterations within the CP that support this migration are much
less understood. Quantitative, high-resolution 3D fluorescence imaging was thus used to detail
inflammatory responses within the CP following induction of experimental autoimmune
encephalomyelitis (EAE) by immunization with myelin oligodendrocyte glycoprotein (MOG)
and Complete Freund’s Adjuvant/pertussis toxin (MOG-CFA/PTX), or adjuvants alone (CFAPTX). MOG-CFA/PTX and CFA/PTX produced near comparable effects, the former being
consistently more severe. Both treatments resulted in accumulation of serum IgG and leukocytes
in the CP stroma, consistent with elevated stromal capillary permeability. They also provoked
remarkable distortions in staining pattern of tight junction (TJ) adaptor protein ZO-1 in the
choroidal epithelium, with diminished staining but no obvious change in pattern of the associated
TJ protein, claudin-2. Only MOG-CFA/PTX triggered visible extravasation of IgG and
leukocytes across the choroidal epithelium. Results suggest CFA/PTX primes the CP for
neuroinflammation by inducing several structural changes that are exacerbated when coadministered with MOG, and reinforce the CP is a gateway for leukocytes to enter the CNS by
accessing the cerebrospinal fluid and meninges.
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2. Introduction
The choroid plexus (CP) is a specialized out-pocketing of the roofs of the third, fourth and
lateral ventricles, and has long been recognized as the site of production of cerebrospinal fluid
(CSF), within which it hangs suspended (14, 19). A highly compartmentalized structure, the CP
contains at its core, a tortuous capillary plexus displaying a fenestrated endothelium more
permeable than that of capillaries forming the blood-brain barrier (BBB) in the CNS parenchyma
(21). This vascular core is surrounded by a layer of choroidal epithelium having a relatively high
density of tight junctions (TJs) and limited permeability, providing the CP its classification as
part of the blood-CSF-barrier (BCSFB) (6, 23). Located between the capillaries and choroidal
epithelium is a confined stromal space.
Since the pioneering work of Helen Cser (35), the CP has been commonly recognized for its
role in generating CSF, as most recently reviewed (36). However, a growing number of reports
has turned attention to the CP as a site through which T cells might enter an initially uninflamed
central nervous system (CNS) to spark neuroinflammatory disease, such as multiple sclerosis
(MS) and its animal model experimental autoimmune encephalomyelitis (EAE) (13, 16-18, 22).
It has been proposed that once encephalitogenic T cells cross the CP and enter the CSF, they can
migrate to the subarachnoid space (SAS) surrounding the brain and spinal cord, and there forge
immune synapses with resident dendritic cells. Cytokine bursts stemming from such synapses, in
turn, are reasoned to activate the endothelial surfaces of nearby microvessels within the SAS,
thereby enabling adhesion and extravasation of leukocytes circulating in the bloodstream (1012). Interactions between these leukocytes and other dendritic cells in the SAS are thought to
follow, ultimately propagating an inflammatory wave along the surface-penetrating microvessels
that enter the CNS parenchyma.
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This scenario begs the question: Are there changes within CP anatomy and integrity during
evolving neuroinflammation that would allow leukocytes to navigate across the TJs of the
choroidal epithelium and enter into the CSF? Currently, direct evidence of leukocyte
extravasation across the CP into the CNS ventricles, or structural arrangements of the choroidal
epithelium that might support this process, is lacking. High-resolution 3D fluorescence imaging,
was thus used to highlight aspects of CP morphological and functional changes not previously
resolved during progression of EAE.
Specifically, immunization with myelin oligodendrocyte glycoprotein (MOG) peptide35-55,
along with Complete Freunds Adjuvant (CFA) and pertussis toxin (PTX), was used to induce
EAE, and at different time-points qualitative and quantitative assessments were made for two TJ
proteins expressed by the CP: claudin-2 (CLN-2) and zonula occludens-1 (ZO-1) (24, 25, 37).
CLN-2 belongs to a large family of claudins (> 20 members), integral membrane proteins that
perform cell-cell bridging, while ZO-1 is a peripheral membrane scaffolding/adaptor protein that
directly or indirectly links claudins (and other integral membrane TJ proteins) to the actin
cytoskeleton (38-40). TJ protein changes were further correlated with leakage of serum
immunoglobulin G (IgG) – a marker of barrier permeability status (41)– and leukocyte
extravasation across the successive CP compartments. As administration of just the adjuvants
CFA and PTX can significantly alter gene expression patterns in the CP (42), MOG35-55immunized mice were contrasted with those receiving these adjuvants alone or no treatment.
Results indicate that ZO-1 and CLN-2 immunostaining patterns within the CP choroidal
epithelium displayed significant, yet different, changes during evolution of EAE, with the former
showing a severely altered morphology, and the latter a gradual decrease in staining intensity.
IgG was detectable at a low level in the CP stroma even in naïve animals, appreciably increased
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during disease, and later in acute disease was observed to extravasate across the CP choroidal
epithelium. A few leukocytes were also detected in the CP stroma of naïve mice. These cells,
showed an acute transient accumulation early in EAE, and then seemed to reduce to near predisease level. Correlating with this decline, leukocytes could apparently be seen in the process of
extravasating across the CP choroidal epithelium and into the ventricles, presenting direct
evidence supporting the theory that the CP is the entry site into the CNS for leukocytes in the
ontogenesis of neuroinflammation (13).

3. Materials and Methods
3.1 Animals: Female C57BL/6 mice, age 8–10 weeks, were obtained from Charles River
Laboratories, Inc. (Wilmington, MA) and used throughout. A total of n = 3 animals/group were
used for each treatment and time-point assessed. All animal experimental procedures were
performed following Animal Care and Use Guidelines of the University of Connecticut Health
Center (Animal Welfare Assurance # A3471-01), and approved under protocol #100346-1214.

3.2 EAE induction: EAE was induced in mice by active immunization with MOG35-55 peptide
(MEVGWYRSPFSRVVHLYRNGK), of murine origin (W. M. Keck Biotechnology Resource
Center, Yale University), as described (43) Briefly, on day 0 (D0), one group of mice was
injected subcutaneously with 300 µg of MOG peptide in complete Freund’s adjuvant (CFA,
DIFCO) into the right and left flank, 100 µl per site. These mice were also injected i.p. with 500
ng pertussis toxin (PTX, List Laboratories, Campbell CA) in PBS on D0 and D2 following the
first immunization (referred to as the MOG-CFA/PTX group). Another group of age-matched
mice received only CFA and PTX (500 ng) injections on D0 and a second injection of 500 ng
PTX on D2 (referred to as the CFA/PTX “control” group). A third group of age-matched mice
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was left untreated (referred to as “naïve” mice), and represented “normal” tissue. Only the
MOG-CFA/PTX group developed EAE. Mice typically showed development of acute clinical
symptoms at ~ D12, followed by ascending paralysis and chronic disease (44). Animals were
killed at D0 (naïve), D6, D9 and D15 post-injection (with MOG and/or CFA/PTX). Animals
were monitored for clinical disease severity and mean clinical scores were calculated where 0
=normal; 1 = tail limpness; 2 = limp tail and weakness of hind legs; 3=limp tail and complete
paralysis of hind legs; 4 = limp tail, complete hind leg and partial front leg paralysis; and 5 =
death. The time-points selected for analysis, D6, D9 and D15, represent pre-clinical (score 0),
early (score 0-0.5) and acute stages of EAE (score 2-2.5), respectively.

3.3 Tissue preparation and sectioning for 3D analysis: Mice were anesthetized by
intraperitoneal injection of Ketamine (80 mg/kg) and Xylazine (10mg/kg) in phosphate-buffered
saline, pH 7 . 4 ( PBS). Animals were then transcardially perfused (via the left ventricle) first
with Heparin-PBS (10 usp/ml) to eliminate vascular blood content, and then with fixation
Buffer (2% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4), as described previously (43)
Brains were embedded in OCT cryomatrix compound (Thermo Fisher Scientific, Waltham,
MA) prior to sectioning. Cryosections of 2 0µm thickness were obtained using a Microm HM
505M cryostat (Mikron Instruments; Oakland, NJ) maintained at -25°C, and deposited onto polyL-lysine coated slides.

3.4 Immunostaining for 3D analysis: Sections were permeabilized with 0.6 % Triton X-100
in PBS for 30 min, and non-specific binding blocked by incubation with Power block® for 10
min in Ultrapure (GIBCO) distilled water (41). The CP capillary endothelium was stained by rat
anti-mouse CD31 antibody (BD Pharmingen) at 1:160 dilution, followed by incubation with goat
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anti-rat Alexa Fluor® 555 antibody (Life Technologies) at 1:250 dilution. Choroidal epithelial
cells were stained using monoclonal pan-cytokeratin-FITC antibody (Sigma) at 1:160 dilution.
Rabbit polyclonal antibodies to CLN-2 (Invitrogen) at 1:160 dilution, CLN-3 (Abcam) at 1:100
dilution, ZO-2 (Invitrogen) at 1:100 and ZO-1 (Invitrogen) at 1:160 dilution, followed by Alexa
Fluor® 488 goat anti-rabbit IgG (Life Technologies) at 1:250 dilution, were used to stain
epithelial TJs. Alexa Fluor® 488 goat anti-mouse IgG Fab fragment (Life Technologies) at 1:160
dilution was used to detect endogenous IgG within the CP. DRAQ5 (Biostatus Ltd.,
Leicestershire, UK) was used at 1:1000 dilution to stain nuclei. Alexa Fluor® 647 anti-mouse
CD45 (Biolegend) at 1:160 dilution was used to stain for leukocytes. Sections were mounted in
Mowiol (Sigma-Aldrich).

3.5 Image acquisition and quantitative analysis of TJ proteins, IgG and leukocytes in the
CP: Confocal z-stacks (multi-track scan) were acquired using a Zeiss LSM 510 Meta equipped
with Zeiss Fluar 40X/1.30, 63X Plan-neofluar/1.25, and 100X Plan-apochromatic/1.4 oil
immersion objective lenses. Thereafter, z-stacks were imported into Bitplane Imaris® suite
version 7.1 x64 software (Bitplane Inc., South Windsor, CT), as described previously (41).
The CP tissues specifically located in the lateral ventricles were evaluated in all
experiments, as complexity and developmental changes of TJ proteins have been reported to
show differences among the CP locales in rat (Kratzer et al., 2012). Images of these TJ proteins
were first isosurface rendered to obtain a measure of total surface area, and the epithelial nuclei
were represented as spots to estimate the number of epithelial cells per image. The total area of
TJ protein staining per epithelial cell was calculated as follows:
Total TJ area/epithelial cell = Total surface area of green isosurface
No. of epithelial nuclei

	
  

11	
  

A slightly different method was used for relative 3D quantification of endogenous IgG that had

extravasated from the circulation into the CP. Specifically, a volumetric approach was taken as
IgG became diffusively distributed throughout the CP by D15 of EAE. Images of extravasated
IgG were isosurface rendered, and mean voxel intensities determined. IgG staining along the
endothelial lining of the capillaries was specifically masked in order to quantify only the IgG
that leaked out of the vasculature. This was done by creating an isosurface of the capillary
staining (CD31) and assigning all the included green (IgG) voxel intensities to zero. A mean red
voxel intensity value of the capillary isosurface was then obtained. The volume of extravasated
IgG per volume of capillaries was calculated as follows:
Volume of IgG/ Volume of capillaries = Total green intensity
Total red intensity
Total green intensity = Mean green intensity X no. of green voxels
Total red intensity = Mean red intensity X no. of red voxels

Leukocyte quantification was performed using the measurement points module of the
Imaris® software suite, first representing the CD45+ cells as ‘spots’ and then counting the total
number of spots present in the field of view. The surface area of the capillaries was determined
by creating an isosurface of the capillary staining (CD31), and the number of leukocytes per
capillary surface area of the CP was calculated as follows:
Total number of leukocytes/capillary area =

Total no. of spots x 104
Total surface area of the red isosurface

3.6 LCM and qRT-PCR
Immunohistochemistry-guided LCM was performed as recently detailed (42). In brief, naïve
animals were euthanized by gradual CO2 inhalation. Brains were immediately removed, snapfrozen in dry ice-cooled 2-methylbutane (Acros; Geel, Belgium), and embedded in cryomatrix
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compound (Thermo Fisher Scientific, Waltham, MA) for cryosectioning. Coronal sections (7µm)
were cut on a Microm HM 505 M cryostat (Mikron Instruments; Oakland, NJ) and affixed to
uncoated, pre-cleaned glass slides (Fisher Scientific, Pittsburgh, PA). The CP stromal capillaries
were stained using a substrate combination of nitro-blue tetrazolium chloride/5-bromo-4-chloro3'-indolyphosphate p-toluidine salt (Vector Labs, Burlingame, CA) to detect the endogenous
alkaline phosphatase activity in endothelial cells. The choroidal epithelial cells were
immunostained with monoclonal pan-cytokeratin-FITC antibody (Sigma). A PixCell IIe laser
capture microscope (Life Technologies, Foster City, CA) was used to retrieve CP choroidal
epithelial tissue from the lateral ventricles. LCM samples were solubilized in Cell Lysate Buffer
(Signosis; Sunnyvale, CA) for direct reverse transcription and relative cDNA levels were
quantified by qRT-PCR using an ABI 7900HT Fast Real-Time PCR System (Life Technologies
Corp, and normalized to housekeeping gene RPL-19 as described previously (34). Samples were
probed for TJ proteins – CLN-1, -2 , -3, -11, occludin and ZO-1 – and the purity of captured
LCM material was assessed by epithelial marker (cytokeratin-8) and endothelial marker (CD31)
levels.

4. Statistical Analysis
Two CP sections from each animal and a total of three animals were used for each group:
naïve, control (CFA/PTX) and EAE (MOG-CFA/PTX). Data from all experiments was initially
assessed for normality using a Shapiro-Wilk test. Accordingly, data from ZO-1, IgG and
leukocytes determinations was subsequently analyzed by a one-way non-parametric KruskalWallis test followed by Dunn’s post-test analysis, while data from CLN-2 determinations were
analyzed by a one-way ANOVA followed by Bonferroni post-test. All statistical analyses were
performed using GraphPad Prism 5 (GraphPad, La Jolla, CA). Results were considered
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significant at p≤0.05.

5. Results
5.1 Relative expression of genes encoding TJ proteins in the CP
The normal CP choroidal epithelium was first analyzed by laser capture microdissection
(LCM) to establish the relative expression of TJ components in this tissue layer of naïve mice
(Fig. 1). Prior descriptions by this laboratory (42) have highlighted the ability of LCM to resolve
with high purity the choroidal epithelium from the vascularized core. Analysis of LCM-derived
choroidal epithelial tissue by qRT-PCR revealed expression of cytokeratin 8 (K8), as well as
mRNAs encoding the TJ proteins ZO-1, CLN-1, CLN-2, CLN-3 and CLN-11, which have also
been previously identified in the CP in situ by immunocytochemistry as well as in cultured
choroidal epithelial cells (24, 25, 37, 45).

Notably, expression of CD31 – found in all

endothelial cells but not choroidal epithelial cells – was barely detectable, reinforcing the high
precision of the LCM process. Because of their relatively prominent expression,
immunofluorescence studies of ZO-1 and CLN-2 were further pursued to determine whether
cytological changes of these CP TJ components were correlated with functional aspects of
neuroinflammation during evolving EAE.

5.2 Distribution of TJs proteins, IgG and leukocytes within the CP of naïve mice
Initial studies sought to demonstrate the status of the normal CP in naïve mice (Fig. 2). With
respect to ZO-1 and CLN-2 distribution (Fig. 2a and 2b, respectively), strong immunostaining
for both these TJ proteins revealed a smooth contour and continuous pattern, delimiting the
junctions of all choroidal epithelial cells. A scarce amount of IgG could be detected within the
CP stroma of naïve mice (Fig. 2c), along with a few leukocytes (Fig. 2d). The approaches used to
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perform relative quantification of ZO-1, CLN-2, IgG and leukocytes in the CP are illustrated in
Fig. 3.
5.3 Distribution of ZO-1 in the CP following immunization
Subsequent studies evaluated immunostaining of TJ proteins and IgG at different time-points
in both control mice (receiving CFA/PTX) and mice following EAE induction (receiving MOGCFA/PTX) (Fig. 4a). The staining pattern of ZO-1 was altered in both groups, but the changes
varied in scope. In CFA/PTX-treated control mice, immunostaining of ZO-1 was a bit distorted
at D6, showing ridge-like irregularities in the contour at some locales that persisted through D15.
Treatment with MOG-CFA/PTX to induce EAE resulted in more drastic alterations in ZO-1
staining pattern. Similar ridge-like irregularities were initially obvious along some choroidal
epithelial cells at D6, but these became more pronounced through the disease course. By D15,
the ZO-1 staining pattern was severely crenulated throughout the choroidal epithelium, giving a
palisade appearance. To quantify these changes in TJ staining patterns, total area of ZO-1
staining within the CP epithelium of each image was related to the number of CP epithelial
nuclei (Fig. 4b) as shown in Fig. 3. Control mice evidenced no changes in this parameter over the
time-points evaluated, while mice with EAE showed a step-wise elevation, with significant
changes at D9 and D15 (compared to naïve). As this suggested an increase in individual CP
epithelial cell surface area during evolving EAE, inter-nuclei distances were also determined as a
surrogate for corresponding volume/cell-size changes. At D15 EAE, mean inter-nuclei distance
in CP epithelial cells was nearly three-fold higher than that found in naïve mice, suggesting a
significant increase in CP epithelial cell volume during neuroinflammatory disease (see Figure,
Supplemental Digital content 1, which shows an increase in CP epithelial inter-nuclei distance).
These observations were further supported by a significant increase in perimeter of ZO-1
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staining in CP epithelial cells in D15 EAE mice compared to naïve mice (see Figure,
Supplemental Digital content 2, which shows an increase in perimeter of ZO-1 staining within
the CP epithelium).
5.4 Distribution of CLN-2 in the CP following immunization
The response of CLN-2 was different both qualitatively and quantitatively from that of ZO-1
(Fig. 5a). The immunostaining pattern of CLN-2 did not appear to change in control mice
receiving CFA-PTX alone, remaining relatively linear at intercellular borders. There was,
however, a slight change in the staining intensity by D15. Likewise, the overall CLN-2 staining
pattern remained unaltered following EAE induction with MOG-CFA/PTX, though a steeper
reduction in staining intensity was more noticeable in this group, which by D15 revealed sites of
sharp discontinuities (arrows). The ratio of total area of CLN-2 immunostaining to number of CP
epithelial cell nuclei was calculated as for ZO-1 (Fig. 5b). This parameter did not significantly
change in control mice until D15, but was significantly reduced earlier in mice with EAE –
showing a decrease at D9 and an even greater decline at D15 of MOG-CFA/PTX treatment as
discontinuities became more evident.
Given the strongly disparate responses between ZO-1 and CLN-2, additional studies were
carried out to determine whether the different patterns of TJ protein redistribution might be
related to these proteins being of peripheral and integral membrane classes, respectively (see
Figure, Supplemental Digital Content 3, which shows ZO-2 and CLN-3 staining in the CP from
naïve and MOG-CFA/PTX-treated mice). ZO-2, another peripheral membrane TJ protein,
demonstrated a response much like that of ZO-1, showing a similarly crenulated pattern while
apparently maintaining constant intensity following MOG-CFA/PTX immunization. In contrast,
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the response of CLN-3, another integral membrane TJ protein, paralleled that of CLN-2,
exhibiting a less intense and discontinuous pattern.
5.5 Distribution of IgG in the CP following immunization
Increased IgG staining was seen in both control mice and in mice following EAE induction,
though to different extents (Fig. 6a). It increased in CFA/PTX-treated control mice by D6, and
displayed greater elevation through D15. The IgG appeared to be restricted to the CP stroma, as
none could be readily seen to infiltrate the choroidal epithelium. These changes in IgG were even
more dramatic in mice subjected to EAE by MOG-CFA/PTX treatment. A visible increase in
IgG immunostaining was first noted by D6, becoming more extreme by D15. At this later time
IgG was clearly seen permeating across the choroidal epithelium. Because IgG staining became
extremely diffuse by later stages of EAE, relative IgG leakage within the CP was quantified by
relating its total volumetric staining to total volumetric staining of capillaries within each image
(Fig. 3). An increase in IgG leakage was established in both control mice and those with EAE,
with a greater level (~ three-fold) seen in the latter by D15 (Fig. 6b).
5.6 Distribution of leukocytes in the CP following immunization
CFA/PTX injection alone resulted in increased apprearance of leukocytes in the CP,
compared to that seen in naïve mice (Fig. 7a). However, these leukocytes appeared to be in close
association with the CP capillaries and/or confined to the stroma. This moderate leukocyte
increase was reversed to normal level by D9, where it remained through D15. MOG-CFA/PTX
also resulted in an apparent influx of leukocytes in the CP at D6 and D9, which reverted by D15.
Notably, at D15 leukocytes could be seen closely associated with the choroidal epithelium, a few
apparently caught in the act of extravasating past the epithelial barrier. That these leukocytes
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were, in fact, outside of the CP stroma, was revealed by rotation of 3D images, wherein some
extravasated leukocytes in the CSF could be seen still tethered to the luminal surface of
choroidal epithelium (see Video, Supplemental Digital content 4, which shows leukocytes
attached to the CP epithelium). It is important to emphasize here that any leukocytes fully
extravasated into the CSF are unlikely to be represented in these images, as the cells would not
be retained in the ventricles following tissue sectioning and immunostaining. Quantification
showed that the number of leukocytes significantly increased in the CP at D6 following
CFA/PTX treatment, and also did so at D6 and D9 after MOG-CFA/PTX, before returning to
normal levels (Fig 7b).

6. Discussion
While the appearance and developmental regulation of TJs in the CP have been rigorously
investigated over nearly five decades (24, 25, 46-57), much less is understood of the alterations
of these junctions and their protein constituents during neuroinflammatory disease and their
relation to BCSFB permeability and leukocyte extravasation (58). Hence, high resolution, 3D
imaging of the CP was performed in this study to track and quantify such alterations and their
functional correlates; i.e., extravasation of IgG and leukocytes, during evolving EAE, and to
distinguish MOG-associated changes from those due to adjuvants alone.
Our use of LCM/qRT-PCR to selectively analyze the CP choroidal epithelium confirmed the
relative gene expression of major TJ proteins in the particularly MOG-sensitive C57BL/6 mouse,
a similar pattern having previously been described in the Sprague-Dawley rat by standard qRTPCR of total RNA from whole CP tissues (25). These results reinforced emerging LCM
technology as a critical tool to probe gene changes in discrete compartments of the CP (42), and
focused our attention on TJ proteins ZO-1 and CLN-2 for detailed, 3D image analysis.
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Strong and smooth immunostaining of both ZO-1 and CLN-2 was associated with all
intercellular junctions of CP epithelial cells in naïve mice, as has been previously reported in
these cells from various species (24, 37, 45, 59). However, ZO-1 and CLN-2 showed markedly
different responses to MOG immunization or injection of adjuvants. The pattern of ZO-1
immunostaining became moderately distorted after CFA/PTX alone, and more drastically
crenulated following MOG immunization. To the best of our knowledge, this is the first
description of such alterations in TJ staining in vivo. Recent in vitro reports have given similar
accounts of “ruffled” or “wavy” ZO-1 patterns associated with loosening of epithelial TJs of
cultured Caco-2 and MDCK cells following application of nanoparticles or mechanical stretch
(60, 61). Together, these observations seemingly highlight a common manifestation of ZO-1
redistribution that accompanies epithelial barrier disruption.. While the basis and physiological
significance of the peculiar alteration of ZO-1 appearance noted here remain unknown, Samak et
al. (43) noted the comparable disruption in Caco-2 cells to be associated with JNK-2-, c-Src- and
MLCK-dependent mechanisms. Interestingly, radical ultrastructural changes in CP epithelial
cells, e.g., widening of intercellular clefts, have been reported following experimental traumatic
brain injury (62), and the two findings may be related to observations in the current study. The ~
three-fold increase in both the mean inter-nuclei distance and ZO-1 perimeter of CP epithelial
cells during EAE is further consistent with a significant increase in cell volume, and points
toward an even more gross histopathology associated with EAE than has been previously
imagined. Interestingly, while describing distributions of TJ proteins at the CP more than a
decade ago, Wolburg et al. (24) did not note any changes in ZO-1 distribution in EAE afflicted
mice, and specifically commented on the difficulties of obtaining quantitative results by
immunohistochemistry when using conventional confocal microscopy. The advantages afforded
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by state-of-the-art high-resolution 3D imaging may thus have uniquely enabled us to uncover
and quantify the remarkable ZO-1 responses in the CP choroidal epithelium.
By contrast to the observed effects on ZO-1, changes in CP epithelial CLN-2 following
immunization appeared much more subtle. CLN-2 showed no obvious alterations in pattern after
CFA/PTX treatment and a minimal decrease in the amount of immunoreactivity. A similar trend
was observed following MOG immunization, but with a sharper decrease in immunoreactivity of
CLN-2 that ultimately presented a fragmented appearance. Wolburg et al.(24) similarly observed
the immunostaining of CLN-2 to be “interrupted” in the CP choroidal epithelium following EAE
immunization, but did not resolve whether this was due to MOG or adjuvant effects. Kooij et
al.(45) also recently described a comparatively tempered loss of CLN-3 immunostaining in this
tissue in mice immunized for EAE, possibly suggesting this type response is common among the
different CLN proteins of the CP during neuroinflammation, as opposed to the more peculiar
change in pattern evidenced by ZO-1.
That the responses of the two classes of TJ proteins, ZO-1/ZO-2 and CLN-2/CLN-3, were
vastly different from each other could reflect their respective positions and roles within the TJ
complex. Peripheral membrane ZO proteins, lying internal to CLNs and directly connected to the
actin cytoskeleton (38-40), might transduce the disruptive inflammatory signal to their integral
membrane CLN protein partners. Inasmuch as the epithelial actin cytoskeleton can become
severely disorganized during both PTX treatment and inflammation (63, 64), this could
potentially lead to retraction of ZO proteins from its membrane locale and disengagement from
CLNs. No longer bound to ZO proteins, CLNs might be susceptible to rearrangement and/or
degradation (41, 43).

Whatever their cause, the different effects on these two proteins

underscores the complexity of actions taking place at the level of the TJ in the CP choroidal
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epithelium, and that the response of individual TJ proteins cannot be assumed to be similar.
Disparities in responsiveness among various TJ proteins have also been reported in cultured CP
choroidal epithelial cells (65). In this case, CLN-2 showed reduced protein level by Western
blotting following treatment with protein kinase C activator, phorbol 12-myristate 13-acetate,
while levels of CLN-1, ZO-1 and occludin were spared.
In line with the characterization of the fenestrated CP capillaries as normally “leaky” (15, 66,
67), there was some evidence – albeit scarce – of IgG immunostaining and a few leukocytes in
the CP stroma of naïve mice. In contrast, while using the same technology as employed here,
virtually no IgG or leukocytes were detected around parenchymal CNS microvessels in the naive
situation (41, 43). It would thus appear that while CP capillaries in the healthy state are
somewhat more permeable than the BBB, their perception as being “highly permeable” (68) and
“allowing the free passage of molecules and cells (69)” may merit some reconsideration. This
would concur with the description of fenestrated endothelia in airway exchange vessels having
permeabilities to plasma proteins that are about the same as found in continuous endothelia (70).
CP capillaries nevertheless seemed to become significantly more leaky in response to
CFA/PTX or MOG-CFA/PTX, allowing for extravasation of IgG and leukocytes into the stromal
compartment. It is possible that some of the IgG appearing in the stroma might have derived
from intrathecal synthesis by B cells. However, the fact that IgG levels continually increased
while leukocytes decreased in the CP stroma at later time points argues against B cells being the
exclusive or major source of IgG observed, suggesting a significant amount of this protein was
serum-derived. The basis for this effect is unclear at this time, as the presence of TJs or other
less-restrictive junctional specializations in CP capillaries has not been confirmed (68).
Nevertheless, CLN-5, occludin and ZO-1 have been reported in this vascular bed (45, 53) and
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could possibly be targets of CFA/PTX or MOG-CFA/PTX action. A previous finding by this
laboratory that the chemokine CCL2 is elevated within the CP capillary plexus following
CFA/PTX or MOG-CFA/PTX treatment (42) may thus relate to the enhanced IgG leakiness
noted here, as this chemokine has been linked to downregulation and/or redistribution of
endothelial CLN-5, occludin and ZO-1 in association with increased permeability (43, 71-75).
Appearance of IgG leakage across the CP choroidal epithelium was only observed following
MOG-CFA/PTX, and may be due to the more severe alterations in TJ proteins that accompany
neuroinflammation.
The observation that few leukocytes were present in the CP stromal space in naïve mice is
consistent with other recent descriptions (45, 76), and may reflect a limited permeability of
normal CP capillaries to blood cellular elements. Specifically, scant CD3+ and CD4+ T cells, and
CD68+ cells of myeloid lineage (dendritic cells and macrophages) have been shown to normally
reside in this CP compartment (13, 77, 78). Both CFA/PTX and MOG-CFA/PTX produced a
transient increase in the CP leukocyte population. The pathway(s) by which leukocytes
accumulate in the CP stroma remains uncertain, as previous reports using immunohistochemistry
at the light and ultrastructural levels noted expression of adhesion molecules, ICAM-1, VCAM-1
or MAdCAM-1, on the CP choroidal epithelium but not along the CP capillaries in SJL mice
with EAE induced by immunization with CFA/PTX and proteolipid protein (79, 80). However,
this laboratory recently utilized laser capture microdissection to detect upregulated gene
expression of VCAM-1, E-selectin, P-selectin and Smad-3 in the CP capillary bed of C57BL/6
mice following CFA/PTX or MOG-CFA/PTX, with Smad-3 exclusively among these showing
super induction during MOG-CFA/PTX-induced EAE (42). Reinforcing the relevance of these
gene findings, E- and P-selectin immunoreactivity has also been described in the CP vasculature
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of patients with non-neurological disorders (13). Previously noted examples of up-regulated
chemokine expression in these microvessels, e.g., CCL2, CCL5 and CCL19 (42) may thus act
cooperatively with elevated adhesion molecule expression to drive leukocyte extravasation
across the CP capillaries into the stroma. At present, we are unaware of any descriptions of the
CP bearing specialized post-capillary venules – the preferred sites of exit of leukocytes from the
circulation (81) – but are mindful of the possibility that leukocyte extravasation from the
circulation could occur at the transitional regions between the CP capillary plexus and draining
venules (13).
Only MOG-CFA/PTX treatment showed clear evidence of leukocyte extravasation across the
CP choroidal epithelium – which, for CCR6-bearing Th17 cells, is thought to be mediated, in
significant part, by epithelial expression of the chemokine CCL20 (22). That the CD45+ cells
observed clinging to the apical side of the CP choroidal epithelium actually represent
extravasating leukocytes, is strongly supported by the sequence of images following MOGCFA/PTX immunization, which showed these cells first appearing in the CP stroma, then in
association with the basolateral epithelial surface, and finally attached to the apical epithelial
surface facing the CSF. To the best of these authors’ knowledge, the scenario shown is the first
histological evidence of such directed transit through the entire CP. This finding is also in accord
with inability of CFA/PTX treatment, alone, to cause clinical EAE in these mice (42), and
directly supports that the rudimentary processes underlying neuroinflammatory diseases such as
MS and EAE originate via the trafficking of leukocytes through CP into the CSF (13, 16-18, 22).
The prior observation by Schmitt et al.(77), that CFA/PTX, alone, resulted in a subtle but
definite increase in the number of myeloid cells in the extraventricular CSF spaces, could
suggest that this adjuvant combination promotes modest leukocyte extravasation across the CP
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choroidal epithelium but at a level too low to be readily detected even by high-resolution, 3D
confocal microscopy. In this regard, histologically capturing leukocytes in the act of
extravasating across the CP choroidal epithelium is particularly challenging, as they are, in
effect, washed away after entering the CSF.
As with the observed IgG leakage at this site, the more profound perturbations in TJ proteins
caused specifically by MOG-CFA/PTX treatment may enable leukocytes accumulating within
the CP stroma to more effectively migrate between the choroidal epithelial cells and into the
CSF, as depicted schematically in Fig. 8.

Alternatively, other factors induced by MOG-

CFA/PTX, e.g., chemokines and/or adhesion molecules, may facilitate leukocyte extravasation at
this level, which, in turn, alters the integrity of the CP choroidal epithelium leading to the TJ
protein manifestations and IgG leakage observed. The fact that the CP stroma showed apparent
reduction in the leukocyte population from D9 to D15 may further represent time needed for
leukocyte extravasation across the CP choroidal epithelium.
While no absolute cause and effect relationship between the observed TJ alterations and
IgG/leukocyte extravasation can be established at this time, it is significant to point out that
neither IgG nor leukocytes were seen permeating the CP choroidal epithelium until D15
following MOG-CFA/PTX, while changes in both ZO-1 and CLN-2 were observed earlier (D9).
This time frame is thus consistent with the noted structural changes in CP choroidal epithelial TJ
proteins having functional consequences that encourage extravasation of IgG and leukocytes.
Collectively, these results reinforce the notion that CFA/PTX instigates a series of molecular
and structural changes associated with neuroinflammation that is augmented when this adjuvant
combination accompanies MOG immunization. At present, it is unclear whether only one or both
adjuvants were responsible for the observed effects, as our objective was to specifically highlight

	
  

24	
  

changes in TJ protein distribution and IgG/leukocyte extravasation stemming from MOG
immunization versus collective adjuvant action. CFA and PTX have each been shown to
separately disrupt TJs and increase permeability at the BBB in other settings (82, 83). However,
PTX was not found to disrupt barrier function in epithelial Plexus choroideus-derived monolayer
cultures (84), suggesting that CFA might be responsible for the effects noted here or that the two
adjuvants cooperate to alter TJs and structural integrity of the CP capillaries and/or choroidal
epithelium in vivo in support of IgG and leukocyte extravasation.
This laboratory previously reported that CFA/PTX alone elicited significant changes in the
expression of numerous immune response associated genes in both CP capillary and choroidal
epithelium compartments (42), while MOG-CFA/PTX resulted in super induction of some of
these genes as well as stimulated a novel cadre of genes in this same functional category. In the
current report we extend these findings to show CFA/PTX further instigates structural changes in
the CP that may facilitate the autoimmune response to MOG. Thus, while it has been reported
that PTX, in particular, can drive CNS autoimmunity via regulation of TLR4 signaling and
opening up the BBB (85, 86), CFA/PTX appears to act more broadly to “raise the floor” of a
collective of inflammatory processes in the CP necessary for neuroinflammatory disease, like
EAE, to develop. A couple of implications are worth noting here. Attempts to attribute gene or
histological changes seen in EAE as being a specific autoimmune response to MOG, might
overlook significant contributions by CFA and/or PTX. Also, the fact that CFA/PTX exerts
prominent effects in the CP – considered a possible gateway for leukocytes to invade the
uninflamed CNS (8, 9, 87) – calls attention to the prospect that other environmental toxins with
activities like CFA or PTX might target this brain structure to help trigger cases of CNS
autoimmunity (88)
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Further clarification of the modes of leukocyte trafficking through the CP should enable
more efficient drug targeting to this organ and significantly broaden the prospects to treat
neuroinflammatory disease (89, 90).

	
  

26	
  

	
  

	
  
FIGURE 1. LCM analysis of tight junction gene expression in choroidal epithelial cells. The CP of a naïve
mouse was double immunostained for LCM analysis. (a) CP tissue section before LCM retrieval. Capillaries
were stained by immunohistochemistry for CD31, employing alkaline phosphatase detection and NBT/BCIP
substrate (dark purple); choroidal epithelial cells were stained by immunofluorescence using FITC-conjugated
antibody to pan-cytokeratin (green). (b) Laser shots showing the retrieval of choroidal epithelial cells and their
deposition on the cap (c). (d) CP tissue section after LCM retrieval of epithelial cells, showing capillaries left
behind. (e) Collection of LCM shots of epithelial cells on the cap used for gene expression analysis. (f) qRTPCR analysis of LCM-derived CP epithelial tissue, indicating expression of the epithelial marker K8, and several
tight junction proteins.	
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FIGURE 2. Distribution of tight junction proteins, IgG and leukocytes in normal CP tissue. Representative
sections of the CP of naïve mice are depicted. Capillaries were immunostained for CD31 (red) in all images,
and isosurface rendered in images (a – c). Nuclei of the choroidal epithelial cells were stained with DRAQ5
(blue) in images (a – c). (a) ZO-1 immunostaining (green) and (b) CLN-2 immunostaining (green) appear
uniform and smooth along the inter-epithelial junctions, as highlighted in the insets. (c) IgG immunostaining
(green) is scant and seen in only focal deposits apparently within the stroma (white arrow, insert). (d)
Choroidal epithelial cells were immunostained for cytokeratin (green); leukocytes were immunostained for
CD45 (blue), and isosurface rendered to highlight their 3D appearance and spatial relation to the different
compartments of the choroid plexus. A few leukocytes are clearly present, seemingly associated with
capillary network or in the stroma (insert)
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FIGURE 3. 3D quantification of CP tight junction protein, IgG and leukocytes during evolving EAE. Representative
sections of the CP of mice at D15 EAE are depicted to elaborate the approaches used for quantification of diseaseassociated changes in CP tight junction protein and IgG leakage. (a, d, g) show composite 3D data sets of confocal zstacks. The 3D frames are presented to display the holistic acquisition of the data. (b, c), (e, f) and (h-i) show 2D
depictions of the images in (a), (d) and (g), respectively. Such 2D projections of 3D images served as the sources
from which quantitative data were obtained. Isosurface rendering was performed to highlight the tortuous nature and
3D disposition of the respective CP compartments. Capillaries were immunostained for CD31 (red) and isosurface
rendered throughout. ZO-1, shown as an example of tight junction protein within the choroidal epithelium, was
immunostained (green) in (a – c), and isosurface rendered in (c). IgG was also shown immunostained (green) to
exemplify serum protein leakage (d – f) , and isosurface rendered in (f). Choroidal epithelial nuclei were stained with
DRAQ5 (blue) in (a-f) while leukocytes were stained for CD45 (blue) in (g-i); DRAQ5- and CD45-stained
structures were reconstructed as “spheres” in (c) and (i) respectively. Inserts in (c) show the total ZO-1 staining
(top) and nuclei staining (bottom) used to calculate relative amount of tight junction protein/choroidal epithelial cell.
Inserts in (f) show total IgG staining (top) and capillary staining (bottom) used to calculate relative amount of leaked
IgG/capillary mass. Inserts in (i) show the total number of leukocytes (top) and total capillary staining (bottom) used
to calculate relative number of leukocytes/ capillary surface area.
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FIGURE 4. ZO-1 distribution in the choroid plexus during evolving EAE. (A) Representative sections of the CP
were collected at the indicated time-points in control mice (CFA/PTX) or in mice following EAE induction
(MOG-CFA/PTX). Capillaries were immunostained for CD31 (red), and isosurface rendered in all images to
highlight the swelling of these microvessels during disease. Choroidal epithelial cells were stained with DRAQ5
(blue) to identify their nuclei and immunostained for ZO-1 (green). Insert highlights area of extensive crenulation
of ZO-1 immunostaining in mice at D15 EAE. (B) 3D quantification and analysis of the changes in total area of
ZO-1 per epithelial cell nuclei for both the groups: CFA/PTX and MOG-CFA/PTX. A significant increase in area
is seen in D9 and D15 EAE compared to naïve ZO-1 staining, *p<0.05, ***p <0.001
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FIGURE 5. CLN-2 distribution in the choroid plexus during evolving EAE. (A) Representative sections
of the CP were collected at the indicated time-points in control mice (CFA/PTX) or in mice following
EAE induction (MOG-CFA/PTX). Capillaries were immunostained for CD31 (red), and isosurface
rendered in all images to highlight the swelling of these microvessels during disease. Choroidal epithelial
cells were stained with DRAQ5 (blue) to highlight their nuclei and immunostained for CLN-2 (green).
White arrows show focal disruptions in CLN-2 staining by D15 EAE. (B) 3D quantification and analysis
of the changes in total area of CLN-2 per epithelial cell nuclei for both the groups: CFA/PTX and MOGCFA/PTX. A significant decrease in area corresponding to the loss in focal staining is seen in D9 and D15
EAE compared to naïve CLN-2 staining, **p<0.01, ***p<0.001. CFA/PTX group showed a significant
decrease in area by D15 as well, *p<0.05
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FIGURE 6. IgG distribution in the choroid plexus during evolving EAE. (A) Representative sections of the
CP were collected at the indicated time-points in control mice (CFA/PTX) or in mice following EAE induction
(MOG-CFA/PTX). Capillaries were immunostained for CD31 (red), and isosurface rendered in all images to
highlight the swelling of these microvessels during disease. Choroidal epithelial cells were stained with
DRAQ5 (blue) to highlight their nuclei, and IgG was immunostained (green). IgG can be seen extravasating
across the choroidal epithelium in mice increasing with extending timepoints in CFA/PTX and with increased
severity in MOG-CFA/PTX (white arrows, insert). (B) 3D quantification and analysis of the changes in total
IgG per total capillaries for both the groups: CFA/PTX and MOG-CFA/PTX. A significant increase in
extravasating IgG can be seen in D15 Control and, D9 and D15 EAE compared to naïve IgG staining, *p<0.05,
**p<0.01 and ***p<0.001
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FIGURE 7. Leukocyte extravasation in the choroid plexus during evolving EAE. Representative sections of the
CP were collected at the indicated time-points in control mice (CFA/PTX) or in mice following EAE induction
(MOG-CFA/PTX). Capillaries were immunostained for CD31 (red). Choroidal epithelial cells were
immunostained for cytokeratin (green). Leukocytes were immunostained for CD45 (blue), and isosurface rendered
in all images to highlight the 3D appearance of these cells and their spatial relation to the different compartments
of the choroid plexus. In control choroid plexus, the number of leukocytes appears to increase at D6 but returns to
near naïve level by D9 and D15. The leukocytes in these mice appear to remain associated with the capillaries or
stroma. In choroid plexus of mice with EAE, an increase in leukocytes is apparent at D6 and D9, which reverses to
naïve level by D15. Insert highlights leukocytes that can be seen associated with the apical surface of the
choroidal epithelium, likely extravasating into the CSF at D15 EAE. (b) 3D quantification and analysis of the
changes in total number of leukocytes per total surface area of capillaries for both the groups: CFA/PTX and
MOG-CFA/PTX. A significant increase in accumulation of leukocytes can be seen in D6 Control and, D6 and D9
EAE compared to naïve CD45 staining, *p<0.05, **p<0.01 and ***p<0.001.
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FIGURE 8. Schematic diagram of the Choroid Plexus. “Leaky” fenestrated capillaries (1) are surrounded by a
“tight” layer of epithelial cells (2) that express tight junctions (3), forming the BCSFB. The stroma (4) lies in
between the two layers. Loss of BCSFB integrity during neuroinflammation is associated with alteration of tight
junctions (3), leakage of serum protein IgG (5) and extravasation of leukocytes (6) across the BCSFB into the
CSF. Leukocyte extravasation is depicted as occurring paracellularly; i.e., between choroidal epithelial cells, as
it accompanies junctional disruption, though the precise mode has not been established.	
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Supplemental Fig. 1 Measurement of inter-nuclei distances between CP choroidal epithelial cells. (a)
Representative sections of the CP from naïve and MOG-CFA/PTX-treated mice at D15. Scale bars represent
5µm (naïve) and 10µm (MOG-CFA/PTX). Capillaries were immunostained for CD31 (red) and isosurface
rendered. Choroidal epithelial cells were stained with DRAQ5 (blue) to highlight nuclei, and immunostained
for ZO-1 (green). Inter-nuclei distances were calculated by placing a measurement point in the center of each
epithelial cell nucleus and measuring the distance between adjacent points, as highlighted in the inserts and
described in Materials and Methods. Note that the distance bars connecting the adjacent center points are in all
three planes; this, together with the different scales, makes some longer distance bars in the MOG-CFA/PTX
sample ‘appear’ artificially smaller than shorter distance bars in the naïve sample. (b) A significant increase in
inter-nuclei distances between CP epithelial cells was found in MOG-CFA/PTX-treated (EAE) mice compared
to naïve mice, *p<0.001.
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Supplemental Fig. 2 Measurement of the perimeter of ZO-1 staining in choroidal epithelial cells. (a)
Representative sections of the CP from naïve and MOG-CFA/PTX-treated mice at D15. Scale bars represent
5µm (naïve) and 10µm (MOG-CFA/PTX). Choroidal epithelial cells were immunostained for ZO-1 (green).
Measurement points were placed along epithelial ZO-1 staining to recreate the ZO-1 staining boundary as
described in Materials and Methods. The sum of the all the distances between adjacent points provided an
estimate of the perimeter of ZO-1 staining. (b) A significant increase in ZO-1 perimeter was found between
naïve and MOG-CFA/PTX-treated (EAE) mice, consistent with cellular enlargement, *p<0.001. (c) Schematic
showing effects of inflammation on choroidal epithelial cell TJ proteins, ZO-1 and CLN-2, in association with
disruption of the cytoskeleton (CSK). An increase in epithelial cell size is concomitant with visible distortion of
ZO-1, and fragmentation of CLN-2, immunostaining patterns.
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Supplemental Figure 3. ZO-2 and CLN-3 distribution in the choroid plexus during evolving EAE. (a)
Representative sections of the CP from naïve and MOG-CFA/PTX-treated mice at D15. Choroidal epithelial
cells were immunostained for ZO-1 (green) and epithelial nuclei were stained with DRAQ5 (blue). Insets
highlight the smooth TJ staining in naïve CP, which begins to rearrange into a crenulated pattern by D15. (b)
Choroidal epithelial cells were immunostained for CLN-3 (green) and epithelial nuclei were stained with
DRAQ5 (blue). Insets highlight the smooth TJ staining in naïve CP, which drastically decreases by D15.
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Chapter III: Spinal cord in evolving EAE
Spatiotemporal resolution of spinal meningeal and parenchymal inflammation
during experimental autoimmune encephalomyelitis
1. Abstract
Experimental Autoimmune Encephalomyelitis (EAE), animal model suggestive of
neuroinflammatory events similar to that of Multiple Sclerosis, has a very typical course of
disease. The inflammation is known to predominantly localize to the spinal cord with disease
pathology known to begin from the caudal most end of the cord, as indicated by the clinical
exacerbations following EAE induction in C57BL6 mice. EAE induced mice regress from
showing no clinical signs to partial limp tail followed by a paralyzed tail. The paralysis gradually
moves towards the hind limbs, followed by the forelimbs and finally to a moribund state at the
peak of the disease. However, how the patterns of inflammation propagate within and along the
length of the cord is relatively unknown. Lesser known still is the extent and pattern of
meningeal inflammation within the cord, which reportedly has been associated with the
pathology within the spinal cord parenchyma including axonal loss and increasingly recognized
co-relation to the clinical evolution of the disease. This report provides a detailed
immunohistochemical analysis of the patterns of inflammation including the waves of immune
cells along the cord throughout the course of the disease. Results indicate that meningeal
inflammation precedes parenchymal inflammation at all levels of the spinal cord, but does not
develop equally or simultaneously throughout the SAS, beginning at the caudal end and working
its way to the rostral extreme of the spinal cord. These differences in inflammation patterns
within the sections of the spinal cord was further illustrated by immune-LCM assisted selective
capture and immune gene profiling of the meningeal and parenchymal vessels within the cervical
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and lumbar sections of the spinal cord. Each of these segments, meningeal and parenchymal
vessels within the cervical and lumbar regions showed a varied pattern in expression of
significantly regulated immune genes along the course disease progression.

2. Introduction
As mentioned in earlier chapter II, multiple sclerosis (MS) and its surrogate animal model,
experimental autoimmune encephalomyelitis (EAE), are widely considered chronic, immunemediated, demyelinating diseases of the central nervous system CNS, with CD4+ T cells most
commonly accused of being the major suspects (1-5, 91, 92). Dysfunction of the blood-brain
barrier (BBB) - the specialized microvascular endothelium that normally restricts passage of
soluble and cellular elements between the CNS and circulation, and accompanying leukocyte
infiltration of the CNS parenchyma are noted hallmarks of both diseases (6, 7, 93). Such
leukocyte infiltrates in the CNS have long begged the question: How do the earliest myelinreactive T cells initially breach the formidable BBB of the uninflamed brain?
The “two-wave” model of neuroinflammation offers some possibilities (8, 9),
highlighting a previously unappreciated role for the choroid plexus (CP). A specialized outpocketing of the roofs of the third, fourth, and lateral ventricles, the CP is comprised of two
distinct tissue layers: a highly vascularized core of “leaky” fenestrated capillaries with resident
perivascular macrophages and dendritic cells entwined in a stromal matrix, encapsulated by a
“tight” layer of epithelial cells (94, 95). Because of this arrangement of apparently permeable
capillaries closely opposed to a relatively impermeable epithelium, CP is the designated part of
the blood-cerebrospinal fluid barrier (BCSFB)(23, 68). The CP has further long been recognized
as the major site of production of cerebrospinal fluid (CSF), within which it hangs suspended(19,
35). However, more recent studies have also identified this structure as the locale where pioneer
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T cells first gain a foothold in CNS territory (22, 27, 96). It is thought that following
extravasation across the CP capillaries and choroidal epithelium into the CSF, T cells are
gathered up by bulk CSF flow, and exit the fourth ventricle via the lateral foramina of Lushka
and medial foramen of Megendie. They then travel within the CSF stream to the subarachnoid
space (SAS) between the arachnoid and pial meningeal membranes covering the brain and spinal
cord. Once in the SAS, T cells can forge immune synapses with resident dendritic cells as part of
normal immune surveillance, thus concluding the “first wave” of neuroinflammation. The flare
of cytokines resulting from these T cell: dendritic cell interactions, in turn, activates endothelial
surfaces of nearby microvessels within the SAS, fostering adhesion and extravasation of
leukocytes circulating in the bloodstream. Subsequent interactions between these invading
leukocytes and other dendritic cells in the SAS and Virchow-Robbins space (with which the SAS
is continuous) are thought to follow, ultimately propagating a “second wave” of non-specific
leukocyte infiltration along the surface-penetrating microvessels that enter the CNS parenchyma.
In this manner, the two-wave model consists of a neuroinflammatory “impulse” that originates in
the SAS (first wave) and then is transmitted to the parenchyma (second wave).
  

While the animal model EAE has provided vast opportunity to gauge the significant role of

meningeal inflammation in MS and other neuroinflammatory conditions (97), it obliges still
other questions. Why does conventional EAE result primarily in spinal cord inflammation with a
trajectory of ascending paralysis(5, 98-100)? Does the most caudal region of the spinal cord
parenchyma display the first signs of inflammation? If so, is this because meningeal
inflammation begins first at the caudal region as well? Or, might it be that meningeal
inflammation is equally florid throughout the spinal cord from disease onset, but the
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neuroinflammatory impulse is first conducted to the caudal parenchyma from which it then
spreads rostrally?
  

To address these questions, studies were carried out to document when and where the first

signs of inflammation appear in both the meninges and parenchyma along the entire spinal axis.
Specifically, high-resolution 3-dimensional (3-D) confocal microscopy was performed to
visualize, in detail, the development of leukocyte infiltration at distinct regions of the spinal
cord. In addition, holistic examination of the entire spinal cord by “virtual slides” was also
conducted using fluorescence microscopy to reveal the direction and relative magnitude of the
propagation of inflammatory intensity along the length of the same spinal cord. To further
determine whether a difference in inflammatory gene expression by meningeal and parenchymal
microvessels along the spinal axis reflects the course of ascending paralysis in EAE, laser
capture microdissection (LCM) coupled with gene expression profiling was performed.
  

Results indicate that meningeal inflammation precedes parenchymal inflammation at all

levels of the spinal cord, but does not develop equally or simultaneously throughout the SAS.
Instead, meningeal inflammation is initially most obvious in the caudal SAS, from which it then
proceeds to the directly underlying parenchyma, paralleling the first signs of clinical disease in
the tail and hind limbs. Meningeal inflammation then extends in the caudal-to-rostral direction,
followed by a similar, but delayed, trajectory of parenchymal inflammation. LCM further
allowed selective profiling of immune genes within the meningeal and parenchymal vessels of
the different regions of the spinal cord in its extremes: cervical and lumbar spinal cord.

3. Materials and methods
3.1 Animals
Female C57BL/6 mice, age 8–10 weeks were obtained from Charles River Laboratories, Inc.
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(Wilmington, MA). A total of n = 3 animals/group were used for each treatment and time-point
assessed. All animal experimental procedures were performed following Animal Care and Use
Guidelines of the University of Connecticut Health Center (Animal Welfare Assurance # A347101), and approved under protocol # 100937-0917.
3.2 EAE induction
EAE

was

induced

in

mice

by

active

immunization

with

MOG35-55

peptide

(MEVGWYRSPFSRVVHLYRNGK), of murine origin (W. M. Keck Biotechnology Resource
Center, Yale University), as described [21], following Animal Care and Use Guidelines of the
University of Connecticut Health Center (Animal Welfare Assurance # A3471-01). Briefly, on
day 0 (D0), mice were injected subcutaneously with 300 µg of MOG peptide in complete
Freund’s adjuvant (DIFCO, BD , Sparks MD) into the right and left flank, 100 µl per site. On D0
and D2 mice were also injected intraperitoneally (i.p.) with 500 ng pertussis toxin (List
Laboratories, Campbell CA) in PBS. Another group of age-matched mice was left untreated
(referred to as “naïve” mice), and represented “normal” tissue. Mice typically showed
development of acute clinical symptoms at ~ D12, followed by ascending paralysis and chronic
disease (44). Animals were killed at D0 (naïve), D9 and D15 post-injection. Animals were
monitored daily for clinical disease severity and scored as follows: 0 = normal; 1 = tail limpness;
2 = limp tail and weakness of hind legs; 3 = limp tail and complete paralysis of hind legs; 4 =
limp tail, complete hind leg and partial front leg paralysis. The time-points selected for both
histological and gene expression a
3.3 Tissue preparation and sectioning for 3D imaging
Mice were anesthetized by i.p. injection of Ketamine (80 mg/kg) and Xylazine (10mg/kg) in
PBS. Animals were then transcardially perfused first with Heparin-PBS (10 usp/ml) to
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eliminate vascular blood content, and then with fixation buffer (2% paraformaldehyde in 0.1 M
phosphate buffer) as described previously [20]. Spinal columns were harvested and the
vertebrae removed via laminectomy (41). Spinal cords were then embedded in OCT
cryomatrix compound (Thermo Fisher Scientific, Waltham, MA) for cryosectioning.
Cryosections of 60µm thickness were obtained using a Microm HM 505M cryostat (Mikron
Instruments; Oakland, NJ) maintained at -25°C, and deposited onto poly-L-lysine-coated slides
for 3D confocal imaging.
3.4 Tissue preparation and sectioning whole spinal cord scan imaging
Spinal cords were harvested after identical perfusion fixation to that used for 3D imaging,
except that laminectomy was not performed. Instead, whole spinal cord with intact vertebrae
were embedded in OCT cryomatrix compound prior to sectioning. It was important to maintain
the vertebrae to preserve the integrity of the meninges lying underneath. Due to the brittleness of
the vertebrae, individual 7 µm-thick sections were captured on to an adhesive tape (Cryofilm
type IIC, Section-Lab, Japan) and rolled for a smooth, intact cut. Adhesive tape strips were then
glued (sections facing up) onto glass sides using an optical adhesive (Norland products,
Cranbury, NJ) under UV light for 10 min. The glass slides with the sections were then used for
whole spinal cord scan imaging.

3.5 Immunostaining and Image acquisition for 3D analysis and whole image scan
Sections (both for 3D analysis and whole image scans) were permeabilized with 1% Triton X100 in PBS for 30 min, and non-specific binding blocked by incubation with Power block® for
10 min in Ultrapure (GIBCO) distilled water (41). The spinal cord vessels were stained with rat
anti-mouse CD31 antibody (BD Pharmingen) at 1:160 dilution, followed by incubation with
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goat anti-rat Alexa Fluor® 555 antibody (Life Technologies) at 1:250 dilution. Epithelial cells
were stained with monoclonal pan-cytokeratin-FITC antibody (Sigma) at 1:160 dilution.
DRAQ5 (Biostatus Ltd., Leicestershire, UK) was used to stain nuclei at 1:1000 dilution. Alexa
Fluor® 647 anti-mouse CD45 (Biolegend) at 1:160 dilution was used to stain leukocytes.
Sections were mounted in Mowiol (Sigma-Aldrich). Confocal z-stacks (multi-track scan) were
acquired using a Zeiss LSM 510 Meta equipped with a Zeiss Fluar 40X/1.30, 63X Planneofluar/1.25 and 100X Plan-apochromatic/1.4 oil immersion objective lens. Thereafter, zstacks were imported into Bitplane Imaris® suite version 7.1 x64 software (Bitplane Inc., South
Windsor, CT), as described previously (41). Whole scan spinal cord images were acquired
using a Zeiss Axioscan.Z1 at 10X and images imported into Ziess microscope software Zen
(Thornwood, NY, USA) for analysis.
3.6 Tissue preparation and immunostaining for LCM
Immunohistochemistry-guided LCM was performed as recently detailed (42, 96). Naïve animals
were euthanized by CO2 inhalation. Spinal cords were immediately removed, cleaned off of extra
tissue and dissected into cervical (C1-C8) and lumbar (L1-L5) sections with the vertebrae intact.
The spinal cord segments were then snap-frozen in dry ice-cooled 2-methylbutane (Acros; Geel,
Belgium), and embedded in cryomatrix compound (Thermo Fisher Scientific, Waltham, MA) for
cryosectioning. Longitudinal sections (7µm) were cut on a Microm HM 505 M cryostat (Mikron
Instruments; Oakland, NJ) and affixed to uncoated, pre-cleaned glass slides (Fisher Scientific,
Pittsburgh, PA). The spinal cord vessels were stained using a substrate combination, nitro-blue
tetrazolium chloride/5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt (Vector Labs,
Burlingame, CA), to detect the endogenous alkaline phosphatase activity in endothelial cells.
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3.7 Laser Capture Microdissection (LCM) and cDNA synthesis
A PixCell IIe laser capture microscope (Life Technologies, Foster City, CA) was used to retrieve
the meningeal and parenchymal vessels. Obtained LCM tissue was solubilized in Cell Lysate
Buffer (Signosis; Sunnyvale, CA). Cell Lysate Buffer® extracts were treated with Turbo DNase
and inactivation reagent (Ambion; Austin, TX) according to the manufacturer’s instructions.
Samples were then reverse transcribed using the SuperScript III (Invitrogen) standard protocol
with random hexamers (Roche; Indianapolis, IN).

3.8 Pre-amplication of cDNA and qRT-PCR
Pre-amplification was carried out for array analysis out using TaqMan® PreAmp Master Mix
and a PreAmp Pool containing all the primers for detection by the Mouse Immune Panel
TaqMan® Low density Array (TLDA; Life Technologies Corp., Foster City, CA) as previously
described (42). This panel contains 93 immune-related genes plus three housekeeping control
genes. Pre-amplification was carried out with an initial hold at 95°C for 10 min, followed by 14
cycles at 95°C for 15 sec and 60°C for 4 min. Relative cDNA levels were quantified by qRTPCR using an an ABI 7900HT Fast Real-Time PCR System (Life Technologies Corp, and
normalized to housekeeping gene GAPDH as described previously (34). Expression of genes
relative to GAPDH was then represented as percent expression of GAPDH. Custom TaqManW
primers/probes were used for the Mouse Immune Panel TLDA.
3.9 Statistical Analysis
All statistical analyses were performed using GraphPad Prism 5 (GraphPad, La Jolla, CA). For
all sets of comparisons (meningeal vs parenchymal vessels in cervical and lumbar regions, and
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cervical vs lumbar regions within meniges and parenchyma) individual genes from the two sets
being compared were first subjected to Shapiro-Wilk normality test. Genes that passes the
normality test were then compared for significance using paired, 2-tailed T-test, or MannWhitney U test was used for genes that did not pass the normality test. Results were considered
significant at P≤0.05.

4. Results
4.1 Regional sections of spinal cord show varying levels of leukocyte infiltration during
EAE
Fig. 9a highlights the extent of leukocytes in the respective meningeal and parenchymal
compartments of the spinal cord during EAE, as revealed by CD45 staining, is dependent on
time and segmental level. At D6, several days before clinical disease is typically manifest, CD45
staining is barely detectable in the meninges of the cervical spinal cord, and undetectable within
the parenchyma at this time. Similarly, meningeal and parenchymal leukocyte infiltration of the
lumbar spinal cord is sparse as well. Just prior to commencement of clinical disease at D9, the
cervical spinal cord reveals limited leukocyte infiltration of the meninges but as yet no readily
discernible leukocytes in the parenchyma. The lumbar spinal cord also demonstrates scant
leukocytes in both the meninges and parenchyma at this time. By day 15, during the acute phase
of clinical EAE disease, the cervical spinal cord displays extensive meningeal leukocytes, while
the underlying parenchyma just shows signs of incipient leukocyte infiltration. Meningeal
leukocyte infiltration within the lumbar cord is even more florid at this time, and appearance of
leukocytes in the parenchyma, while apparently less than that of the overlying meninges, is still
vast and far more pervasive than that seen at the cervical level. Fig. 9b confirms the differential
extent of leukocyte infiltration in the meningeal and parenchymal compartments at the cervical
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and lumbar levels of the spinal cord at D15. Nuclear staining shows there is much denser
perivascular cellularity in the lumbar versus cervical meninges, as well as in the lumbar
parenchyma compared to the cervical parenchyma. Additionally, perivascular cellularity is
greater in the meninges versus the parenchyma at both levels of the spinal cord. The differential
cellularity within the respective meningeal and parenchymal compartments at the cervical and
lumbar levels of the spinal cord during the progression of EAE is depicted in Suppl. Fig. 4.

4.2 Whole spinal cord image scans reveal an ascending wave of leukocyte infiltration
To acquire better appreciation of the segmental distribution of leukocytes along a single spinal
cord at different time-points of EAE, whole spinal cords with intact vertebrae and preserved
underlying meninges were analyzed. Fig. 10 shows the immunostaining patterns of several
marker proteins in the spinal cord of a naïve mouse, as a reference. Notably, CD45 staining is
restricted to the vertebral column, most likely representing leukocytes of the spinal marrow
(Kenyon et al., 1997). Absent from the naïve cord is any clear leukocyte infiltration of the spinal
meninges or parenchyma. The method of sectioning and attachment of a longitudinal section of
whole spinal cord to adhesive film is depicted in Suppl. Fig. 5. Leukocyte distribution patterns
along the entirety of spinal cords from animals at the acute (D15) and chronic (D23) stages of
EAE are seen in Fig. 11a.

At D15, CD45 staining is apparent in the lateral meninges of the

lumbar and thoracic levels of the cord, and in the dorso-medial sulcus where the penetrating
meninges bisect the spinal parenchyma into the dorsal white matter columns and grey matter
horns. Some CD45 staining of the lumbar parenchyma is also seen at this time. By D23, a wave
of CD45 staining appears to proceed up the cord and is concentrated at the thoracic level in and
around the dorso-medial sulcus. This wave appears more obvious in the intensity charts shown in
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Fig. 11b. In the spinal cord of a naïve mouse CD45 staining is confined to the vertebral column –
likely reflecting hematopoietic activity of spinal bone marrow (Shah and Hanrahan, 2011) – with
no discernible signs of leukocyte infiltration into spinal tissue. At D15 EAE, leukocyte
infiltration is overt in the meninges (including the dorso-medial sulcus) of the lumbar region with
comparatively sparse CD45 staining seen in the upper levels of the cord. By D23, intensity of
CD45 staining of the lateral meninges of the lumbar region is even more florid and manifest
diffusely in the parenchyma as well. Severely heightened staining in the dorso-medial sulcus at
the thoracic level is also observed at this later stage. The clear distinction in degree of cellularity
in the spinal meninges versus parenchyma, and between cervical and lumbar levels, is seen at
higher magnification in Fig. 12, along with what appears to be meningeal leukocyte clusters at
D15. Fig. 13 shows the disparity in regional parenchymal cellularity becomes even more
pronounced by D23, as the most caudal spinal cord becomes suffused with nuclear and CD45
staining, while increased cellularity in the meninges has progressed to the cervical level.

4.3 Varying patterns in immune profiling of meningeal and parenchymal vessels of the
cervical and lumbar spinal cord.
Further analysis of differences between the cervical and lumbar regions of the spinal cord within
the meningeal and parenchymal vessels was done using LCM. Site-specific isolation of these
vessels coupled with TLDA arrays allowed probing of immune genes including adhesion
molecules, cytokines, chemokines, statins, interleukins, T cell activation markers, co-stimulatory
molecules, transcription factors and apoptotic markers. As the disease progressed from a naïve
state to clinical acute EAE at D15, varying patterns of immune gene expressions was seen. Proinflammatory gene expression in the naïve spinal cord was very minimal and not significantly
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different in between either the meningeal and parenchymal sections or cervical and lumbar
regions of the spinal cord. Fig. 14 highlights the genes that were significantly different in these
regions in D9 of evolving EAE. Comparisons were made between two distinct sets. 1. Meningeal
versus parenchymal vessels separately within first, the cervical region followed by the lumbar
region (Fig. 14a-b): Fig 14a depicts cervical region has significant differences in expression of
Ptgs2, CCR2, STAT1, VEGFa, Col4a5, Cd68 and Ski 2 between the meningeal and parenchymal
vessels. In Fig 14b lumbar region shows significant differences in Ski, STAT1. VEGFa, STAT3,
Socs2, Ece1, Edn1, Bax between the meningeal and parenchymal vessels. 2. Cervical versus
lumbar regions separately within the meninges and then the parenchyma (Fig. 14c-d): Fig 14c
highlights significant differences between the meninges of cervical and lumbar regions observed
for Socs2, Ski, CCR2, IL18, STAT1, VEGFa, Bax, CD8a, Csf1, H2-Ea. Fig 14d shows that
cervical and lumbar regions have significant differences in CD28, Cxcr3, CD3e, Bcl2, Il2ra,
CCR2 and Col4a5. Similarly, the same set of comparisons was carried out for D15 EAE spinal
cord in Fig. 15(a-d). Fig. 15a shows the differences between meningeal and parenchymal vessels
in the cervical region in CD38, CD86, Socs2, TGFβ1, STAT1, CD68, Il18 and Gzmb while
lumbar region shows differences in VEGFa, VCAM1, Csf1, Ikbkb, Ski, Stat3, CCL2, Edn1 and
CCR2 as depicted in Fig 15b. As shown in Fig 15c, meninges between the cervical and lumbar
regions differed significantly in expression of Socs2, CD80, Stat1 and CD38 while meninges in
the parenchyma showed significant differences in NOS2, Nfkb2,Tgfb1, Smad3, VCAM1, Ptprc,
STAT3, Col4a5 and Cxcl1 as shown in Fig. 15d.
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5. Discussion
Results from this study reinforce and advance awareness that the meninges are sites of
significant immune activity and feature prominently in the development of neuroinflammation in
MS (101) and its animal model, EAE(10, 13, 102, 103). Specifically, our findings provide new
histological evidence of a progressive, spinal meningeal inflammation that proceeds in the
caudal-to-rostral direction during development of EAE. A similar trajectory of parenchymal
inflammation was also observed, but delayed compared to that of the meninges at all levels of
the spinal cord. This scenario is consistent with inflammation being propagated from meninges
to parenchyma (8, 9). The possibility remains, however, that once parenchymal inflammation
takes hold in the caudal spinal cord, it can then spread rostrally through both parenchymal and
meningeal channels.
Whole spinal cord intensity scans most clearly exposed what appears to be an ascending
pulsatile wave of leukocyte infiltration in both the meningeal and parenchymal compartments of
the spinal cord during EAE progression. While particular sensitivity of the lumbar (L5) region
of the spinal cord to autoimmune inflammation has been resolved by ultrahigh-field MRI (104)
and reported to be mediated by regional neural stimulation (105, 106), this is the first report we
are aware of that documents preferred sites of meningeal involvement during evolving EAE.
Moreover, whole spinal cord intensity charts reflect a conspicuous ascending wave of leukocyte
infiltration in the meninges, which precedes an underlying parenchymal infiltration that advances
in the same direction during EAE progression. The order of these similar, advancing patterns of
meningeal inflammation and parenchymal inflammation is consistent with the interpretation that
the former helps drive the latter.
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Immune gene profiling of selectively isolated meningeal and parenchymal vessels by
immune LCM further correlated the differences in the inflammatory gene patterns between the
sections of the spinal cord. The distinctly different set of genes expressed by the meningeal
vessels in the lumbar versus the cervical region, depict the possible variations in immune
regulation depending on the level of the spinal cord. As evidenced by the individual regional
spinal cord and whole scan images, accumulation of CD45 positive cells were first visible within
the meninges of the lumbar spinal cord by D15, and minimally present during D9. This could
correlate with the majority of significantly different genes (Socs2, Ski, CCR2, IL18, Stat1,
Vegfa, Bax and Csf1) highly expressed in the meninges of the lumbar region when compared to
the cervical region during D9 (Fig 14c). Although immune cell accumulations are not very
evident during D9, the differential expression could provide factors increasing the susceptibility
of this region to be inflamed first at a later stage in D15. Comparisons also show that meningeal
vessels have significantly higher expressed genes-Ski, Stat1, VEGFa, Stat3, Socs2 and Bax than
parenchymal vessels at this time point. This could point toward genes such as VEGFa, STAT1
and Ski possibly aiding in the earliest inflammation first noted within the meninges of the lumbar
spinal cord evidenced by clusters of CD45. Parenchymal vessel inflammation is minimal at this
point as evidenced by the spinal cord images. Differential set of genes is significantly expressed
during this time in the parenchymal vessels of the lumbar region versus cervical region and in
comparison with the meningeal vessels of both within the cervical and lumbar regions. CCR2
seems to be highly expressed in the parenchymal vessels of the cervical region, more so that the
meningeal expression.
Figures 9, 11 and 12 show the florid meningeal inflammation all along the cord including
immune cell accumulations seen infiltrating into the sub-pial parenchyma within the lumbar
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region. Immune profiling of D15 EAE meningeal and parenchymal vessels highlights gene
differences that co-relate with this pattern of inflammation as shown in Fig. 15. Only a limited
number of genes, minimally expressed (Socs2, CD80, Stat1, CD38) are significantly higher in
the meninges of the lumbar regions compared to the cervical region. Whereas, the parenchyma
demonstrates significant differences between the cervical and lumbar regions, with STAT3,
Ptprc, Nos2, Nfkb2, Tgfb1 and Smad3 highly expressed in the lumbar region. Also to be noted,
is the entirely different set of genes expressed by the parenchymal vessels within the cervical and
lumbar regions that prove that each region is unique in its expression of immune genes.
Interestingly, both CCL2 and CCR2 are significantly higher in the meningeal vessels of the
lumbar region at D15, relating to the evidenced immuno-modulatory effects of CCL2 (44, 107,
108). These results point towards the possibility that each region of the spinal cord is unique in
its immune gene expression pattern, which could be the result of its location and differential
regulation.
Once the immune cells enter the SAS and are triggered to release inflammatory
cytokines, by nature of the anatomy of meningeal vessels lying within the CSF filled SAS (109),
inflammation within these vessels could be swift and rampant as reported by Kivisakk et al. by
detection of meningeal T cell infiltration through out the CNS(11). Parenchymal vascular
inflammation of the underlying white matter tracks that succeeds SAS inflammation however,
could be subject to segmental vulnerability. Intimate and convoluted arrangement of meninges
within the cauda equina (hair-like endings of the lumbar spinal cord) could uniquely allow
inflammatory signals to be readily relayed from SAS meningeal vessels to parenchymal vessels
in the lumbar segment. In support, reports by Arima et al. show that autoreactive T cells access
the CNS parenchyma via the fifth lumbar spinal cord, this region being defined by an
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upregulated CCL20, CCL2 and IL6 (105), important players in inflammation in EAE. Hence, the
parenchymal vessels in the lumbar region compared to cervical region showed

different

immune profile with earlier signs of inflammation by up-regulating their immune profile. We
noticed heightened immune response within the meningeal compared to parenchymal vessels
during earlier stages (D9), followed by inflammation in the parenchymal vessels in the later
stages (D15) beginning from the lumbar segment.
In summary, results obtained from imaging and further validated by immune profiling of
meningeal and parenchymal vessels from cervical and lumbar regions give a sense of directed
progression of immune cells accumulation and inflammation during evolving neuroinflammation
summarized in a schematic (Fig. 18). The sequence of events in developing EAE begin with
CD45 cells accumulating within the CP and crossing through the BCSFB into the CSF flowing
within the SAS (96) typically around D6 to D9 with the clinical score ranges from 0-0.5. This is
followed by the accumulation of infiltrating immune cells seen within the meninges, more
distinct within the lumbar region due to these cells penetrating the pial membrane and
accumulating within the parenchyma as well, typically evidenced around D15, where EAE
induced animals display a clinical score ranging from 0.5-2. By D23, the animals display
symptoms of peak disease with a score from 2-3 with increased accumulations of infiltrating
immune cells seen within the cervical meninges and added infiltration into the underlying
parenchyma. Results from this report highlight the role of meningeal inflammation in initiating
the disease course leading to propagation of disease pathology. Reports have shown similar
instances that support the idea that the meninges are a gateway for immune cell access into the
CNS corresponding with clinical exacerbations in EAE (102). This brings into light the
importance of therapies possibly targeted directly to the meninges that might prove more
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effective with controlling disease progression. Drug delivered regionally within the meninges of
a section of the spinal cord, would be able to modulate the disease and contain the inflammation
before it propagates to other regions of the spinal cord. In addition, meningeal targeted therapies
would allow drug delivery without the Blood Brain Barrier (BBB) permeability concerns or the
need for a systemic immunosuppression as seen with the current FDA approved drugs for MS
treatment, hence allowing for novel therapeutic interventions.
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Figure 9: Spinal cord regions (cervical and lumbar) showing leukocyte extravasation within the meninges and
parenchyma during evolving experimental autoimmune encephalomyelitis (EAE). (a) Representative sections of
spinal cord regions were collected at days 6, 9, 15 (D6, D9, D15) from mice affter EAE induction. Vessels are
immunostained for CD31 (red) and isosurface rendered to highlight the meningeal vessels penetrating into the
parenchyma; leukocytes are immunostained for CD45 (blue) and CytoK (green) was used to immunostain for any cells of
epithelial nature. White arrows in D15 cervical spinal cord meninges show the cytokeratin positive CD45 cells
accumulated within the meninges and infiltrating into the parenchyma across the pial membrane. (b) Cervical and lumbar
regions showing meningeal and parenchymal cellularity collected on D15 at 20x magnification with nuclei stained for
DRAQ5 highlighting differences in cellularity between cervical and lumbar sections. White arrowheads show increase in
cell accumulations
around deeper parenchymal vessels.
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Figure 10: Whole spinal cord image scans in different channels. Representative sections of whole spinal
cords collected on day 0 (Naïve) mice are shown. DIC shows the differential interphase contrast, CytoK was
used to immunostain for epithelial cells, CD45 for leukocytes, DAPI for cellularity, CD31 for vessels and
Merge for all the channels together. Same pattern of scans was carried for the timepoints in the study-D9,D15
and D23.

	
  

	
  

	
  

56	
  

	
  

	
  

	
  

	
  
Figure 11: Changes in leukocyte distribution patterns within the meninges and parenchyma along the
spinal cord during evolving experimental autoimmune encephalomyelitis (EAE). (a) Representative
sections of whole spinal cords were collected on day 0 (Naïve) 15 and 23 (D15 and D23) from mice after EAE
induction. Sections were immunostained for CD45 to highlight the distribution patterns during developing
stages of disease. (b) Quantitative distribution of CD45 shown in intensity plots.
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Figure 12: Whole spinal cord showing leukocyte extravasation within the meninges during D15 EAE.
(a)Representative section of spinal cord collected on day 15 (D15) showing CD45 +ve leukocyte infiltration
within the meninges along the entire spinal cord during evolving EAE. (b)and (c) Insets from the cervical and
lumbar regions of the spinal cord showing CD45 cells within the meninges and parenchyma highlighted with
brackets. White arrowhead in (b) showing a meningeal vessel and in (c) showing clusters of CD45 cells
accumulating within the meninges of the lumbar spinal cord.
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Figure 13: Whole spinal cord showing leukocyte extravasation within the meninges during D23 EAE.
(a)Representative section of spinal cord collected on day 23 (D23) showing CD45 +ve leukocyte infiltration
within the meninges and parenchyma along the entire spinal cord during evolving EAE. (b)and (c) Insets from
the cervical and lumbar regions of the spinal cord showing CD45 cells within the meninges and parenchyma.
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Figure 14: Differential expression of immune genes within spinal cord regions during D9 EAE. (a),
(b)Comparison between meningeal and parenchymal vessels within the Cervical and Lumbar regions in their
immune gene expression profile during D9 of evolving EAE. (c), (d) Comparison between Cervical and Lumbar
regions within meningeal and parenchymal vessels in their immune gene expression profile.
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Figure 15: Differential expression of immune genes within spinal cord regions during D9 EAE. (a),
(b)Comparison between meningeal and parenchymal vessels within the Cervical and Lumbar regions in their
immune gene expression profile during D15 of evolving EAE. (c), (d) Comparison between Cervical and
Lumbar regions within meningeal and parenchymal vessels in their immune gene expression profile.
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Figure 16: Schematic showing the directed progression of inflammation during evolving neuroinflammation
in EAE. Inflammation begins with the accumulation of leukocytes in the Choroid Plexus, followed by entry into
the CSF and regional accumulation within different regions of the spinal cord. Immune cells are first seen within
the meningeal spaces of the subarachnoid space then with the progression of the disease, into the parenchymal
spaces. The events in disease progression from D6 through D23 have been shown in correlation with
corresponding scores in the table within the schematic.
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Supplemental figure 4: Spinal cord regions (cervical and lumbar) showing cellularity within the meninges
and parenchyma during evolving experimental autoimmune encephalomyelitis (EAE). (a)Representative
sections of spinal cord regions were collected on days 6, 9, 15 (D6,D9,D15) from mice affter EAE induction
with myelin oligodendrocyte glycoprotein(MOG) at 63X magnification. Vessels are immunostained for
CD31(red) and isosurface rendered to highlight the meningeal vessels penetrating into the parenchyma and
DRAQ5 (blue) stains for cell nuclei.
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Supplemental figure 5. Spinal cord sectioning for whole spinal cord image scans. (a)Whole spinal columns
were embedded in OCT and sectioned to expose the spinal cord. (b)An adhesive tape was then applied on top of
the section and rolled in place. (c) Adhesive tape post sectioning containing the entire spinal cord with
surrounding vertebrae remaining intact.
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Supplemental figure 6. Inflammation within the lumbar spinal cord region during D15 EAE. (a) Representative
section of lumbar spinal cord collected on day 15 (D15) showing CD45 +ve leukocyte infiltration within the
meninges evolving EAE. Insets (b)-(e), from left to right, focus on regional CD45 clusters. (b) and (e) showing
the spinal fissure being populated with CD45 cells. (e) Green arrowheads show meningeal vessels within the
fissure and red arrowheads show parenchymal vessels being inundated with infiltrating leukocytes. (c) and (d)
show meningeal accumulations of CD45 cells during disease.
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Supplemental figure 7. Inflammation within the lumbar spinal cord region during D23 EAE. (a) Representative
section of lumbar spinal cord collected on day 23 (D23) showing CD45 +ve leukocyte infiltration within the
meninges evolving EAE. Insets (b)-(d), from left to right, focus on regional CD45 clusters. (b) and (e) showing
the spinal fissure being populated with CD45 cells. (e) Green arrowheads show meningeal vessels within the
fissure and red arrowheads show parenchymal vessels being inundated with infiltrating leukocytes. (c) and (d)
show meningeal accumulations of CD45 cells during disease.
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Chapter IV: CCL2 sources in evolving EAE
Resolution of central nervous system astrocytic and endothelial sources of
CCL2 gene expression during evolving neuroinflammation
1. Abstract
The chemokine CCL2 is a critical mediator of neuroinflammation in diseases such as
multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis
(EAE). CCL2 drives mononuclear cell infiltration into the central nervous system (CNS), alters
expression and distribution of microvascular endothelial tight junction proteins, and disrupts the
blood-brain and blood-spinal cord barriers. Immunohistochemistry has consistently revealed
astrocytes to be a source of this chemokine during neuroinflammation, while providing less
uniform evidence that CNS endothelial cells may express CCL2 as well. Moreover, the relative
contributions of these cell types to the CNS pool of CCL2 during MS/EAE are unclear and
require further investigation. CCL2 gene expression was determined by qRT-PCR in different
populations of CNS cells at different times following EAE induced by immunization with
MOG35-55 peptide and adjuvants, or after injection with adjuvants alone. CNS cells types were
isolated by two different protocols: bulk isolation to yield crude microvascular and parenchymal
fractions (containing astrocytes, other glia, and neurons), or laser capture microdissection (LCM)
to more precisely acquire microvascular endothelial cells, astrocytes or other parenchymal cells.
Both CNS microvessel and parenchymal populations isolated by crude bulk isolation showed upregulation of CCL2 mRNA following MOG immunization or injection of adjuvants alone. More
exact dissection by LCM revealed microvascular endothelial cells and astrocytes to be the
specific sources of CCL2 gene induction following MOG immunization, while only astrocytes
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showed elevated CCL2 mRNA in response to just adjuvants. Astrocytes displayed the greatest
degree of stimulation of CCL2 gene expression following EAE induction. High precision LCM
affirmed both microvascular endothelial cells and astrocytes as the major CNS sources of CCL2
gene expression during EAE.

Given the high accessibility of the CNS microvascular

endothelium, endothelial-derived CCL2 could prove a viable target for therapeutic intervention
in neuroinflammatory disease.

4. Background
Numerous human and animal studies have highlighted the chemokine CCL2 (formerly known as
MCP-1 (110)) as a critical mediator of the neuroinflammatory disease multiple sclerosis (MS)
and its animal model experimental autoimmune encephalomyelitis (EAE)(2, 4, 8). While long
recognized for its chemotactic properties in guiding leukocyte migration, CCL2 has also been
shown to destabilize tight junctions of microvascular endothelial cells that comprise the bloodbrain and blood-spinal cord barriers (71, 111-113). This multifunctional status underscores
CCL2’s value as a potential therapeutic target. However, for therapeutic measures to be most
effective the sources of CCL2 in the central nervous system (CNS) have to be defined and the
timing of CCL2 expression during neuroinflammation elaborated. While astrocytes are widely
recognized in reviews as a major CNS source of CCL2 during MS and EAE, BMEC have
received only limited acknowledgement as expressing this chemokine (108, 114, 115). The
scarce recognition of BMEC as a critical CCL2 source in situ may in part stem from the routine
use of conventional immunohistochemistry to confirm expression, as this technique may not be
sufficiently sensitive to reliably detect perhaps smaller, vesicular quanta of endothelial CCL2
(116). The use of adjuvants to induce EAE, e.g., Complete Freund’s Adjuvant (CFA) and
pertussis toxin (PTX), can affect CCL2 expression in some endothelial cell types (42, 117), and
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might further contribute to ambiguity of BMEC-derived CCL2 during neuroinflammatory
disease. Previous reports have not examined the adjuvant issue. The status of BMEC CCL2 gene
expression in neuroinflammation thus remains equivocal.
Herein, we report use of two highly sensitive, qRT-PCR-based approaches to clarify the
relative contributions of the parenchymal and vascular compartments to CNS CCL2 gene
expression during evolution of EAE induced by immunization with myelin oligodendrocyte
glycoprotein (MOG) peptide35-55 along with adjuvants. One approach used a crude separation of
CNS parenchymal and microvessel fractions, based on a common preparative method from
homogenized CNS tissue. The other employed the laser capture microdissection (LCM), to more
precisely retrieve separate BMEC, astrocyte and other parenchymal cell types. Additionally, we
assessed CCL2 expression levels following MOG immunization as well as after injection of
these adjuvants alone, to highlight the effects due to MOG immunoreactivity.

3. Material and Methods
3.1 Animals
Female C57BL/6 mice, age 8–10 weeks were obtained from Charles River Laboratories, Inc.
(Wilmington, MA) and were euthanized by CO2 inhalation, following Animal Care and Use
Guidelines of the University of Connecticut Health Center (Animal Welfare Assurance # A347101). All the experimental procedures conducted have been approved under the protocol #1003461214.
3.2 EAE induction
Mice were immunized with MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; W. M. Keck
Biotechnology Resource Center, Yale University) as detailed previously (42). Briefly, on day 0
(D0), female mice 7-9 weeks of age were injected subcutaneously with 300 µg of MOG peptide

	
  

69	
  

in Complete Freund’s adjuvant (CFA) (DIFCO, Detroit, MI, USA) containing 1mg/ml
Mycobacterium tuberculosis. Mice were also injected intraperitoneally with 200 ng pertussis
toxin (List Laboratories, Campbell CA, USA) in phosphate buffered saline (PBS) on D0 and D2
following MOG immunization. Mean clinical scores were calculated from animals monitored for
clinical disease severity and scored as 0 =normal; 1 = tail limpness; 2 = limp tail and weak- ness
of hind legs; 3=limp tail and complete paralysis of hind legs; 4 = limp tail, complete hind leg and
partial front leg paralysis; and 5 = death. The time-points selected for analysis, D9, D15 and
D23, represent early EAE (score 0-0.5), acute EAE (score 2-2.5) and chronic EAE (score 2.53.5), respectively.
3.3 Bulk isolation of parenchymal and microvessel fractions
Bulk isolations were prepared from each naïve, control and EAE group at all the time-points
assessed. Separate parenchymal and microvessel fractions were obtained in bulk from freshly
dissected brain and spinal cord using a modification of previously described methods (118).
After removal of meninges and large blood vessels, ½ of the brain and spinal cord tissue was
homogenized in ice cold PBS using a 7 mL Dounce tissue grinder (Kimble/Kontes,Vineland, NJ,
USA). Brain and spinal cord tissue were combined for bulk isolation of parenchymal and
microvessel fractions, in keeping with other reports detailing CNS CCL2 expression during EAE
(119-121). The remaining spinal cord tissue was snap-frozen in dry ice-cooled 2-methylbutane
(Acros; Geel, Belgium), and stored at 80°C until used for LCM.

The homogenate was

centrifuged at 400 x g for 15 min, and the resulting pellet resuspended in 18% (w/v) dextran
(mwr 60,000 – 90,000) and centrifuged at 4,500x g for 10 min to sediment the crude
“microvessel” fraction. The dextran supernatant and floating layer of myelinated axons were
collected together to generate the crude “parenchymal” fraction and diluted in PBS; microvessels
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were resuspended in PBS and both fractions were washed twice by sedimentation at 720 x g for
10 min and rinsing in PBS. Microvessels were washed of blood cells by filtering through a 40
µm cell strainer (Becton Dickinson Labware, Franklin Lakes, IN, USA) and eluting with PBS.
This procedure eliminated a significant fraction of the smaller capillaries, which passed through
in the filtrate, while retaining the vast portion of larger venules on the filter (122). The filterbound-microvessels were then solubilized with lysis buffer from the RNeasy Mini kit (QIAGEN,
Valencia, CA).
3.4 Laser Capture Microdissection (LCM) of parenchyma, astrocytes and BMEC
Frozen spinal cords were embedded in cryomatrix compound (Thermo Fisher Scientific,
Waltham, MA), and 7µm-thick frozen sections obtained. Immunohistochemstry-guided LCM
was performed using a PixCell IIe laser capture microscope (Life Technologies Inc., Foster City,
CA), as previously described by this laboratory (123). Significantly, this LCM approach has
been shown to yield highly purified populations of microvascular endothelial cells and
astrocytes, respectively. Tissue was captured from within the dorsolateral columns along the
entire length of the spinal cord, as pathology in this EAE model proceeds up the CNS axis in a
caudal-to-rostral direction (124), with lesions prominent in the spinal white matter. Briefly, antiCD31 was used to label endothelial cells, along with alkaline phosphatase detection employing
NBT-BCIP as chromogenic substrate. The endothelial cells of venules (10 – 50 µm in diameter)
were specifically acquired (33) as these microvascular tributaries are the preferred sites of
leukocyte extravasation (125), and were thus reasoned to express the highest CCL2 expression.
This further allowed for a more equitable comparison with the bulk-isolated microvessels, which
were enriched in venules. Anti-GFAP immunofluorescence was carried out to identify astrocytes
in the same tissue sections. Areas of “other” parenchymal cells selected for LCM were those
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that did not stain with CD31 or GFAP, and thus contained neurons, oligodendrocytes and/or
microglia. LCM tissue was solubilized in Cell Lysis Buffer® (Signosis; Sunnyvale, CA).
3.5 RNA isolation, cDNA synthesis and qRT-PCR
Total RNA was isolated from bulk microvessel and parenchymal fractions using the RNeasy
Mini kit (QIAGEN), and treated with Turbo DNAse (Ambion, Austin, TX, USA). cDNA was
generated using SuperScript III (Invitrogen, Carlsbad, CA, USA) and relative CCL2 RNA level
determined by qRT-PCR using SYBR green (AB Applied Biosystems, Foster City, CA, USA) as
described previously (44). LCM tissue was subjected to DNAse treatment using Turbo DNAse
followed by reverse transcription, using SuperScript III. LCM-derived cDNA was then preamplified using TaqMan PreAmp Master Mix and a PreAmp Pool containing all primers for
detection by the Mouse Immune Panel TaqMan Low density Array (TLDA; Life Technologies
Corp., Foster City, CA) and probed for CCL2 by qRT-PCR using a single-plex gene expression
assay (42). An ABI 7900HT Fast Real-Time PCR System (Life Technologies Corp.) was used to
detect amplicon amount for both bulk and LCM preparations. RPL-19 was used as a reference
for relative CCL2 gene expression for bulk isolation as detailed previously (44) and GAPDH for
LCM preparation (42), both genes having been shown to be largely invariant during EAE.
Relative quantitation was performed using the 2-[Δ][Δ]Ct method of Fleige et al (126). Results
were analyzed using a one-way non-parametric Kruskal-Wallis test followed by Dunn’s post-test
analysis using GraphPad Prism 5 (GraphPad, La Jolla, CA). Results were considered significant
at P≤0.05.

4. Results and Discussion
CCL2 expression levels were first evaluated in separate parenchymal and microvessel fractions
prepared by bulk isolation from brain and spinal cord tissue of either MOG-CFA/PTX-treated
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(EAE) or CFA/PTX-treated (Control) mice. Analysis was performed at different days after initial
injection, which represented onset (D9), peak (D16) and chronic (D23) phases of clinical EAE
disease (Fig. 18). As determined by qRT-PCR, relative expression of CCL2 by microvessels was
significantly higher in both treatment groups (CFA/PTX and MOG-CFA/PTX) compared to
naïve animals at D9 and D16, with a return to naïve level by D23 (Fig.18A, C). The parenchymal
fraction showed a similar trend of significantly increased CCL2 expression in both treatment
groups compared to naïve animals at D9 and D16 (Fig. 18B, D).
Next, we performed a time-course analysis with CNS tissue that was more precisely
dissected into endothelial cells (CD31), astrocytes (GFAP) and “other” parenchymal cells
(selected areas devoid of CD31 and GFAP immunostaining) by LCM. As was the case with bulk
preparation of microvessels, endothelial cells showed elevated CCL2 expression in MOGCFA/PTX-treated mice at D16 compared to naïve mice (Fig. 19D). However, corresponding
endothelial samples from CFA/PTX-treated mice did not show a similar increase (Fig. 19A).
Astrocytes exhibited significantly elevated CCL2 expression at both D9 and D16 in the MOGCFA/PTX-treated group (Fig. 19E), and a significant increase at D9 in the CFA/PTX-treated
cohort (Fig. 19B). In contrast to that observed with the bulk parenchymal preparations, other
parenchymal cells isolated by LCM failed to display an increase in CCL2 expression either in
MOG-CFA/PTX-treated (Fig. 19F) or CFA/PTX-treated (Fig. 19C) mice compared to naïve
mice at any time-point.
These findings underscore several points. Expression of CCL2 is significantly induced in
both astrocyte and endothelial cell populations in the MOG-induced EAE paradigm. The fact that
CCL2 mRNA level appeared higher in endothelial cells than in astrocytes in naïve mice may
reflect the capture of some circulating leukocytes along with endothelial cells, as the mice were
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not perfused prior to LCM. Interestingly, while CFA/PTX injection resulted in elevated CCL2
expression in isolated microvessels, it did not do so in LCM-acquired endothelial cells. This
suggests that sources other than endothelial cells contributed to the altered CCL2 mRNA level in
the bulk microvessel fraction. As astrocytes lie in close proximity to endothelial cells within the
neurovascular unit (NVU) (127, 128) and can contaminate microvessel preparations (129, 130),
a priori these particular glial cells may be a significant source of CCL2 mRNA detected in bulkisolated microvessels. This caveat reinforces LCM as a critical technology to more effectively
resolve sources of gene expression in situ.
Our LCM results further suggest astrocytes are the preeminent parenchymal sources of
induced CCL2 gene expression during EAE, since the other parenchymal cells acquired by this
technique showed no significant stimulation of CCL2 mRNA. As increased immunostaining of
CCL2 in microglia has been reported in EAE (131), this may represent up-regulation at the
protein rather than the RNA level. It may also be that the percentage contribution of microglia in
the other parenchymal cells acquired by LCM, was not high enough to show overall elevation of
CCL2 gene expression in these samples from diseased mice. CCL2 mRNA detected in other
parenchymal cells from naïve mice could possibly reflect a low level of constitutive CCL2
expression by neurons as well (132).
Lastly, CFA/PTX alone can stimulate CCL2 expression in astrocytes (Fig. 19B), possibly
providing a priming function for supernumerary stimulation due to MOG effects

(Fig. 19E).

This is consistent with reports that peripheral inflammation induced by CFA or Mycobacterium
resulted in CNS glial activation (133, 134). Previous results from this laboratory indicated
CFA/PTX injection also up-regulated expression of CCL2 by choroid plexus capillary
endothelial cells. Thus, it is imperative that any measure of gene expression following the
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typical MOG immunization protocol be compared to effects seen after injection of CFA/PTX
alone, to discern what gene changes are associated specifically with MOG-induced pathogenesis.
These results reinforce the CNS microvascular endothelium as a significant source of CCL2
[9, 10, 12], as well as spotlight LCM as a critical tool for the selective enrichment of vascular or
other CNS cell types for gene expression studies (33, 42, 123).

Moreover, given the

microvascular endothelium is highly accessible from the circulation – as compared to the
astrocyte population, which lies behind the BBB and BSCB – endothelial-derived CCL2 may be
a “druggable” target in neuroinflammatory disease (44, 135).
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Figure 18: CCL2 gene expression in CNS microvessel and parenchymal fractions obtained by bulk
preparation. Separate, crude microvessel (A, C) and parenchymal (B, D) fractions were prepared by bulk isolation
from combined brain and spinal cord tissue of mice injected with CFA/PTX (A, B) or immunized with MOGCFA/PTX (C, D). Analyses were performed at D9, D16 and D23 following beginning of either injection regime, and
relative CCL2 mRNA levels are plotted on a log scale. Comparisons were made to naïve mice. * P≤0.05; **P≤0.01;
and ***P≤0.001. Data has been presented as mean +/- SEM. For each experiment, bulk isolations were performed
from three individual mice from each naïve, control (CFA/PTX) and EAE (MOG-CFA/PTX) group, and
experiments were conducted twice.
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Figure 19: CCL2 gene expression in CNS microvascular endothelial cells, astrocytes and other
parenchymal cells isolated by LCM. Endothelial cells (A, D), astrocytes (B, E), and other parenchymal
cells (C, F) were separately acquired by LCM from spinal cord tissue of mice injected with CFA/PTX (AC) or immunized with MOG-CFA/PTX (D-F). Analyses were performed at D9, D16 and D23 following
either injection regime, and relative CCL2 mRNA levels are plotted on a log scale. Comparisons were
made to naïve mice. *P≤0.05; **P≤0.01; and ***P≤0.001. Data has been presented as mean +/- SEM. For
each experiment, LCM was performed on tissue from three individual mice from each naïve, control
(CFA/PTX) and EAE (MOG-CFA/PTX) group.	
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CHAPTER V: Conclusion
CP has been established as one of the alternate routes for immune cell entry during
EAE/MS (15, 18) but the changes within CP anatomy that allow this access to the leukocytes
was still unknown. Prior to this work, CP barrier integrity had not been evaluated in MS/EAE to
the extent of the details as provided by this report. As important was the need to find evidences
leading to possible changes in permeability of CP that could aid in leukocyte extravasation. Tight
junction breakdown is co-relative with barrier alterations, since the complexity of TJ between
adjacent cells constitutes the physical presence of a barrier. There has been very limited work
addressing the status of TJ within BCSFB. Few preliminary reports were available before this
work and they had been more suggestive than conclusive. Wohlburg et al. noted altered
localization of CP TJ proteins claudins 1,2 and 11, occludin and ZO-1 during EAE (24). These
reports are more qualitative and did not address progressive changes in TJs through developing
stages of disease. Changes in CP TJs following peripheral inflammation have also been reported
by Marque et al. (20) and Mitchell et al. (136), providing further evidence that CP TJs are thus
subject to alterations in an inflammatory scenario.
Other reports provide indirect links to possibly altered integrity of CP during disease.
Severe cerebrospinal venal insufficiency (CCSVI); an abnormality in blood drainage in the brain
and spinal cord associated with MS (137), has been linked to altered CSF dynamics (138) which
could be due to a disrupted BCSFB. Invitro evidence shows BCSFB alterations in trans epithelial
electrical resistance and increase of para cellular flux after TNF stimulation, a potent
inflammatory cytokine, which is markedly increased during inflammation (139). These reports
point toward changes in BCSFB integrity and permeability during inflammation. We proposed to
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quantify these changes using novel 3D quantification technique previously standardized by the
lab (41).
Previous reports with the proposed claudins in CP have provided suggestive evidence that
they are altered during disease (24, 25). Quantification of TJs in naïve, control and EAE groups
painted a similar picture of stable expression in the naïve group, slightly altered levels in the
control groups (CFA/PTX alone without the MOG peptide may not have significant effects on
TJ regulation), with EAE mice showing the most altered values due to barrier changes and
breakdown in disease. The quantification protocol of the TJs was previously used in the lab with
experience in IMARIS based applications and has standardized the procedures (41). However,
given that the CP epithelial cells are a lot more tortuous (19) than the parenchymal vessels
where the quantification method was previously standardized. This opened new challenges in
imaging as well as quantification allowing us to add novel modules and techniques into
addressing the quantification of tight junctions, permeability of the barrier and leukocyte
extravasation.
TJ protein dynamics such as linkage with cytoskeleton and the interactions between the
dimers of TJ complex could be subject to changes during the process of disease (140-142).
However, imaging molecular changes at this level is beyond the scope of the type of imaging
and quantification carried out within this report. Nevertheless effects of such structural
alterations can be linked to increase in trans epithelial transport (143) and hence, to changes in
permeability, which we have assessed and quantified in our study as well. 3D quantification of
IgG diffusion across the CP had never been done before and quantification advances in other
systems have only been in 2D (144).
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Inflammation of the meninges, another established route of immune cell entry into the SAS
has been shown to precede that of the underlying parenchyma, which leads to lesions causing
neuroinflammation in EAE/MS (145, 146). This suggests an important role of this compartment
in the development of neuroinflammation within the CNS. More recent evidences point out that
inflammatory cells are localized around the meningeal venules within this specialized SAS
compartment (10, 11, 27). However, it is not clear as to why the SAS meningeal venules are
inflamed earlier than the parenchymal vasculature or why does the inflammation progresses from
the SAS into the parenchyma. Constitutive expression of P-selectin (required for initial
attachment of leukocytes with the vascular endothelial cell) in meningeal vasculature but absent
within the resting parenchymal vessels is a possible direction suggesting differential expression
of immune genes in different types of vasculature (13, 147). Kivisakk et al. reports suggestive
differential expressions of E-selectin and adhesion molecules such as ICAM and VCAM as well
(13). Moreover, our reports show that extensive arrays of genes that are important contributors in
inflammation are differentially expressed within these vascular locales. This study probed into an
array of adhesion molecules, cytokines, chemokines, statins, interleukins, T cell activation
markers, co-stimulatory molecules, transcription factors and apoptotic markers investigating
their possible differential regulation between meningeal and parenchymal vessels.
Differential expression pattern of immune genes in meningeal and parenchymal venules
as shown by this study provide supportive evidence to explain why some regions of the spinal
cord are more prone to lesions in EAE. Reports of ascending paralysis have long been around
(148) but the reasons for this ascension from lumbar to cervical segment of the cord has
remained unexplained. A detailed segmental analysis of immune profiling of both these vessel
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types was done, the technique perfected by the group and shown in varied LCM applications (30,
31, 33) in addition to recent reports on coupling it with TLDA analysis (42, 149).
Reports included in this work investigated how the tight junctions between the epithelial
cells of BCSFB changed during disease. We assessed the status of junctional integrity and
permeability of CP choroidal epithelium at different timepoints during developing EAE using
immunostaining, 3D imaging and quantification. We then continued to study the effects of EAE
within the meningeal venules that reside in the SAS and the underlying parenchymal venules via
regulation of inflammatory genes within these vessels. This allowed a unique opportunity to
study the differential inflammation patterns between the venules of the two regions- meninges
and parenchyma and the possibility of relay of inflammatory signals between the cervical,
thoracic and lumbar spinal cord segments. We were able to characterize and compare the
inflammatory gene expression patterns between meningeal and underlying parenchymal venules
from three distinct spinal cord segments (lumbar, thoracic and cervical) at different timepoints
during developing EAE using immune-LCM coupled to TLDA array analysis.
Studies within this report helped fill in the gaps that are crucial to understanding the
initial sequence of events that trigger inflammation and spread of immune cascade as the disease
progresses. With an unknown etiology, the main trigger behind MS remains enigmatic. It is
probable that more than one factor, a culmination of genetics and environmental players are
accountable for the susceptibility of this disease. The field has progressed in terms of identifying
the alternate routes other than the BBB that usher in immune cells, which could eventually lead
to the breakdown of the BBB, the known hallmark of this neurodegenerative disease. However,
the sequence of events that makes the alternate routes-CP and SAS susceptible in the first place
has largely been unknown. As puzzling are the events that guide inflammation from these initial
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sites to inner parenchyma where the BBB resides. This project aimed to cover these critical
questions, answers to which provide a fundamental basis in identifying possible therapeutic
avenues within the earliest events of the disease, perhaps the most sensitive to drug interventions
as well.
This project assessed TLDA gene analysis of 93 immune genes through EAE progression:
from earliest pre-clinical to late chronic disease phase. Results have provided us with an array of
information on gene regulation from onset through progression of inflammation, highlighting the
genes significantly regulated at different stages of inflammation in different regions of the spinal
cord. This data provides us with valuable early and late disease stage biomarkers that could be
further co-related with disease pathology. This is important because an ideal biomarker would be
an early and accurate indicator of immunological activity and would co-relate with key endpoints
in MS patients such as relapse activity, disability and disease progression and possibly early
detection. Although this concept is in its incipient pre-clinical stage, further confirming
experiments with these markers, could help us screen MS patients and relate them with the stage
of the disease they might be in, as well as foresee the possible progression of their inflammation
or relapses. With this valuable information of disease stages, we could design targeted antiinflammatory therapies against co-relating genes in developing inflammation, and successfully
impede the looming relapses.
The current measure of disease for MS patients are MRI images of brain and spinal cord
lesions, which are essentially end stage results of disease progression. Genetic biomarkers can
provide a much-needed shift in gauging the disease, possibly finding it as early as possible,
earlier than the manifestation of inflammation resulting in lesions as captured by imaging
diagnostics. This late stage is far along the damaging inflammatory cascade for effective
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prophylactics leaving room only for therapies targeted to symptomatic relief, as is the case with
current FDA approved treatments for MS patients. These treatments could also possibly be
paired with new targets of inflammation identified by the study, which would provide a multidirectional approach to treating MS. In another light, the current treatments have a holistic
immune-suppressive effect subjecting patients to novel infections they were protected against
with an otherwise functional immune system. This study could highlight inflammatory markers
related to a particular subset of immune pool, allowing targeted suppression instead of an entire
immune pool ablation.
An extension to the CP work, future in-vitro experiments can be carried out to confirm
changes in TJs using BCSFB culture mediums. Reports have provided convincing epithelial
culture systems with BCSFB properties (150-152) that can be manipulated with inflammatory
cytokines and transcription factors to study TJ changes due to inflammation. CP TJs have been
assessed with whole tissue extracts as well (25, 136). This system of tissue isolation however
defies our purpose of resolving the changes in the choroidal epithelium within the complex
layers of the CP (i.e. the inner capillary endothelial layer surrounded by a stroma and outlined
by the outermost epithelial layer). None-the-less, this approach can provide overall changes or
effects of inflammatory markers on the CP as a whole.
A probable alternative to LCM of meningeal and parenchymal vessels could be vessel
isolation from the extracted spinal cord, for which the lab has previous reports with vessel
isolation protocols (118, 122, 153). However, those isolations were using brain tissue providing
more material to work with, while spinal cord vessel extraction has proved to be more
problematic in terms of yield. Working with smaller segments of spinal cord as needed for the
purpose of this study, would provide lesser material to work with. Vessel isolation from
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extracted meninges of these individual sections of spinal cord segments can prove further
problematic in terms of isolation as well as the amount of material that can be extracted from
these thin sheets of meninges from small sections. A proper and successful extraction would
however provide an invaluable method to understand the gene expression within these unique
sections as well as provide an opportunity to co-relate and validate our LCM- gene expression
analysis.
Also as a possible future direction from this project, potential therapeutic targets could be
narrowed down from the pool of regulated genes changed in inflammation to the most potent
regulators, by successive invitro analysis that can analyze the extent of inflammatory roles
played by individual up regulated markers. Invitro analysis can be carried out in similar vascular
in-vitro systems including but not limited to murine BMECs (Brain Microvascular Endothielial
Cells), both on primary and commercially available cell lines and moving translating it further
with Primary Human Brain Microvascular Endothelial Cells (ACBRI 376). This will provide a
sharper focus in identifying a potential effective biomarker of inflammatory stages. We could
also potentially be looking at a novel route of drug delivery. Our results reveal that inflammation
primarily begins in the meningeal vessels compared to the parenchymal vessels, so targeted drug
delivery into the meningeal compartment, directly into the CSF via intrathecal delivery could
prove to be more beneficial rather than an intravenous or subcutaneous method of drug delivery,
although this route does pose the risk of being more invasive. Hence future directions to the
continuation of this concept of biomarkers will make strides in understanding MS pathology and
regulation providing possible avenues for therapeutic interventions.
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List of abbreviations:
BBB: Blood Brain Barrier
BCSFB: Blood Cerebrospinal Fluid Barrier
CFA: Complete Freund’s Adjuvant
CLN- Claudin
CSF: Cerebrospinal Fluid
CNS: Central Nervous System
Col4a5: Collagen type IV alpha 5.
CP: Choroid Plexus
EAE: Experimental Autoimmune Encephalomyelitis
Ece 1: Endothelin Converting Enzyme 1
Edn1: Endothelin 1
H2-Ea: Histocompatibility 2 class II antigen E alpha
LCM: Laser Capture Microdissection
MCP: Monocyte Chemoattractant Protein
MOG: Myelin Oligodendrocyte Glycoprotein
MS: Multiple Sclerosis
NOS2- Nitric Oxide Synthase 2
PTX: Pertussis Toxin
SAS: Sub Arachnoid Space
SKI-2: Super Killer-2
SOCS-2- Supressor Of Cytokine Signaling-2
STAT 1: Signal Transducers and Activators of Transcription-1
TJ: Tight Junctions
TGFβ: Transforming Growth Factor β
VEGF: Vascular Endothelial Growth Factor
VCAM: Vascular Cell Adhesion Molecule
ZO: Zonula Occludens
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The CCL2 synthesis inhibitor bindarit targets cells
of the neurovascular unit, and suppresses
experimental autoimmune encephalomyelitis
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Abstract
Background: Production of the chemokine CCL2 by cells of the neurovascular unit (NVU) drives critical aspects of
neuroinflammation. Suppression of CCL2 therefore holds promise in treating neuroinflammatory disease.
Accordingly, we sought to determine if the compound bindarit, which inhibits CCL2 synthesis, could repress the
three NVU sources of CCL2 most commonly reported in neuroinflammation – astrocytes, microglia and brain
microvascular endothelial cells (BMEC) – as well as modify the clinical course of neuroinflammatory disease.
Methods: The effect of bindarit on CCL2 expression by cultured murine astrocytes, microglia and BMEC was
examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Bindarit action on mouse brain
and spinal cord in vivo was similarly investigated by qRT-PCR following LPS injection in mice. And to further gauge
the potential remedial effects of bindarit on neuroinflammatory disease, its impact on the clinical course of
experimental autoimmune encephalomyelitis (EAE) in mice was also explored.
Results: Bindarit repressed CCL2 expression by all three cultured cells, and antagonized upregulated expression of
CCL2 in both brain and spinal cord in vivo following LPS administration. Bindarit also significantly modified the
course and severity of clinical EAE, diminished the incidence and onset of disease, and evidenced signs of disease
reversal.
Conclusion: Bindarit was effective in suppressing CCL2 expression by cultured NVU cells as well as brain and spinal
cord tissue in vivo. It further modulated the course of clinical EAE in both preventative and therapeutic ways.
Collectively, these results suggest that bindarit might prove an effective treatment for neuroinflammatory disease.
Keywords: CCL2, Neuroinflammation, Blood–brain barrier, Neurovascular unit, Brain microvascular endothelial cells,
Astrocytes, Microglia

Background
The chemokine CCL2 (formerly called MCP-1) is a critical mediator of neuroinflammation in a myriad of diseases states, including multiple sclerosis (MS) and its
animal model experimental autoimmune encephalomyelitis (EAE) [1], HIV-1 encephalitis [2], Guillain-Barré
Syndrome [3], Alzheimer’s disease [4], ischemia [5], neurotrauma [6], epilepsy [7], neurogenic hypertension [8]
and alcoholism [9]. While its precise mechanisms of
* Correspondence: Ge@uchc.edu
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action remain to be elaborated, among CCL2’s widely
recognized effects are disruption of the blood–brain barrier (BBB) [10-12] and stimulated migration of mononuclear leukocytes into the central nervous system
(CNS) [13-17].
These actions and pathogenic role, along with the fact
that constitutive expression of CCL2 in the healthy central nervous system is severely limited [18], render CCL2
an ideal target for therapeutic intervention in neuroinflammatory disease [17,19,20]. Indeed, there is already
strong suggestion that pharmacological suppression of
CCL2 expression [21,22], oligomerization [23,24] or
binding to its cognate receptor, CCR2 [25,26], can

© 2012 Ge et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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mitigate aspects of EAE. Pharmacologic blockade of
CCL2 binding to glycosaminoglycans (GAGs) has also
been reported to antagonize an autoimmune inflammatory condition of the neural retina, experimental autoimmune uveitis [27].
While highly effective in moderating neuroinflammation experimentally, many pharmacological agents that
abrogate CCL2 expression and/or activity have nevertheless failed clinically. This disappointing performance in
clinical trials might stem, in part, from overly broad suppression of microglia and astrocytes, a potential caveat
that could curtail beneficial action of these cells in resolving neuroinflammation [28,29], as well as redundancy of chemokine binding sites and targets [30,31]. An
alternative approach that more selectively targets CCL2
synthesis might therefore hold therapeutic promise in
the treatment of human neuroinflammatory disease.
An attractive candidate in this regard is the well-char
acterized compound 2-((1-benzyl-indazol-3-yl) methoxy)2-methyl propionic acid (bindarit) [32]. A small, synthetic
indazolic derivative that preferentially inhibits transcription of the monocyte chemoattractant subfamily of CC chemokines (MCP-1/CCL2, MCP-2/CCL8 and MCP-3/CCL7)
[33], bindarit has shown clinical efficacy in a broad array
of experimental inflammatory, autoimmune and vascular
disorders involving peripheral organ beds [34-38], as well
as success in recent clinical trials for diabetic nephropathy
[39] and lupus nephritis [40]. Such efficacy has been associated with bindarit’s ability to interfere with monocyte
recruitment, which is also a critical feature in neuroinflammatory disease [13-17].
Given this clinical history of bindarit suppressing various examples of peripheral inflammation, we investigated
its effect on expression of CCL2 in culture by the three
cell types that represent the most frequently reported
CNS sources of this chemokine during neuroinflammation: astrocytes, microglia and brain microvascular endothelial cells (BMEC). These cells serve as integral
components of the neurovascular unit (NVU) [41] and,
via their expression of CCL2, can impact the BBB and
course of neuroinflammatory disease [42,43]. As a complement to these culture studies, the ability of bindarit to
suppress LPS induction of CNS CCL2 expression in vivo
was well determined. And to gauge bindarit’s potential
clinical efficacy, its effect on EAE, a prototypical neuroinflammatory disease [44,45], was also examined. Results
indicate bindarit significantly suppressed CCL2 gene expression in culture, as well as blunted lipopolysaccharide
(LPS)-induced expression of CCL2 in the CNS. It also
inhibited various facets of clinical EAE, and showed signs
of promoting disease recovery. Collectively, these data
suggest that bindarit might offer promise, either alone or
in conjunction with other therapies, in the treatment of
human neuroinflammatory disease.
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Methods
Reagents

All reagents and antibodies were purchased from SigmaAldrich (St. Louis, MO, USA), unless specified otherwise. Bindarit was synthesized by and obtained from
Angelini (Angelini Research Center-ACRAF, Italy).
MOG peptide35-55 was synthesized by the WM Keck
Biotechnology Resource Center at Yale University,
New Haven, CT, USA.
Preparation of bindarit

For experiments with cultured cells, a stock solution of
100 mM bindarit was prepared in dimethyl sulfoxide
(DMSO), and dilutions (50, 100, 300 and 500 μM) of the
DMSO stock were made in culture medium. For in vivo
experiments, bindarit was prepared as a suspension in
0.5% methylcellulose (MTC) at a concentration of
20 mg/ml as previously described [37].
Mice

C57BL/6 mice were obtained from the Charles River
Laboratories, Inc. (Wilmington, MA, USA). All animal
studies were performed, and CO2-mediated euthanasia
carried-out, according to the Animal Care and Guidelines
of the University of Connecticut Health Center (Animal
Welfare Assurance #A3471-01).
Isolation and culture of mouse astrocytes and microglia

Brain tissue obtained from mice at postnatal days 2 to 3
was used as the source of astrocytes and microglia. After
decapitation, brains were removed immediately and separate astrocyte and microglial cultures prepared following a modified version of the protocol described by Ge
and Pachter [46]. Cerebral cortices were first cut into
small pieces (approximately 1 mm), and the minced tissue incubated in dissecting medium (Hank’s Balanced
Salt Solution, from Gibco/BRL, Rockville, MD, USA),
containing 0.5% glucose, 0.7% sucrose, 20 mM: hydroxyethyl piperazineethanesulfonic acid (Hepes) (pH 7.4)
with 0.03% trypsin at 37 °C for 20 to 30 minutes. The
tissue extract was then centrifuged at 1000 × g for 5 minutes and the resulting pellet washed and resuspended in
astrocyte culture medium (Earl’s Modified Eagle Medium,
from Gibco/BRL) containing 10% fetal bovine serum, 10%
horse serum, 2 mM glutamine, 20 mM D-glucose, 4 mM
sodium bicarbonate, 100 μg/ml penicillin and 100 μg/ml
streptomycin. The tissue was mildly triturated to produce
a single cell suspension, and the dissociated cells plated
onto tissue culture flasks (T-75 cm2) coated with polylysine (BD Biosciences, Bedford, MA, USA). Cultures were
maintained up to 1 week in plating medium in a humidified atmosphere (5% CO2) at 37 °C. After this time, cultures were shaken at 200 rpm for 2 hr at 4 °C, and
supernatants containing dislodged microglia collected.
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Supernatant material was then centrifuged at 1000 × g for
5 minutes to pellet microglia. Microglia were then resuspended in microglia culture medium (Dulbecco’s modified
Eagle Medium, from Gibco-BRL) supplemented with 10%
heat-inactivated fetal calf serum, 100 μg/ml penicillin and
100 μg/ml streptomycin) and cultured in a 24-well plate.
Following removal of microglia from the initial mixed glial
cultures, the latter were shaken for an additional 18 hr at
37 °C to remove residual neurons. The enriched astrocyte
population that remained was further depopulated of
remaining microglia by treatment with L-leucine methyl ester (LME) [47]. LME was dissolved in astrocyte culture medium, and the solution adjusted to
pH 7.4 and filtered prior to adding to cultures to
achieve a final concentration of 50 mM. After 90
minutes of LME treatment, astrocyte-enriched cultures were washed thoroughly and re-incubated with
fresh astrocyte culture medium. Cell purity was determined by immunocytochemistry using a monoclonal antihuman glial fibrillary acid protein (GFAP) antibody, and
cultures assessed to be ≥ 98% astrocytes (GFAP+).
Isolation and culture of mouse brain microvascular
endothelial cells

BMEC were isolated as previously detailed by this laboratory [10,48]. Primary cultures were typically grown
for approximately five days prior to sub-culturing for
experiments. At that time, purity was gauged to be ≥ 98%
BMEC, according to diI-acetylated LDL uptake [48].
BMEC also exhibited common endothelial characteristics, e.g. CD31 and vWF immunostaining, plus displayed
expression of the tight junction-associated proteins ZO-1
and occluding, found enriched at the BBB.
Treatment of cultured cells

To examine effects of bindarit on basal CCL2 expression, cultured microglia and BMEC were incubated with
different concentrations of bindarit for 4 hr or exposed
to 300 μM bindarit for different time. To gauge effects
of bindarit on LPS-stimulated CCL2 expression, astrocytes and microglia were pretreated with 300 μM bindarit for 1 hr; then cells were incubated with ± 100 ng/ml
LPS (Escherichia coli Serotype 026:B6) for 4 or 20 hr in
the continued presence of bindarit. After treatments, cells
were extracted for RNA purification.
Separation of brain microvessels and parenchyma

Distinct brain microvessel and parenchymal fractions
were obtained using a modification of the method to
prepare BMEC [10,48]. In brief, after removal of the
brain from the cranium, the meninges and big vessels
were discarded, and the whole brain diced into approximately 1 mm pieces. Brain tissue was then homogenized
with a 7 mL Dounce tissue grinder (Kimble/Kontes,
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Vineland, NJ, USA) in PBS. The homogenate was then
transferred to a 15 ml conical tube and centrifuged at
400 × g for 15 minutes in an Eppendorf Model 5804R
centrifuge/A-4-44 rotor. The resulting pellet was resuspended in 18% dextran (v/v, molecular weight 60 000 to
90 000; USB Corporation, Cleveland, OH, USA) and
centrifuged at 4,500 × g for 15 minutes to pellet the
crude microvessel fraction. The dextran supernatant and
floating layer of myelinated axons were separated from
the crude microvessel pellet, then diluted 1:2 with PBS
and centrifuged at 720 × g for 10 minutes to sediment
the parenchymal fraction. Both microvessel and parenchymal fractions were washed twice with PBS to eliminate traces of dextran. Microvessels were further washed
free of blood cells by filtering through a 40 μm cell
strainer (Becton Dickinson Labware, Franklin Lakes, IN,
USA) and eluting with PBS. Eluted microvessels were
pelleted by centrifugation at 16,000 × g in a table-top
microcentrifuge.
Treatment of animals

To determine effects of bindarit on LPS-stimulated
CCL2 expression in brain and spinal cord, C57BL/6 female mice were given intraperitoneal (i.p.) injection of
bindarit (200 mg/kg) or methylcellulose vehicle, once a
day, for 4 consecutive days. At 30 minutes following the
last bindarit injection, mice were given i.p. injection of
LPS (5 mg/kg; Escherichia coli Serotype 026:B6). Then,
4 hr after LPS injection, mice were euthanized and brain
and spinal cord dissected for CCL2 mRNA and protein
analysis.
For active induction of EAE, C57BL/6 female mice
were immunized with MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) of rat origin, by a modification
of the method previously described [49]. Briefly, on day 0
female mice 7 to 9 weeks of age were injected subcutaneously with 150 μg of MOG peptide and 300 μg
of Mycobacterium tuberculosis (DIFCO, Detroit, MI, USA)
in complete Freund’s adjuvant (CFA) (DIFCO) into the
right and left flank, 100 μl per site. Mice were also injected
i.p. with 200 ng pertussis toxin (List Laboratories,
Campbell CA, USA) in PBS on days 0 and 2 following the
first immunization. Animals were monitored and scored
daily for clinical disease severity according to the following
scale: 0 = normal; 1 = tail limpness; 2 = limp tail and weakness of hind legs; 3 = limp tail and complete paralysis of
hind legs; 4 = limp tail, complete hind leg and partial front
leg paralysis; and 5 = death. Several disease parameters
were calculated as described [49]. The mean day of onset
was calculated by averaging the time when clinical symptoms, that is, a clinical score ≥ 1, were first observed for
two consecutive days in each mouse. The mean maximum
clinical score was calculated by averaging the highest score
for each mouse. The disease index was calculated by
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adding the daily average clinical scores in each group, dividing by the mean day of onset, and multiplying by 100. In
the case that an animal showed no disease, the day of
onset was arbitrarily counted as one day after the last day
of the experiment (for example, day 22). And the disease
incidence was the fraction of mice experiencing EAE.
To investigate the effects of bindarit on both the clinical course of EAE and CCL2 level during disease, mice
were given daily i.p. injection of bindarit (or vehicle
MTC) at 200 mg/kg for three consecutive days, beginning the day before MOG immunization (day −1), then
injections every other day till day 20. This schedule was
designed to mitigate, as much as possible, trauma associated with daily injections at times of peak neurologic
disease and physical compromise.
RNA purification from cell cultures

Total RNA was extracted from cell cultures using the
RNeasy kit according to the manufacturer’s instructions.
RNA was treated with Turbo DNAse (Ambion, Austin,
TX, USA) according to the protocol provided by the
manufacturer. RNA yield and purity were determined by
spectrophotometry absorption at 260 and 280 nm.
RNA purification from CNS tissue

RNA and protein were differentially extracted from the
same mouse brain and spinal cord samples using the
AllPrep RNA/Protein kit (QIAGEN, Valencia, CA) following the manufacturer’s instructions. RNA was treated
with Turbo DNAse (Ambion, Austin, TX, USA) according to the protocol provided by the manufacturer. RNA
yield and purity were determined by spectrophotometry
absorption at 260 and 280 nm. Protein level was determined using the Micro BCA protein assay kit (Pierce,
Rockford, IL, USA), using bovine serum albumin as a
standard.
Reverse transcription

cDNA was synthesized from the total RNA using a
SuperScript III (Invitrogen, Carlsbad, CA, USA) Firststrand synthesis system for RT-PCR with a standard
protocol. The resulting cDNA was stored at −80 °C until
used for further analysis.
CCL2 RNA determination by quantitative RT-PCR

Measurements of cDNA levels were performed by quantitative (q) RT-PCR using an ABI PRISM 7500 Sequence
Detection System Version 1.3, and SYBR green (AB
Applied Biosystems, Foster sity, CA, USA) fluorescence
was used to quantify relative amplicon amount. Separate
controls included a no template-control and no reverse
transcriptase-control, and standard curves were constructed for all primers used. Cycle time (Ct) values for all
samples were normalized to RPL-19, the housekeeping
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gene encoding the 60 S ribosmal protein L19. Specifically,
relative amplicon quantification was performed using the
formula: ð1 þ Eref ÞCtðref Þ=ð1 þ EtargetÞCtðtargetÞñ 100%,
with ref: RPL19; target: CCL2; E: primer pair efficiency;
and Ct: threshold cycle.
For all cell culture studies and in vivo LPS studies, relative CCL2 gene expression values (after normalization to
RPL19) were expressed as percentage of control. For EAE
studies, relative CCL2 gene expression values were designated as percentage of RPL-19 expression, as control
CCL2 level (time-point 0) was undetectable. The primer
sequences used in this study were as following: for mouse
CCL2, 5′- GGC TCA GCC AGA TGC AGT TAA-3′ (forward) and 5′- CCA GCC TAC TCA TTG GGA TCA −3′
(reverse); for RPL-19, 5′- CGC TGC GGG AAA AAG
AAG-3′ (forward) and 5′- CTG ATC TGC TGA CGG
GAG TTG −3′ (reverse).
CCL2 protein determination

The level of CCL2 was measured with mouse JE/CCL2
commercial enzyme-linked immunoassay kit (BioSource
International Inc., Camarillo, CA) according to the manufacturer’s instructions.
Statistical analysis

Statistical significance of differences between mean
values of bindarit-treated cultures and control cultures
was analyzed using a paired two-tailed t-test, while comparisons of bindarit treatment on LPS-treated mice were
performed using a two-tailed t-test for independent
samples. For analysis of bindarit effects on clinical
EAE, a chi-squared (χ2) test was used for comparisons
of disease incidence; a Mann–Whitney U-test was
used for comparisons of disease index; and a twotailed t-test for independent samples was used for
comparison of disease onset. A P-value < 0.05 was
considered significant in all cases.

Results
Bindarit differentially suppresses CCL2 expression by
cultured CNS cells

The effects of bindarit on cultured glial and BMEC were
investigated first (Figures 1, 2, 3). Figure 1 shows that
cultured microglia demonstrated both a dose and time
dependency of bindarit effect on CCL2 mRNA level.
Suppression of basal CCL2 mRNA was seen beginning
with the lowest dose of 50 μM for 4 hr, amounting to
nearly 75% reduction. Increasing the dose to 300 and
500 μM resulted in still further diminution of CCL2
mRNA to approximately 10% and 5%, respectively, of
control level. Treatment with bindarit at 300 μM for as
little as 2 hr resulted in near 60% reduction in CCL2
mRNA level, and treatment for longer times at this
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Figure 1 Bindarit effects on CCL2 mRNA in cultured microglia.
Microglia, prepared from C57BL/6 mouse brain, were incubated with
bindarit at the indicated concentrations for 4 hr (A), or exposed to
300 μM bindarit for the indicated times (B). Control cultures
received only vehicle. Relative CCL2 RNA levels were determined by
qRT-PCR, and effects of bindarit treatment reported as % change
compared to control cultures. *P < 0.05; #P < 0.01 (compared to
control at 0 concentration or 0 time of bindarit).

Figure 2 Bindarit effects on CCL2 mRNA in cultured BMEC. Brain
microvascular endothelial cells (BMEC), prepared from C57BL/6
mouse brain, were incubated with bindarit at the indicated
concentrations for 4 hr (A), or exposed to 300 μM bindarit for the
indicated times (B). Control cultures received only vehicle. Relative
CCL2 RNA levels were determined by qRT-PCR, and effects of
bindarit treatment reported as % change compared to control
cultures. *P < 0.05; #P < 0.01 (compared to control at 0 concentration
or 0 time of bindarit).

concentration resulted in suppression of CCL2 mRNA
to ≥ 90% of control level.
BMEC demonstrated a similar qualitative response
in basal CCL2 mRNA to increasing bindarit concentration, but suppression was not as severe as seen
with microglia (Figure 2). Significant reduction was
not observed until 100 μM, and the maximal suppression achieved was about 20% that of control. The
time course of bindarit action on BMEC also differed.
Maximal suppression by 300 μM bindarit was
achieved at the earliest time-point of 2 hr, reaching a
level of approximately 20% of that of the control.
Longer time-points, however, appeared to result in a
lesser effect. It is important to reemphasize that, in

the normal CNS, CCL2 expression is barely detectable. This would suggest that both cultured microglia
and BMEC, possibly removed from a normally suppressive microenvironment, are in a somewhat activated state.
This situation appears different for astrocytes. In
this case, bindarit’s effects on constitutive CCL2 gene
expression could not be accurately assessed, as level
of this chemokine’s mRNA in murine culture of these
cells is very low. Astrocyte cultures were thus stimulated with LPS for different lengths of time to greatly
induce CCL2 mRNA, and the effect of bindarit on
this CCL2 induction was assayed (Figure 3A). Stimulation with 100 ng/ml LPS for both 4 hr and 20 hr
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It was next investigated whether bindarit could suppress
LPS-induced CCL2 expression in the CNS in vivo
(Figure 4). In the normal, resting state, CNS CCL2
mRNA level is barely detectable in C57BL/6 mice
[50], but is elevated 50- to 100-fold shortly after peripheral LPS injection [51]. Pretreatment with bindarit
was nevertheless able to effectively block this induction both in the brain and spinal cord, by 92% and
86%, respectively. In addition to abrogating LPSinduction of CCL2 mRNA in the CNS, bindarit was
also effective at reducing CCL2 protein level in both
brain and spinal cord, though not to the same extent
as mRNA.
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Figure 3 Bindarit effects on LPS-stimulated CCL2 mRNA in
cultured astrocytes and microglia. Separate cultures of astrocytes
(A) and microglia (B), prepared from C57BL/6 mouse brain, were
pre-treated with 300 μM bindarit for 1 hr, then incubated
with ± 100 ng/ml lipopolysaccharide (LPS) in the continued presence
of bindarit. Astrocytes cultures were exposed to LPS for the
indicated times to stimulate CCL2 expression. Microglial cultures
were only exposed to LPS for 4 hr, as these highly express CCL2
even under basal conditions. Control cultures received only vehicle.
Relative CCL2 RNA levels were determined by qRT-PCR, and effects
of bindarit treatment reported as % change compared to control
cultures. Brackets designate comparison between the two respective
groups. *P < 0.05; #P < 0.01.

produced similar elevations in CCL2 gene expression,
and bindarit treatment at 300 μM similarly suppressed, by
40 to 60%, the induction of CCL2 mRNA at both timepoints.
In light of bindarit’s success at mitigating induction
of CCL2 in astrocytes, we next assayed whether it
was similarly effective in preventing induction in LPSstimulated microglia. Figure 3B shows that this was in
fact the case, bindarit completely suppressing the induction and reducing CCL2 mRNA level to 15% of
the control (basal) value.
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Figure 4 Bindarit’s effects on CCL2 mRNA and protein in brain
and spinal cord following LPS. Mice received i.p. injection of
200 mg/kg bindarit (or vehicle) once a day for 4 days, followed by i.
p. injection of 5 mg/kg lipopolysaccharide (LPS) at 30 minutes after
the last bindarit treatment. At 4 hr after LPS injection, brain and
spinal cord were prepared for CCL2 mRNA (A) and protein (B)
determinations. LPS + bindarit-treated brain or spinal cord samples
were compared to corresponding samples treated with LPS + vehicle
(control). *P < 0.05; #P < 0.01.
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Bindarit therapeutically modifies clinical EAE

a maximum mean clinical score of 1.5. A third therapeutic
effect was apparent reversal of disease course. After experiencing rapid onset, control mice showed a plateau in
disease score typical of this monophasic MOG-induced
EAE [52,53]. However, in marked distinction, bindarittreated mice demonstrated a consistent downward trend
in disease score following their delayed and attenuated
peak in clinical presentation. A summary of the effects of
bindarit treatment on clinical EAE is presented in Table 1.
We next sought to examine how bindarit modifies
CCL2 expression in the brain during EAE. First, the
temporal expression of CCL2 was determined only in
MOG-immunized mice not receiving any bindarit, to
gauge the window of opportunity during which bindarit
might act. As seen in Figure 6, CCL2 RNA is barely
detectable at the time of immunization. Its expression
then accelerates beginning around day 9, is significantly

The ability of bindarit to modify clinical EAE was examined next. Figure 5 shows that, with a bindarit schedule
of daily injections for the first three days, and beginning
at day −1, then injections every other day till day 20,
bindarit yielded several therapeutic effects. By the criterion that disease is manifest when a clinical score of at
least 1 is demonstrated for at least two consecutive days
[49], bindarit delayed onset of EAE. Specifically, control
mice developed acute disease beginning at day 8, while
bindarit-treated mice did not show evidence of clinical
disease until days 14 to 15. A second therapeutic effect
observed was reduced disease progression and severity.
Control mice showed rapid progression of EAE, proceeding towards a maximum mean clinical score of
approximately 2.1 to 2.2 by day 9. Bindarit-treated
mice evidenced slower progression, and only reached
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Figure 5 Bindarit effects on clinical experimental autoimmune encephalomyelitis (EAE). Mice were subject to EAE by active immunization
with MOG peptide, beginning on day 0, as detailed in Methods. Bindarit (or vehicle) was injected i.p. at 200 mg/kg according to the schedule
indicated, beginning at day −1 (one day before MOG immunization). Mean clinical score (A) and % incidence of EAE (B) were determined. EAE
was diagnosed when animals demonstrated a clinical score ≥ 1 for two consecutive days.
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Table 1 Summary of bindarit effects on clinical experimental autoimmune encephalomyelitis (EAE) parameters
Group

Sick/total, number

MTC

14/14

BND

8/14
-

P-value

Mean day of onseta

Mean max clinical score

Mean disease indexb

11.42 ± 1.76

2.43 ±0.47

163.7 ± 20.53

16.85 ± 2.17

1.52 ± 0.88

99.3 ± 10.21

<0.005

<0.001

<0.01

Mean presented ± SD.
a
Day of onset established when clinical score ≥ for two consecutive days.
b
Disease index calculated at day 21.

elevated by day 14, rapidly declines at day 17, and
reaches near basal level by day 21. Because bindarit has
been shown to most effectively suppress stimulated, rather than basal, CCL2 expression [33,54], bindarit effects
on CCL2 were analyzed selectively during this peak
interval. Additionally, brain tissue was resolved into
microvascular and parenchymal fractions to further
identify targeted cell types. This resolution was deemed
important, as both microvessels (BMEC) and parenchymal neural cells (astrocytes and microglia) have been
reported as sources of CCL2 during EAE [55-58], though
microvessels only contribute < 1% to brain volume [59].
It was thus reasoned that parenchymal effects could
overshadow possible bindarit-induced changes in microvascular CCL2 expression if only whole-brain levels were
evaluated. Figure 7 reveals that bindarit significantly
reduced peak CCL2 expression during EAE in both
microvascular and parenchymal fractions, in agreement
with what was found in our culture studies. Also, bindarit did not affect CCL2 expression outside the peak
window, reinforcing that its action appears restricted to
activated cells within and outside the CNS [33,54].
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Figure 6 CCL2 expression profile during experimental
autoimmune encephalomyelitis (EAE). Mice were immunized with
MOG peptide to induce EAE. At the indicated days
post-immunization, mice were sacrificed and CCL2 mRNA levels
determined in the whole brain. CCL2 expression is seen to rapidly
rise and fall between days 9 to 21, showing the highest level at day
14.

Discussion
Given the success of the CCL2 synthesis inhibitor bindarit
in ameliorating several animal disease models and human
clinical conditions associated with peripheral inflammatory disease, initial studies were conducted to examine its
effects on elements critical to neuroinflammatory disease.
Focusing on the three main cell types responsible for
CCL2 expression during neuroinflammation, experiments
revealed bindarit significantly suppressed CCL2 in cultured BMEC, microglia and astrocytes. Bindarit was
further shown to be effective in vivo in two neuroinflammatory paradigms: 1) it blocked LPS induction of CCL2 in
both brain and spinal cord; and 2) it therapeutically modified the course of EAE while suppressing CCL2 expression in both brain microvascular and parenchymal
compartments.
As to the effects on the seminal sources of CCL2, it
was critical to determine whether each was susceptible
to bindarit, as the specific cellular pool(s) responsible for
CCL2’s pathogenic actions during neuroninflammatory
disease remain unclear [51]. While all three cell types
responded with significant reduction in CCL2 mRNA,
microglia were the most sensitive - experiencing > 90%
diminution in this chemokine’s expression. This high
sensitivity to bindarit holds particular significance, as
microglia are widely considered the primary immune effector cells in the CNS [60-63], and their expression of
CCL2 has been linked to monocyte recruitment into the
CNS [64,65]. As CCL2 can also direct recruitment and
proliferation of microglia [66-68], as well as activation of
these cells [68], microglial expression of CCL2 can potentially support a self-sustaining cycle of neuroinflammation.
Bindarit action, however, might effectively abrogate such a
scenario.
That bindarit also suppressed CCL2 mRNA in BMEC
is noteworthy. As these cells form the first line of
defense in the BBB [69], their expression of CCL2 might
strongly influence incipient steps of neuroinflammation
[70]. Indeed, elevated CCL2 expression by BMEC has
been reported in MS [71] and EAE [55,56], as well as in
autoimmune inflammation of the peripheral nervous
system [3]. Furthermore, intravenously administered antiCCL2 antibody blocked heightened leukocyte adhesion to
pial venular endothelium in vivo in mice suffering acute
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Figure 7 Effects of bindarit on CCL2 expression in central nervous system (CNS) fractions during experimental autoimmune
encephalomyelitis (EAE). Mice were immunized with MOG peptide to induce EAE, and were injected with bindarit (or MTC vehicle) as in
Figure 5. At the indicated days post-immunization, mice were sacrificed and CCL2 mRNA levels determined in microvascular (A) and parenchymal
(B) fractions. Bindarit treated groups were compared to vehicle treated groups. *P < 0.01.

EAE [72], as well as prevented recurring clinical episodes
in a chronic relapsing EAE model [73], possibly by antagonizing CCL2 at the luminal endothelial surface. Supporting this possibility, CCL2 harbors in its C-terminal α-helix
a binding site for GAGs typically found on the luminal
endothelial surface [74], and has been shown to bind
to the luminal surface of cultured endothelial cells
and then trigger firm adhesion followed by transmigration of mononuclear leukocytes [75,76]. Binding of
CCL2 released from BMEC in culture has most recently been shown to switch from the luminal to the
abluminal surface following cytokine-induced activation [77], possibly reflecting the changing roles of this
chemokine pool from first promoting leukocyte adhesion to later directing extravasation into the parenchyma. Thus, by targeting the BMEC reservoir of
CCL2 during disease, bindarit might be able to blunt
neuroinflammation at different stages.

Bindarit action on CCL2 expression by cultured astrocytes had to be studied in the context of LPS stimulation, as these cells exhibit barely detectable CCL2
mRNA in culture or in situ in the naïve state [50,51].
Yet despite significant induction, astrocyte CCL2 mRNA
was reduced by half or more following bindarit exposure. As astrocytes constitute the most abundant glial cell
population in the CNS [78], suppression of their CCL2
production by bindarit in vivo might well exert profound
influence on pathologic events.
That bindarit could indeed act in vivo to effectively
suppress neuroinflammation was evident in both the
LPS and EAE paradigms. Injection of bindarit dramatically reduced LPS-stimulated expression of CCL2 in both
brain and spinal cord, dropping mRNA levels to near
10% of vehicle-injected control values, while cutting protein levels approximately by half. In this case, the efficacy of bindarit in suppressing brain CCL2 may have
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been aided by the fact that LPS can severely disrupt the
BBB [79,80], and thereby possibly facilitate bindarit entry
into the CNS parenchyma. As CCL2 can also disrupt tight
junctions leading to elevated BBB permeability [10-12],
CCL2 generated early after LPS injection may have contributed to its subsequent suppression by further enabling
bindarit CNS access.
The effects of bindarit on clinical EAE suggest that bindarit exerted both preventative and therapeutic actions.
Preventative action is indicated by the considerable delay
in disease onset in the bindarit-treated group, as well as
the reduced incidence and severity of disease displayed by
these mice. Possible therapeutic action is conveyed by the
steady decline in disease severity following diminished
peak clinical score. Such decline was in marked contrast
to the typical plateau in clinical score exhibited by EAE
mice given vehicle. These results are qualitatively similar
to those recently reported by Laborde et al. [81] who,
employing a regimen of twice daily oral dosage of a novel
heteroaroylphenylurea antagonist of CCL2 function, also
described delayed disease onset and resolution of EAE
symptoms. In the case of bindarit, however, clinical symptoms seemed to steadily remit following attenuated peak
disease, and a reduced incidence was also noted. Both
studies nevertheless highlight the prospect that selective
targeting of CCL2 activity might prevent EAE, as well as
reverse its course.
The effect of bindarit on clinical EAE was accompanied by significant reduction of CCL2 mRNA in both
brain microvessel and parenchymal fractions, consistent
with bindarit’s mechanism of action being inhibition of
CCL2 transcription [33]. Reinforcing this point, global
knockout of the CCL2 gene has been shown to similarly
delay EAE onset, and reduce both disease incidence and
severity, effects that have been attributed to absence of
CCL2 expression within the CNS compartment [81,82].
This, along with demonstration that CCL2-deficient
mice also exhibit reduced neuroinflammatory responses
to peripheral LPS injection [83,84], underscores CCL2’s
non-redundant role in neuroinflammatory disease and
accentuates its value as a therapeutic target. Results with
bindarit and EAE may further suggest that both microvascular and parenchymal sources of CCL2 contribute
to pathogenesis. If this is so, it could further imply bindarit would not have to penetrate the BBB in order to
reach at least one of its targets, BMEC. In contrast to
the acute situation with LPS, which acts directly on the
endothelium, it is reasoned that the BBB was more intact in EAE mice receiving bindarit, as mean disease
score only reached approximately 1.5. Thus, a likely
scenario is that bindarit also sufficiently crossed the
BBB to suppress the astrocyte and/or microglial response as well. This lends promise that bindarit can
access the CNS parenchyma during the early stages of
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neuroinflammatory disease, when BBB breakdown is
not yet manifested.

Conclusions
In summary, the CCL2 synthesis inhibitor bindarit,
previously shown to be highly effective in myriad experimental disease models as well as human conditions having inflammatory involvement [34-40], was
observed to significantly reduce steady state and LPSinduced CCL2 expression in cultured microglia,
BMEC and astrocytes, as well as LPS-stimulated
CCL2 mRNA and protein levels in CNS tissue in situ.
Bindarit was further effective in delaying, preventing
and attenuating clinical EAE, and evidenced signs of
possibly reversing disease course while also suppressing elevation of CCL2 in brain microvascular and
parenchymal compartments. Collectively, these data
are consistent with the widely proposed critical role
for CCL2 in neuroinflammation [18-20], and suggest
bindarit, by targeting cells of the NVU [41], might
have therapeutic success in the treatment of MS and/or
other human neuroinflammatory diseases.
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a b s t r a c t
Immuno-laser capture microdissection (immuno-LCM) enables highly selective retrieval of designated
cell populations from their in situ locations in complex tissue like the brain. However, the amount of
tissue acquired by immuno-LCM is extremely limited, and the RNA purification, amplification and labeling steps necessary for expression analysis by hybridization microarray are tedious and time consuming.
This report therefore describes a protocol in which these RNA steps are eliminated altogether, yet allows
for global gene profiling. Specifically, immuno-LCM tissue was solubilized and the extract directly subjected to reverse transcription to generate cDNA. Pre-amplification of cDNA was performed next, and
then relative expression of 96 different immune-related genes simultaneously determined by quantitative real-time PCR using a microfluidic card TaqMan® Low Density Array (TLDA). This protocol was
highly reproducible and extremely sensitive, demonstrating high correlation of raw Ct values among both
technical and biological replicate samples when using only 1/32 of total pre-amplified cDNA obtained
from as little as 500 LCM ‘shots.’ As this abridged protocol takes only approximately 7 h from LCM tissue acquisition to analysis by TLDA, it can prove a very effective tool for both screening and validation
purposes when investigating gene regulation in health and disease of the nervous system and other
tissues.
© 2012 Elsevier B.V. All rights reserved.

1. Introduction
The endothelium shows considerable phenotypic and molecular
diversity along the CNS vascular tree (Ge et al., 2005). Segmental heterogeneity exists between the endothelium of parenchymal
microvessels (e.g., arterioles, capillaries and venules) and surface macrovessels (e.g., arteries and veins), and even between the
endothelium of the respective microvascular tributaries. There is
also regional heterogeneity between the endothelium of similar type
vessel segments within different CNS regions.
Endothelial heterogeneity poses challenges to studying CNS
vascular gene expression. Whole brain and/or spinal cord
homogenates suffer from pooling different vascular segments from
different CNS regions, providing at best a mosaic of endothelial
subtypes. This can lead to significant misinterpretation of vascular function. A means to enrich for specific endothelial populations,
coupled to a platform to quantitatively analyze gene expression
efficiently, is needed to accurately assess the CNS endothelium in
health and disease.

∗ Corresponding author. Tel.: +1 860 679 3698.
E-mail address: pachter@nso1.uchc.edu (J.S. Pachter).
0165-0270/$ – see front matter © 2012 Elsevier B.V. All rights reserved.
doi:10.1016/j.jneumeth.2012.02.023

Laser capture microdissection (LCM) enables selective isolation
of cells from microscopic samples of tissue (Espina et al., 2007)
– and presents opportunity to exploit CNS endothelial heterogeneity in depth. This laboratory showed that, when guided by
combined immunohistochemistry/immunofluorescence and coupled to SYBR® Green-based, quantitative real-time PCR (qrt-PCR),
immuno-LCM allowed analysis of endothelial gene expression in
separate populations of CNS arterioles, capillaries and venules
(Macdonald et al., 2010).
Coupling gene expression to LCM has nonetheless been encumbered by the rigors of isolating intact RNA from mere fractions of
cells and, thus, largely limited to analyzing only a few genes at a
time. Moreover, isolating RNA on such a small scale from multiple samples can become unmanageable in time and cost. A method
that would avoid time-consuming and inefficient RNA isolation,
yet allow for more extensive gene profiling, would thus be advantageous.
Here we describe a novel protocol, whereby brain microvascular
endothelial cell (BMEC) tissue retrieved by LCM is lysed and directly
reverse-transcribed, then subject to pre-amplification of cDNA, and
analyzed by TaqMan® Low Density Array (TLDA) for simultaneous
assessment of 96 different genes. Significantly, the high sensitivity
of this approach enables analysis of a modest amount of LCM tissue
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that can be quickly acquired, allowing in situ gene profiling on this
global scale to be completed in approximately 7.0 h from beginning
to end.
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EtOH for 30 s, 100% EtOH for 60 s, 100% EtOH for 90 s, xylene (Fisher
Scientific; Pittsburgh, PA) for 2 min and a final xylene for 3 min.
2.6. LCM [20–30 min]

2. Materials and methods
Specific aspects of immuno-LCM, including examples of
immunostained tissue, discussion of tissue preservation and
confirmation of endothelial purity, have been elaborated in previous reports from this laboratory (Kinnecom and Pachter, 2005;
Macdonald et al., 2008), and not reiterated here. Where appropriate, approximate times are indicated below next to individual steps
in the immuno-LCM/TLDA protocol, to allow comparison to other
procedures used for global gene profiling.
2.1. Animals
Female C57 BL/6 mice, age 8–10 weeks and obtained from
Charles River Laboratories, Inc. (Wilmington, MA), were used to
minimize microvascular heterogeneity due to genetic variability,
sex, and age (Macdonald et al., 2008). Animals were euthanized
by CO2 inhalation, following Animal Care and Use Guidelines of the
University of Connecticut Health Center (Animal Welfare Assurance
# A3471-01).
2.2. Induction of experimental autoimmune encephalomyelitis
(EAE)
EAE was induced in mice by active immunization with MOG35–55
peptide (MEVGWYRSPFSRVVHLYRNGK), of murine origin (W.M.
Keck Biotechnology Resource Center, Yale University), as described
(Juedes et al., 2000). Mice were observed daily and scored on a scale
of 0–4 with gradations of 0.5 for intermediate scores: 0, no clinical
signs; 1, loss of tail tone; 2, wobbly gait; 3, hind limb paralysis; and
4 hind and fore limb paralysis. LCM tissue was acquired at day 16
post-immunization (score ∼2.0).
2.3. Tissue preparation and sectioning
Following euthanasia, the brain was removed, snap-frozen in
dry ice-cooled 2-methylbutane (Acros; Geel, Belgium) and processed for cryosectioning (Macdonald et al., 2008). Coronal sections
(7 !m thick) of cerebellum were cut between Bregma −6.56 mm
and −7.32 mm, adhered to glass slides, and stored at −80 ◦ C until
immuno-LCM.
2.4. Fixation and immunostaining of sections for identification of
microvessels [30 min]
To obtain sufficient material for comparing two samples by
LCM/qrt-PCR analysis, two slides, each containing two consecutive
brain sections, were fixed, stained, and dehydrated simultaneously.
Two sections provided sufficient material for each sample. Pairing
samples this way enabled both samples to experience the same
environmental conditions for the same time (Macdonald et al.,
2008). Double immunostaining of BMEC and astrocyte populations,
by combined immunohistochemistry and immunofluorescence,
respectively, was carried out as detailed (Macdonald et al., 2008).
2.5. Dehydration [8.0 min]
After immunostaining, sections were dehydrated in the following solutions, made by diluting 100% EtOH (Pharmco-AAPER;
Brookfield, CT) with DEPC treated water: 75% EtOH for 10 s, 95%

The Arcturus PixCell IIe microscope (Life Technologies; Bedford,
MA) was used to retrieve BMEC according to the LCM conditions
described (Kinnecom and Pachter, 2005; Macdonald et al., 2008).
In brief, the LCM parameters utilized were as follows: 7.5 !m spot
size; 72 mW power; and 0.950 ms pulse duration. BMEC were captured exclusively from capillaries (∼ 5–9 !m diameter) within the
designated cerebellar boundaries. As LCM can only be performed
on one slide at a time, one of the two simultaneously stained slides
was left at room temperature until action on the first slide was
completed. Tissue samples were captured onto HS® caps (Life Technologies Corp.) by a designated number of ‘shots’ (i.e., laser pulses),
with one cap used per sample. An equal number of LCM shots was
necessary to standardize the amount of input RNA, and was previously shown to provide a highly reproducible amount of tissue
equivalent (Macdonald et al., 2008).
Because LCM acquires material from tissue sections, only “fractions” of cells are obtained with each LCM shot. However, the
following sample calculation may be used to estimate the number of endothelial cells captured in an LCM session: Assuming
the typical endothelial cell is 10–15 !m deep × 25–50 !m long
(Simionescu and Simnionescu, 1977), then in 7 !m-thick sections
each capillary endothelial profile cut in longitudinal section would
represent 0.47–0.7 cells in thickness. Using a 7.5 !m diameter laser
spot size, the number of capillary endothelial cells cut lengthwise would be 0.15–0.3. Hence, the number of endothelial cells
captured/shot = 0.07–0.21 cells; 500 shots would thus represent
35–105 cells, and 1000 shots represent 70–210 cells.
2.7. Tissue extraction [15 min]
Once LCM was completed, tissue was solubilized in Cell Lysate
Buffer® (Signosis; Sunnyvale, CA) for direct reverse transcription.
Cell Lysate Buffer® , pre-heated to 75 ◦ C, was added and the resulting lysate heated at 75 ◦ C for an additional 15 min. Samples of both
extracts were immediately frozen at −80 ◦ C.
2.8. DNase treatment and cDNA synthesis [2 h]
Cell Lysate Buffer® extracts were treated with Turbo DNase
(Ambion; Austin, TX) according to the manufacturer’s instructions.
Specifically, Turbo DNase buffer and DNase were added and samples incubated at 37 ◦ C for 30 min. Next, DNAse inactivation reagent
was added for 2 min at room temperature. Samples were then
reverse transcribed using the SuperScript III (Invitrogen) standard
protocol with random hexamers (Roche; Indianapolis, IN), and
employing an extension temperature of 42 ◦ C – optimal for random hexamers – for 60 min. cDNA was stored at −20 ◦ C until used
for analysis.
2.9. cDNA pre-amplification [1 h 40 min]
Pre-amplification was carried out using TaqMan® PreAmp Master Mix and a custom PreAmp Pool containing all the primers for
detection by TaqMan® Gene Expression Assays. Relative amplification was validated using single gene (single-plex) probes for CCL2,
VCAM1 and GAPDH prior to analysis by TaqMan® Low Density
Array (TLDA) Microfluidic Cards. Both 10 and 14 cycles of preamplification were evaluated initially, with an initial hold at 95 ◦ C
for 10 min, followed by 10/14 cycles at 95 ◦ C for 15 s and 60 ◦ C for
4 min. For TLDA analysis, 14 cycles of pre-amplification were used.
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2.10. qrt-PCR [2 h]
Relative cDNA levels were quantified by qrt-PCR using an ABI
PRISM 7500 Sequence Detection System Version 2.3, and custom
TaqMan® MGB probes. For single-plex assays, separate controls
included no template or no reverse transcriptase, and standard
curves were constructed for all primers used. Custom TaqMan®
primers/probes were used for both single-plex qrt-PCR and the
Mouse Immune Panel TLDA (Life Technologies Corp.). TLDA analysis was conducted as per the manufacturer’s protocol, with 100 !l
sample volumes containing a 1/32 or 1/4 dilution of pre-amplified
cDNA added to each port of the microfluidic card.
2.11. Statistical analysis
Data from single-plex reactions were analyzed in SDS 2.3 and
Microsoft Excel 2007, while that from TLDA plates were imported
to the SDS 2.3 companion software RQ Manager and exported
to Microsoft Excel 2007 for calculations. Linear regression analysis was conducted and a Pearson product-moment correlation
(Pearson r) determined using GraphPad Prism 5.0. Pearson r was
calculated from paired Ct values reflecting expression of each of the
96 genes represented in the Immune Panel TLDA. A Spearman-Rho
rank order correlation (Spearman r) was calculated to determine
if these 96 gene expression values were comparable in rank order
between samples.
3. Results
Because of the extremely low level of RNA from LCM samples, the first step was to determine if cDNA generated directly
from LCM tissue extracted in Cell Lysate Buffer® – without RNA
purification – could be amplified using a commercially available
pre-amplification kit prior to quantification by qrt-PCR. A sampling
of three genes represented on the Mouse Immune-TLDA (GAPDH,
VCAM-1 and CCL2) was individually analyzed in single-plex format.
These genes were selected as they exhibit high (GAPDH), moderate
(VCAM-1), and relatively low expression (CCL2) by BMEC during
acute EAE, the animal model for the neuroinflammatory disease
multiple sclerosis (MS) (Furlan et al., 2009) – and thus provide a
wide spectrum by which to judge efficacy of the pre-amplification.
Fig. 1 demonstrates a 14-cycle pre-amplification significantly lowered Ct values for all three genes. Both GAPDH and VCAM-1 had
their Ct values similarly lowered by 12 cycles, while Ct value of CCL2
decreased by 10.2 cycles, thus indicating the relative abundance of
amplicons was generally preserved through pre-amplification. The
apparent lesser amplification of CCL2 signal may have resulted from
expression of this gene being lower than that which was reliably
detectable in the non-amplified sample.
It was next determined if pre-amplified BMEC cDNA, generated
from Cell Lysate Buffer extracts® without RNA isolation, could be
coupled to the Immune Panel TLDA for simultaneous analysis of 96
genes related to inflammation/autoimmunity. This specific TLDA
was selected as it contains a cadre of genes thought to be involved
in MS/EAE.
Two different dilutions of the pre-amplified cDNA were assayed
to cover a broad range of gene expression and test the limits of
sensitivity. Fig. 2(a) and (b) depicts linear regression analyses of
raw Ct values for the genes represented in the TLDA, contrasting
values obtained from 1/4 and 1/32 dilutions of pre-amplified cDNA
samples generated from 500 or 1000 LCM shots. Notably, raw Ct
values – as apposed to values normalized to a reference gene –
reflect the absolute values of input RNA for qrt-PCR and, thus, reveal
an accurate picture of the reproducibility of the immuno-LCM/TLDA
approach (Chen et al., 2009).

Fig. 1. Pre-amplification of cDNA from Cell Lysate Buffer® proportionally enhances
LCM/qrt-PCR of BMEC. At day 16 following MOG35–55 peptide immunization to
induce EAE (disease score ∼2.0), mouse cerebellar tissue was processed for immunoLCM, and BMEC captured by 1000 LCM shots then extracted with Cell Lysate Buffer® .
BMEC extract then underwent reverse transcription reaction without prior RNA
isolation, and equal aliquots of the resulting cDNA were either not pre-amplified
or subject to 14 cycles of pre-amplification prior to single-plex qrt-PCR detection
with TaqMan® probes/primers for the genes GAPDH, VCAM1 and CCL2. Each qrtPCR reaction was run in duplicate (technical replicates), and the mean Ct values for
each gene are depicted. Pre-amplification of 14 cycles with extract from 1000 shots
of LCM-derived BMEC yielded the following mean !Ct [cDNA – pre-AMP] values:
GAPDH (12.087), VCAM1 (12.34), and CCL2 (10.21). Inherent lower expression of
CCL2 may explain the lesser-detected amplification of this gene.

Raw Ct values considered “undetermined” by the software, or at
a level ≥40 cycles, were excluded from analysis. In the case of 1000
LCM shots, 14 genes were so excluded, while only 6 genes were
omitted from the 500 LCM shot sample. Both 1000 and 500 LCM
shot samples yielded Pearson r values of >0.95, signifying extremely
high linear correlation between technical replicates. These technical replicates originated from the same tissue sections and resultant
cDNA pools, their only difference being they represented either
1/4 or 1/32 dilutions of pre-amplified cDNA applied to the TLDA.
The high Pearson r thus highlights that diluting cDNA samples over
an eightfold range did not distort the relationship between amplicon measurements of the different genes. Such technical replicates
showed a high Spearman r value as well, denoting that raw Ct scores
for each gene maintained their rank position relative to all other
genes in the TLDA when 1/4 and 1/32 dilutions of pre-amplified
cDNA were compared.
Immuno-LCM/TLDA further demonstrated both a high Pearson
r (0.95) and Spearman r (0.93) among raw Ct values obtained from
“biological” replicates (Fig. 2(c)). To obtain biological replicates, 500
LCM shots were performed on separate brain sections of the same
animal, and a 1/32 dilution of pre-amplified cDNA derived from
these respective sections was used in each case. As such, these
biological replicates were subject to potential technical variability
as well. Brain tissue from different animals was intentionally not
compared here, as the immunization protocol itself could produce
varying disease states in individual mice, and the objective was to
isolate any variability due solely to analysis of random BMEC populations. Despite undergoing a multitude of separate acquisition
and processing steps, however, biologic replicates also demonstrated high fidelity. Specifically, linear regression yielded a line
with a slope of 1.03 ± 0.038 (SD) and Y and X intercepts of near
zero – reflecting that raw scores of any specific gene were virtually identical in the biological replicates. These results collectively
demonstrate – for the first time – high efficiency and reproducibility of linking immuno-LCM to TLDA format without need of tedious
RNA isolation and amplification steps.
4. Discussion
Coupling LCM to genomic profiling platforms has greatly
expanded the capacity to probe gene expression within the most
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Fig. 2. Expression profiling of BMEC by immuno-LCM/TLDA with no RNA purification shows high reproducibility. Immuno-LCM of BMEC was carried out on separate EAE
cerebellar sections, and captured tissue extracted with Cell Lysate Buffer® then processed through reverse transcription and cDNA pre-amplification, as in Fig. 1. To gauge
sensitivity and exclusively highlight technical reproducibility, different dilutions (1/4 or 1/32) of pre-amplified cDNA derived from 500 (a) or 1000 (b) LCM shots were analyzed
by qrt-PCR using the Immune Panel TLDA, and linear regression performed on the two corresponding raw Ct values obtained for each gene at the respective dilutions. To
highlight overall reproducibility, while accounting for all potential variation due to both biological and technical components, the results of 500 LCM shots from two different
tissue sections were compared (c), and linear regression performed on the two corresponding raw Ct values obtained for each gene from the respective sections.

discrete CNS domains in situ. Linking LCM to hybridization-based
microarrays, in particular, has enabled transcriptional profiling of
tens of thousands of genes from select cell groups in CNS tissue samples (Rossner et al., 2006). Nevertheless, this particular
combinatorial approach is labor intensive, expensive, and presents
difficulties with quantification and statistical evaluation.
Much of this labor stems from RNA isolation and downstream
amplification steps needed to generate sufficient labeled complementary RNA (cRNA) for detection (usually >1 !g). These steps can
become unmanageable when dealing with multiple samples. Thus,
proceeding directly from solubilization of LCM tissue to reverse
transcription and then cDNA pre-amplification, would save considerable time and effort when comparing a number of variables (e.g.,
stages of disease progression or different drug dosages). Concerns
have also been raised regarding bias in the RNA amplification process (Li et al., 2005). Furthermore, while the wide breadth of genes
that can be analyzed with hybridization-based microarrays may
be advantageous in certain applications (e.g., whole-cell transcriptome analysis), it may not be warranted in others. A limited analysis
may be more desirable when investigating a specific biological process or tissue property. As qrt-PCR is often used to confirm results
of hybridization arrays – which frequently illuminate no more than
a few hundred significantly variable genes – coupling LCM to a qrtPCR-based array format without RNA purification would also prove
an efficient validation or screening tool.
Given these considerations, this report described a simplified
and expeditious approach whereby immuno-LCM of BMEC was followed by tissue solubilization and direct reverse transcription (in
the absence of RNA purification), pre-amplification of the resulting
cDNA, and then simultaneous qrt-PCR analysis of 96 immunerelated genes by TLDA. Because RNA was not isolated in this study,
equal number of LCM shots served as basis for sample comparisons.
Previous work from this laboratory showed utilizing equal numbers of LCM shots was an effective means to standardize RNA input

(Macdonald et al., 2008), this approach yielding no statistically
significant variance in relative gene expression values between
technical or biological replicates as detected by single-plex qrt-PCR.
The number of shots in the present study was capped at 1000 to
minimize the time between immunostaining and processing of RNA
for analysis, as restricting this period to <30 min has been shown to
be critical for reliable qrt-PCR detection (Macdonald et al., 2008).
Notably, 500 LCM shots was able to be performed in <20 min, and
yielded a higher number of detectable genes than did 1000 LCM
shots (90 genes vs. 82 genes, respectively) – perhaps reflecting loss
of RNA with increased LCM time. Both 500 and 1000 LCM shots
nevertheless showed high reproducibility in technical and biological replicates among 96 different genes assayed simultaneously
by TLDA – even in the absence of RNA purification. These results
support the findings of Keays et al. (2005), who coupled LCM to
single-plex qrt-PCR without purifying RNA. But, to the best of our
knowledge, this is the first report to describe linkage of LCM to
microarray while bypassing RNA purification and employing cDNA
pre-amplification.
While there have been more than 100 published reports of
LCM/microarray analysis, the array format used has near exclusively been genomic DNA chip hybridization – necessitating RNA
purification and amplification. Most recently, Balogh et al. (2007)
described coupling LCM of hemotoxylin/eosin-stained tissue to
the Immune Panel TLDA used in this study. However, they utilized a four-step RNA amplification process: first purifying RNA,
then amplifying it based on dT-T7 and switch T7 primers followed
by in vitro transcription, and finally purifying the synthetic RNA
population. The present study averted these steps entirely. It is
further significant that high reproducibility of immuno-LCM/TLDA
was demonstrated with raw Ct scores – not gene expression values
normalized to a housekeeping gene.
The validity of the immuno-LCM/TLDA approach was underscored by the distribution of raw Ct scores obtained – from the
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low 20s to upper 30s – reflecting the variable expression patterns
of genes during evolving EAE. Moreover, preliminary comparison
between naïve and EAE mice revealed several significant differences. Among these were elevated expression of STAT6 and CCR4
(data not shown), both of which have been shown to be upregulated in EAE (Zaheer et al., 2007; Forde et al., 2011).
In summary, the immuno-LCM/TLDA approach described offers
a relatively quick, reliable and inexpensive means to globally profile gene expression patterns of select cell groups in situ. Given
the significant cellular heterogeneity within the nervous system,
immuno-LCM/TLDA holds high promise for elaborating gene regulatory mechanisms in the neurobiology of health and disease, and
could provide a highly efficient clinical diagnostic tool for neuropathologists (McShea et al., 2006).
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Abstract
Background: There is increasing awareness that, aside from producing cerebrospinal fluid, the choroid plexus (CP)
might be a key regulator of immune activity in the central nervous system (CNS) during neuroinflammation.
Specifically, the CP has recently been posited to control entry of sentinel T cells into the uninflamed CNS during
the early stages of neuroinflammatory diseases, like multiple sclerosis (MS) and its animal model experimental
autoimmune encephalomyelitis (EAE). As the CP is compartmentalized into a stromal core containing fenestrated
capillaries devoid of typical blood–brain barrier properties, surrounded by a tight junction-expressing choroidal
epithelium, each of these compartments might mount unique responses that instigate the neuroinflammatory
process.
Methods: To discern responses of the respective CP stromal capillary and choroidal epithelial tissues during
evolving neuroinflammation, we investigated morphology and in situ expression of 93 immune-related genes
during early stages of EAE induced by immunization with myelin oligodendrocyte glycoprotein peptide (MOG35-55).
Specifically, 3-D immunofluorescent imaging was employed to gauge morphological changes, and laser capture
microdissection was coupled to an Immune Panel TaqMan Low Density Array to detail alterations in gene
expression patterns at these separate CP sites on days 9 and 15 post-immunization (p.i.). To resolve CP effects due
to autoimmunity against MOG peptide, from those due to complete Freund’s adjuvant (CFA) and pertussis toxin
(PTX) included in the immunization, analysis was performed on MOG-CFA/PTX-treated, CFA/PTX-treated, and naïve
cohorts.
Results: The CP became swollen and displayed significant molecular changes in response to MOG-CFA/PTX
immunization. Both stromal capillary and choroidal epithelial tissues mounted vigorous, yet different, changes in
expression of numerous genes over the time course analyzed - including those encoding adhesion molecules,
cytokines, chemokines, statins, interleukins, T cell activation markers, costimulatory molecules, cyclooxygenase, proinflammatory transcription factors and pro-apoptotic markers. Moreover, CFA/PTX-treatment, alone, resulted in
extensive, though less robust, alterations in both CP compartments.
(Continued on next page)
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Conclusions: MOG-CFA/PTX immunization significantly affects CP morphology and stimulates distinct expression
patterns of immune-related genes in CP stromal capillary and epithelial tissues during evolving EAE. CFA/PTX
treatment, alone, causes widespread gene alterations that could prime the CP to unlock the CNS to T cell
infiltration during neuroinflammatory disease.
Keywords: Laser capture microdissection (LCM), Choroid plexus, EAE, Pertussis toxin, Neuroinflammation

Introduction
Though the choroid plexus (CP) is commonly recognized
as the production site of cerebrospinal fluid (CSF) [1-3], it
has relatively recently gained attention as a critical player
in central nervous system (CNS) inflammation [4-6]. Specifically, the CP has been suggested as the site of entry
into the uninflamed CNS of pioneer T cells searching for
their cognate antigens during immunosurveillance and in
the early stages of neuroinflammatory diseases such as
multiple sclerosis (MS) and its animal model experimental
autoimmune encephalomyelitis (EAE) [7,8]. Current theory holds that, after crossing the CP into the CSF, pioneer
T cells travel to the subarachnoid space (SAS), where
antigen-presenting cells reactivate them. In turn, reactivation is thought to set off a burst of cytokines and other
mediators that inflames meningeal and parenchymal
venules to initiate disease [9-11].
The anatomy of the CP appears well suited to orchestrating the initial steps of CNS inflammation. It projects from
the roofs of all four ventricles into the CSF, and is composed of two distinct tissue layers: a highly vascularized
stroma encapsulated by a “tight” layer of epithelial cells
[12]. Unlike the parenchymal capillaries forming the restrictive blood–brain barrier (BBB), CP stromal capillaries
are fenestrated and contain pentilaminar junctions whose
outer leaflets are not fused [13] – properties that render the
CP capillary population highly permeable to macromolecules [14]. This juxtaposition of “leaky” capillaries and tight
epithelium constitutes the blood-cerebrospinal fluid barrier
(BSCFB) [15,16], an arrangement construed as enabling
blood-born leukocytes to extravasate into an uninflamed
brain during the incipient stages of MS and EAE [17,18].
Supporting this process, expression of chemokine CCL20
by choroidal epithelial cells is thought to chemotactically
draw T cells – bearing the cognate receptor CCR6 – from
the CP stroma, across the epithelium and into the CSF [8].
In situ hybridization and immuno-electron microscopy
of the CP has further revealed expression of adhesion
molecules, VCAM-1 and ICAM-1, by choroidal epithelial
cells of the healthy CP, and additionally of MAdCAM-1
by these same cells during EAE [19,20]. Also, transcriptome analysis of the whole adult CP has highlighted expression of immune mediators in both healthy mice [21]
and those subject to peripheral inflammation [22], reinforcing the view this organ is a critical conduit linking

immune/inflammatory activities between the periphery
and CNS. But the extremely close apposition of the different CP layers has posed a significant challenge to studying
the depth of their respective contributions to inflammatory processes. In fact, no immune function has yet been
ascribed to the CP capillary endothelium, leaving completely unresolved the factors that drive T cell emigration
into the stroma. And gene regulatory events surrounding
transmigration of T cells across the choroidal epithelium
further remain unsettled.
To elaborate the sequence of events in the CP that set
the stage for CNS inflammation during EAE induced by
active immunization with MOG35-55 peptide, we used
laser capture microdissection (LCM) coupled to qrtPCR-based microarray [23] to establish the time course
of expression of a panorama of immune mediators in
the separate stromal (including capillaries) and choroid
epithelial layers. Morphological changes in the CP associated with MOG immunization were also examined by
quantitative 3-D image analysis following confocal microscopy. Results reveal substantial changes in CP gene
expression and morphology occurred in response to
vspecific aspects of the MOG immunization process.
These results could hold relevance for how combinations of environmental factors trigger neuroinflammatory disease.

Materials and methods
Animals

Female C57BL/6 mice, age 8–10 weeks and obtained
from Charles River Laboratories, Inc. (Wilmington,
MA), were used to minimize microvascular heterogeneity due to genetic variability, sex, and age [24]. Animals
were euthanized by CO2 inhalation, following Animal
Care and Use Guidelines of the University of Connecticut Health Center (Animal Welfare Assurance # A347101). A total of n = 3 animals/group were used for each
treatment and time-point assessed.
Induction of experimental autoimmune encephalomyelitis
(EAE)

EAE was induced in mice by active immunization with
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK),
of murine origin (W. M. Keck Biotechnology Resource
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Center, Yale University), as described [25]; following
Animal Care and Use Guidelines of the University of
Connecticut Health Center (Animal Welfare Assurance
# A3471-01). Briefly, on day 0, one group of female mice
7–9 weeks of age was injected subcutaneously with
300 μg of MOG peptide in complete Freund’s adjuvant
(CFA, DIFCO) into the right and left flank, 100 μl per
site. These mice were also injected i.p. with 500 ng pertussis toxin (PTX, List Laboratories, Campbell CA) in
PBS on days 0 and 2 following the first immunization
(referred to as the MOG-CFA/PTX group). The second
group of age-matched mice received CFA alone and
PTX (500 ng) injections on day 0 and a second injection
of 500 ng PTX alone on day 2 (referred to as the CFA/
PTX group). The third group of naïve age-matched female mice was left untreated. Animals were monitored
and scored daily for clinical disease severity according to
the following scale: 0 = normal; 1 = tail limpness; 2 = limp
tail and weakness of hind legs; 3 = limp tail and complete
paralysis hind legs; 4 = limp tail, complete hind leg and
partial front leg paralysis; and 5 = death. LCM tissue was
acquired at day 9 (score 0) and day 15 (score ~ 2.0) postimmunizations.
Tissue preparation for Immuno-LCM

Brains were snap-frozen in dry ice-cooled 2-methylbutane (Acros; Geel, Belgium), and stored at −80°C. Frozen
brain was embedded in cryomatrix compound (Thermo
Fisher Scientific, Waltham, MA) prior to sectioning.
Coronal sections (7 μm) were cut on a Microm HM
505 M cryostat (Mikron Instruments; Oakland, NJ) and
affixed to uncoated, pre-cleaned glass slides (Fisher Scientific, Pittsburgh, PA) and stored in a slide box at −
80°C. Tissue was processed for LCM within a week of
sectioning.
Immunostaining for Immuno-LCM

Immunostaining was performed as detailed [24,26,27],
with minor modifications. Briefly, sections were fixed in
75% ethanol, on ice, for 3 min prior to staining. The CP
stromal capillaries were stained using alkaline phosphatase substrate NBT (nitro-blue tetrazolium chloride)/
BCIP (5-bromo-4-chloro-3'-indolyphosphate p-toluidine
salt), (Vector Labs, Burlingame, CA) for 3–5 minutes in
100 Mm Tris–HCl (pH 9.5) to detect endogenous alkaline phosphatase activity in the endothelial cells. In this
case, endothelial cells were intentionally not immunostained by anti-CD31/ABC alkaline phosphatase [24,27],
as it resulted in extensive deposition of chromogenic
precipitate, which made the stromal capillaries difficult
to resolve from the choroidal epithelial layer. The choroidal epithelial cells were immunostained with monoclonal pan-cytokeratin-FITC antibody (Sigma) for 10
minutes (diluted 1:10 in 1X PBS + 0.5% Tween-20).
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RNAsinW RNAse inhibitor (Promega, Madison, WI) was
added to all staining reagents. Immediately after immunostaining, sections were dehydrated through graded alcohol and xylenes as described [24].
Laser capture microdissection (LCM)

A PixCell IIe laser capture microscope (ABI, Foster
City, CA) was used to separately procure CP stromal capillary and CP choroidal epithelial tissues, as previously
described for brain parenchymal vessels [24,27,28]. We
refer specifically to CP stromal capillary tissue, instead
of pure capillary endothelium, as it was not possible to
completely resolve vascular from matrix elements (including extravasating leukocytes) within the dense CP
stroma. Likewise, the choroidal epithelial tissue may
contain some epiplexus cells, and so is not described as
pure epithelium. Only choroid plexus material from
within the fourth ventricle and lateral recess of the
fourth ventricle was retrieved.
Tissue extraction

LCM-retrieved tissue was solubilized in Cell Lysate
BufferW (Signosis; Sunnyvale, CA) for direct reverse
transcription. Cell Lysate BufferW, pre-heated to 75°C,
was added and the resulting lysate heated at 75°C for an
additional 15 min. Samples were immediately frozen at
−80°C.
DNase treatment and cDNA synthesis

Cell Lysate BufferW extracts were treated with Turbo
DNase (Ambion; Austin, TX) according to the manufacturer’s instructions. Specifically, Turbo DNase buffer and
DNase were added and samples incubated at 37°C for
30 min. Next, DNAse inactivation reagent was added for
2 min at room temperature. Samples were then reverse
transcribed using the SuperScript III (Invitrogen) standard protocol with random hexamers (Roche; Indianapolis, IN), and employing an extension temperature of
42°C – optimal for random hexamers – for 60 min.
Resulting cDNA was stored at −20°C until used for
analysis.
cDNA Pre-Amplification

Pre-amplification was carried for array analysis out using
TaqManW PreAmp Master Mix and a PreAmp Pool containing all the primers for detection by the Mouse Immune Panel TaqManW Low density Array (TLDA; Life
Technologies Corp., Foster City, CA) [23]. This panel
conatins 93 immune-related genes plus three housekeeping control genes (see Additional file 1: Mouse Immune
Panel TLDA). Pre-amplification was carried out with an
initial hold at 95°C for 10 min, followed by 14 cycles at
95°C for 15 sec and 60°C for 4 min.
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qrt-PCR

Statistical analysis

Relative cDNA levels were quantified by qrt-PCR using
an ABI PRISM 7500 Sequence Detection System Version
2.3, and reported compared to housekeeping gene
GAPDH. Relative quantitation to GAPDH was performed using the standard 2–δCt method of Pfaffl [29],
where δCt = Ct target threshold cycle – Ct reference
(GAPDH) threshold cycle. Expression of genes relative
to GAPDH was then represented as percent expression
of GAPDH. To assure consistency in relating gene expression patterns to a housekeeping gene, GAPDH and
two other housekeeping genes, β-actin and 18 S ribosomal RNA, were evaluated for constant expression across
treatments. Additionally, gene expression values for a
handful of randomly selected immune-related genes
were also determined relative to β-actin and 18 S ribosomal RNA (see Additional file 2: Housekeeping control
genes). Custom TaqManW primers/probes were used for
the Mouse Immune Panel TLDA. TLDA analysis was
conducted as per the manufacturer’s protocol, with
100 μl sample volumes containing a 1/32 dilution of
pre-amplified cDNA added to each port of the microfluidic card [23]. For qrt-PCR analysis of CD31 and Cytokeratin 8, ‘singleplex’ assays were used as neither of these
genes are represented in the mouse Immune Panel
TLDA.

Relative gene expression values are given as mean ±
SEM. Student’s two-tailed test (Microsoft Excel 2003,
Redmond, WA) was employed to assess statistical significance in gene expression values between MOG-CFA/
PTX and CFA/PTX samples from the CP capillary
stroma and CP epithelium groups, separately for the two
different time points assessed. Results were considered
significant at a p ≤ 0.05. Additionally, two-way ANOVA
followed by post-hoc Bonferroni analysis was performed
using GraphPad Prism 5 (GraphPad, La Jolla, CA) to determine interactive effects between immunization treatment and time of analysis post-immunization, and
assessed for each CP compartment.

Immunostaining for confocal microscopy

Frozen cryosections (60 μm) were fixed with 4% paraformaldehyde, permeabilized with 1% Triton X-100 (in
PBS) and incubated with PowerblockW for 10 min. Purified rat anti-mouse CD31 antibody (BD Pharmingen;
1:150 dilution in 10% NBS in 1X PBS + 0.5% TW-20)
was used to stain the CP capillary network followed by
incubation with goat anti-rat Alexa-555 secondary antibody (1:200). Pan-cytokeratin-FITC 1: 150 dilution,
(Sigma) was used to stain the CP epithelium. Next,
Alexa-647 anti-mouse CD45 antibody (1:160 dilution)
was used to stain leukocytes.

Confocal microscopy

Images were acquired on a Zeiss LSM 510 Meta laser scanning confocal microscope, and optical slices (at 2-μm intervals) obtained using a 40x objective. Acquired z-stacks were
background-subtracted, and 3-D isosurface rendering performed using Bitplane IMARIS suite version 7.1 x 64 software (Bitplane Inc. Saint Paul, MN). Each z-stack was
thresholded and the “filament tracker” module used to generate a 3-D traced outline of immunostained vessels in
order to determine the diameter range of the CD31immunostained capillary network within the choroid plexus
across different treatments.

Results
Anatomy of the CP is altered in response to MOGimmunization

First, the anatomy of the CP was investigated using confocal microscopy followed by 3-D isosurface rendering.
The close apposition of stromal capillary and choroidal
epithelial layers in the CP is depicted in Figure 1. The 3D analysis highlights the tortuosity of the capillary
plexus. At day 15 post immunization (p.i.) with PTX and
MOG35-55 peptide in CFA to induce EAE (MOG-CFA/
PTX group), or with PTX and CFA alone (CFA/PTX
group), which does not produce disease in this paradigm, the capillary plexus can be seen to locally ‘swell’ in
certain regions (Figure 1). Specifically, the range in
diameter of capillaries in the MOG-CFA/PTX and CFA/
PTX groups was 1.24 to 11.39 μm and 1.86 to 10.84 μm
respectively, as compared to that found in naïve (1.24 to
6.22 μm) mice. In contrast to that seen within CP capillaries, the morphology of the choroidal epithelial layer
remained relatively constant following immunization.
LCM enables resolution of CP stromal capillaries from the
choroidal epithelium

Studies were next carried out to confirm the ability of
LCM to resolve the stromal capillary and choroidal epithelial layers. Figure 2A shows an example of the highly
selective retrieval of both tissues from naïve and EAE
brain specimens. Microscopic analysis indicates no appearance of fluorescently-stained choroidal epithelial tissue in the LCM-captured capillaries and, conversely, no
alkaline phosphatase-stained capillary tissue in the
retrieved epithelial samples. Figure 2B further highlights
the purity in qrt-PCR detection of LCM tissue from the
respective CP compartments. Using equivalent amounts
of input LCM tissue (1000 laser ‘shots’) from both CP
compartments, the endothelial marker CD31 was significantly enriched in the CP capillary tissue, while the epithelial marker cytokeratin 8 was observed in CP
epithelial tissue alone. The extremely low level of CD31
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Figure 1 Morphological analysis of CP compartments following immunization. CP epithelium was stained with polyclonal antibody to pancytokeratin (FITC, green), and CP stromal capillaries were immunostained with monoclonal anti-CD31 antibody (red). A CD45 antibody was used
to stain for any leukocytes present within the CP (blue). Confocal microscopy z-stack images of thick (60 μm) frozen sections of the CP were
acquired, and three dimensional rendering was performed using Imaris image analysis software. Shown are rendered images of the CP from all
three treatment conditions (MOG-CFA/PTX day 15 p.i., CFA-PTX day 15 p.i. and Naïve), revealing swelling of the stromal capillaries (arrows)
following both immunization protocols. The left side shows leukocyte and capillary staining, emphasizing the distended capillary diameters. The
right side is a composite of leukocyte, capillary, and epithelial staining. Mean capillary diameter ranges for each group were determined using the
Filament tracer module in Imaris. The choroidal epithelium appears unaltered by immunization. ‘p’ indicates brain parenchymal region. Scale:
20 μm.

mRNA detected in CP epithelial tissue may reflect the
few monocytes and/or dendritic cells circulating through
this area in the steady-state mouse brain [29,30]. There
is thus high confidence that LCM effectively separates
CP stromal capillary from choroidal epithelial layers with
high purity.
Expression of immune-related genes by stromal CP
capillary tissue following immunization

The next series of experiments coupled LCM to TLDA
qrt-PCR arrays to further characterize expression

patterns of a panorama of 93 immune-related genes in
the separate CP compartments at different stages of the
neuroinflammatory response to immunization. Expression of these genes relative to housekeeping gene
GAPDH (GAPDH was unaffected across treatments;
Additional file 2: Housekeeping control genes), was determined in three groups of mice: MOG-CFA/PTX, CFA/
PTX and naïve at two time points: day 9 and 15 p.i.
Contrasting these three treatment groups enabled effects
of the adjuvants CFA and PTX to be distinguished from
the autoimmune response to MOG. Furthermore,
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Figure 2 Immuno-LCM allows retrieval of tissue from specific CP compartments. A) Evidence of histological purity. Immunofluorescence
was performed using FITC-conjugated pan-cytokeratin antibody to highlight the CP epithelium (green), while immunohistochemistry using
alkaline phosphatase detection with NBT/BCIP as substrate was carried-out to label the endothelium of CP stromal capillaries (dark brown). LCM
was performed on a Pixcell IIe LCM unit. Images both BEFORE and AFTER LCM, as well as LCM retrieved tissue deposited on the cap, are shown
to highlight selective retrieval of CP stromal capillary (top row) and CP choroidal epithelial tissues (bottom row). B) Evidence of purity by qrt-PCR.
Levels of CD31, an endothelial marker, and Cytokeratin-8, an epithelial marker, were probed to determine the purity of the CP capillary and CP
epithelial tissues, respectively, retrieved by LCM.

examining effects at day 9 p.i. (prior to any evidence of
clinical disease) and day 15 p.i. (after disease onset),
highlighted the progression of gene changes that may be
linked with developing pathology.
At day 9 p.i. (EAE clinical score 0), numerous gene
changes were already evident in the CP stromal capillary
tissue, despite the lack of onset of any clinical disease
signs. Specifically, both MOG-CFA/PTX- and CFA/
PTX-immunized mice showed up-regulated expression
in 49 of the genes in the panel compared to naïve animals, (Table 1), with there being no statistically significant differences between the two immunized groups.
Some prominent inflammatory genes that were equivalently elevated at this time point included: CCL2, CCL5,
CXCL10, Sele (E-selectin), Selp (P-selectin), IL1b, Stat1
and Fasl all of which were modulated more than 10 fold

higher than naïve levels. It would thus appear that, at
this early stage before clinical EAE symptoms are
present, the gene responses in the CP stromal capillary
tissue following MOG immunization may stem largely
from adjuvants CFA and/or PTX.
By day 15 p.i. (EAE clinical score 1.5-2.0), however,
the MOG-CFA/PTX-immunized group surpassed the
CFA/PTX group in up-regulation of several genes, highlighting what might specifically be the autoimmune response of the CP vascular stroma. These genes included
B2m, C3, CCL19, CCL5, CD4, Gzmb, Ptgs2, Ptprc
(CD45), Smad3, Stat4, and CD40l – which were selectively augmented in the CP stromal capillary tissue of the
MOG-CFA/PTX group (Figure 3). The fold changes in
these genes following immunization (Figure 3, bottom)
indicate their super-stimulation by MOG-CFA/PTX
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Table 1 Genes similarly up-regulated in CP stromal
capillary tissue from both MOG-CFA/PTX- and CFA-PTXimmunized mice at day 9 p.i
Genes modulated similarly in stromal CP capillary of MOG-CFA/
PTX mice at day 9 p.i
Gene name

Gene name

B2m{

ll15*

Bcl2l1

ll18*

C3**{

ll1b**

Ccl19{

ll7

Ccl2**

Lrp2

{

Ccl5**

Nfkb1*

Ccr2**

Nfkb2

Cd34**

Ptgs*{

Cd80

Sele**

Cd86*

Selp**

Cd8a

Amad3{

Col4a5

Socs2

Csf1*

Stat1**

Cxcl10**

Stat3

Cxcr3*

Stat4{

Ece1

Stat6

Edn1

Tbx21

Fas

Tfrc*

Fn1

Tgfb1
{

Gzmb

Cd40

Hmox1

Fasl**

Hprt1

Vcam1

lcos

Vegfa

lfng**
genes with * ≥ 5 and ** ≥ 10 fold increase in expression in comparison to Naïve
animals.
Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP stromal capillary tissue from
immunized and naïve mice at day 9 p.i. At this early time-point, all 49
immunization-induced genes were similarly stimulated in both MOG-CFA/PTXand CFA-PTX-immunized mice compared to naïve animals, and only these are
listed. { denotes genes that show specific upregulation later on with disease
progression on day 15.

treatment. The lymphoid chemokine CCL19, expressed
by venules in brain and spinal cord in mice afflicted with
EAE [31], was elevated nearly 80-fold in the MOG-CFA/
PTX immunized mice at this time-point. And CCL5, another chemokine shown to play an important role in
EAE [32], was elevated 146-fold higher than naïve levels.
Expression of Ptgs2 (COX2), suppression of which has
been associated with resistance to EAE [33,34], was near
similarly elevated – having increased 96-fold higher than
that in naïve cohorts. Slightly less elevated was Stat4, a
transcription factor whose absence has been shown to
inhibit EAE [35], which was increased > 40-fold in the
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MOG immunized group. It is further noteworthy that
expression of Ptprc (CD45), the common leukocyte marker, stimulated 219-fold higher, possibly reflecting
increased leukocyte extravasation across the stromal capillaries at this later time-point. Consistent with this interpretation is that message for CD40l (CD154), a
protein primarily expressed on activated T cells [36], was
detected within the CP stromal capillary tissue only following MOG-CFA/PTX immunization.
Notably, the CFA/PTX group indicated some dampening of immune regulation by this time, as certain genes
e.g., Smad3 and Gzmb, dropped back to levels matching
those of naïve mice, after initially displaying an elevation
at day 9. Genes that trended towards elevated expression
following MOG-CFA/PTX treatment (but with p values
slightly > 0.05) are displayed in Additional file 3: Genes
that trended towards elevated expression in MOG-CFA/
PTX- immunized CP stromal capillary tissue compared
to CFA-PTX-immunized mice, at day 15 p.i, while those
that were similarly up-regulated in CP stromal capillary
tissue of MOG-CFA/PTX- and CFA/PTX-immunized
mice compared to naïve mice at day 15 are listed in
Additional file 4: Genes similarly up-regulated in CP
stromal capillary tissue from both MOG-CFA/PTX- and
CFA-PTX-immunized mice at day 15 p.i. Genes that
were undetected in the CP capillary tissue in all treated
and naïve mice at both time-points were the following:
CCR4, CD19, CD3e, CSF3, Ctla4, Cyp1a2, Cyp7a1, H2Ea, IL12b, IL13, IL3, IL4, IL5, IL6, IL9, and Lta.
Expression of immune-related genes by CP choroidal
epithelium following immunization

Immunization also produced a change in expression of
numerous immune-related genes within the CP choroidal epithelium. Moreover, these changes differed from
those observed in the capillary stroma, emphasizing the
differential immune sensitivities of the two tissues.
At day 9 p.i., the CP choroidal epithelium of only
MOG-CFA/PTX-immunized mice displayed increased expression of any immune-related genes compared to that
of naïve cohorts. Specifically, the following eight immunerelated genes were up-regulated: B2m, CCL19, CCL2,
CCR2, CD8a, CXCL10, Sele, and Selp (Figure 4A). B2m
(beta 2 microglobulin), a biomarker for certain peripheral
inflammatory conditions [37] was increased 2.2-fold in
MOG-treated versus naïve mice. The chemokine CCL2
has been demonstrated to play a critical, non-redundant
role in directing mononuclear leukocyte extravasation into
the CNS during EAE [32,38,39], and was stimulated > 24fold higher in the CP choroidal epithelial tissue of MOGCFA/PTX-treated mice compared to that in naïve cohorts.
CXCL10 and CCL19 were 28-and 14-fold higher than
naïve values, respectively. Sele (E-selectin) and Selp
(P-selectin), CCL19 and CD8a further showed pronounced
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Figure 3 Genes super-induced in CP stromal capillary tissue from MOG-CFA/PTX-immunized mice at day 15 p.i. Relative mRNA expression
values were determined by immuno-LCM/TLDA in CP stromal capillary tissue from MOG-CFA/PTX-immunized, CFA-PTX-immunized, and naïve mice at
day 15 p.i. Those genes that were more stimulated; i.e., ‘super-induced’, in MOG-CFA/PTX- versus CFA-PTX-immunized mice at day 15 p.i. (compared to
naïve mice) are graphed. The bar graphs depict those specific genes showing statistically significant differences in relative expression values (p values
indicated by asterisks) between MOG-CFA/PTX and CFA/PTX experimental groups. RNA values are presented as mean percent expression relative to
GAPDH (± SEM) in log scale. * and ** represent comparisons made between MOG-CFA/PTX and CFA-PTX- treatment groups, * p < 0.05, ** p < 0.005,
Student’s t-test, n = 3 animals/group. Fold changes in gene expression normalized to naïve animals are tabulated below the graph. Fold changes of
those genes that were up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’.

stimulation specifically following MOG immunization,
being undetectable in the epithelium of both CFA/PTX and
naïve cohorts. In what appears to reflect the differential
sensitivities of the two CP tissues, CFA/PTX immunization
clearly ‘activated’ the stromal CP capillary tissue on day 9
p.i. at both the anatomical and molecular levels (Figure 1
and Table 1), but produced no detectable changes in the
CP epithelium at this time.
By day 15 p.i., genes B2m and CXCL10 displayed further increases in expression in the CP choroidal epithelium of MOG-CFA/PTX mice compared to that seen in
this cohort at day 9 (Figure 4B), showing > 19-fold and >
800-fold higher levels, respectively, compared to naïve
mice. Expression levels of yet additional genes in MOGtreated mice also became elevated by this time; these
included Bax, Bcl2l1, C3, CD68, Gusb, H2-Eb1 and Ski
(Figure 4B). Moreover, genes CCL19, CCL2, CCR2,
CD8a, Sele and Selp, which had previously shown upregulation only in the MOG-CFA/PTX group at day 9,
became similarly induced in the CFA/PTX group at this
later time-point. Genes that trended towards elevated

expression following MOG-CFA/PTX treatment for
both time points (but with p values slightly >0.05) are
displayed in Additional file 5 and Additional file 6: Genes
that trended towards elevated expression in MOG-CFA/
PTX immunized CP epithelium tissue compared to CFAPTX-immunized mice, at day 9/15p.i., while those that
were similarly up-regulated in CP choroidal epithelial
tissue of MOG-CFA/PTX- and CFA/PTX-immunized
mice compared to naïve mice for both time points are
listed in Additional file 7 and Additional file 8: Genes
similarly up-regulated in CP epithelium from both
MOG-CFA/PTX- and CFA-PTX-immunized mice at day
9/15 p.i. Those few genes that were in the CP epithelial
tissue in both immunized groups and naïve mice
included IL3, IL4, IL5, IL6, Lta.
Interaction between immunization treatment and time

In order to gain further appreciation of the extent to
which time impacted the effect of specific type
immunization on the expression patterns of immunerelated genes, two-way ANOVA was performed to
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deduce interactive effects between immunization treatment (e.g., MOG-CFA/PTX, CFA/PTX or naïve) and
time post-immunization. For example, the expression of
CCL19 in CP stromal capillary tissue following MOG-

Figure 4 (See legend on next page.)
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CFA/PTX immunization was time-dependent (p < 0.05
for positive interaction). Two-way ANOVA was done on
all genes that displayed statistically significant modulation after immunization in at least one of the CP
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(See figure on previous page.)
Figure 4 Genes super-induced in CP choroidal epithelial tissue from MOG-CFA/PTX-immunized mice at days 9 and 15 p.i. Relative
mRNA expression values of 93 immune-related genes were determined by immuno-LCM/TLDA in CP choroidal epithelial tissue from MOG-CFA/
PTX-immunized, CFA-PTX-immunized, and naïve mice at two time-points. Those genes that were more stimulated in MOG-CFA/PTX- versus CFAPTX-immunized mice at day 9 (Figure 4A) and day 15 p.i (Figure 4B) (compared to naïve mice) are graphed. The bar graphs depict those specific
genes showing statistically significant differences in relative expression values (p values indicated by asterisks) between MOG-CFA/PTX and CFA/
PTX experimental groups. RNA values are presented as mean percent expression relative to GAPDH (± SEM) in log scale. * and ** represent
comparisons made between MOG-CFA/PTX and CFA-PTX- treatment groups, * p < 0.05, ** p < 0.005, Student’s t-test, n = 3 animals/group. Fold
changes in gene expression normalized to naïve animals are tabulated below the corresponding graphs. Fold changes of those genes that were
up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’.

compartments (as shown in Figures 3 and 4A, B) in either of the time-points analyzed (twenty-three genes in
total). Interactive effects differed depending on the CP
compartment, further highlighting the unique responses
of the two CP tissues analyzed. Specifically, two-way
ANOVA of CP stromal capillary tissue revealed the following twelve genes displayed positive interaction between immunization treatment and time postimmunization: B2m, C3, CCL19, CCL5, CD4, Gzmb,
Ptgs2, Ptprc, Stat4, CCR2, CD68, Gusb (Figure 5). CP
choroidal epithelial tissue, on the other hand, demonstrated positive interaction for another collective of
genes: B2m, Bax, C3, CXCL10 (Figure 5).
Figure 6 qualitatively summarizes the differential
responses of the CP capillary and CP choroidal epithelial
tissues, respectively, to MOG-CFA/PTX immunization
versus CFA/PTX immunization, contrasting adjuvant
versus autoimmune effects on immune-related gene
regulation over the two time-points analyzed.

Discussion
Due to increasing awareness of the CP as fundamental
to the development of CNS inflammation [4-6],
immuno-LCM coupled to qrt-PCR array was used to
separately acquire CP stromal capillary and choroidal
epithelial tissues and assess their respective patterns of
expression in situ of a wide panorama of immunerelated genes. Gene patterns were evaluated during preclinical and early clinical stages of EAE to appreciate the
switches in gene expression that accompany evolving
disease.
It is clear that the CP responds vigorously to MOG
immunization at both the anatomical and molecular
levels. Interestingly, immunization with CFA and PTX
alone produced striking effects. Swelling of the capillary
plexus occurred to nearly the same extent with injection
of just these agents, as with PTX and MOG in CFA.
PTX is an ancillary adjuvant commonly employed to
elicit EAE, as well as several other experimental autoimmune diseases [40-44]. And while its mechanism of
action in this regard has generally been attributed to increasing vascular permeability [45-47] – most notably
that of the BBB [48-51] – additional hypotheses have
been put forth [52-55]. However, to the best of our

knowledge, this is the first report to turn attention to
the CP as a possible target of PTX. It is of further interest to point out that the distension of CP capillaries
noted here study bears similarity to that seen following
systemic neutralization of VEGF and TGFβ [56]. In the
latter case, CP capillary swelling was accompanied by
loss of fenestrae from endothelial cells and appearance
of multiple caveolae, transport vesicles that transcytose a
variety of cargo [57] – including chemokines [58] – and
are often associated with heightened vascular permeability and inflammation [59,60]. Engelhardt et al. [4] had
also described ultrastructural changes of the CP during
EAE (along with CFA and PTX as adjuvants), but noted
these were mostly restricted to the CP choroidal epithelium. Moreover, as comparison in this latter study was
just between healthy mice and those afflicted with EAE,
it is unclear whether the observed epithelial response
was autoimmune in nature and/or due to adjuvant
action.
Our results suggest that injection of PTX and/or CFA,
alone, might trigger an immune response in the CP capillaries that helps “set the stage” for CNS inflammation
[61]. The CP capillaries might be uniquely responsive in
this regard, as CFA/PTX treatment evoked an early response (day 9 p.i.) in the CP stromal capillary tissue,
while the choroidal epithelium experienced neither overt
morphological nor gene expression changes at this time.
If, as speculated during MS/EAE, Th17 cells first transit
through the CP, and then travel in the CSF to reach their
cognate antigens in the SAS, then the CP capillaries
must somehow initially be rendered capable of supporting T cell extravasation. In the EAE paradigm used here,
PTX and/or CFA might provide the stimulus to evoke
such capability. In this regard, we noted > 10-fold increase in chemokines CCL2, CCL5 and CXCL10 in the
CP stromal capillaries of both MOG-CFA/PTX- and
CFA/PTX-treated mice at day 9 p.i. Constitutive CCL2
expression within the CP stromal tissue has been
reported using in situ hybridization analysis, and shown
to be induced following peripheral tissue inflammation
[62]. The ability of CFA/PTX treatment to stimulate expression of these chemokines could potentially reflect
the actions of one or both of these adjuvants to ‘prime’
the neuroinflammatory process by activating the
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Figure 5 Interaction between immunization treatment and time of analysis post-immunization on expression of immune-related genes
within CP stromal capillary and choroidal epithelial compartments. Interactive effects of treatment (MOG-CFA/PTX, CFA-PTX and naïve) and
time post-immunization were determined by two-way ANOVA on the 23 immune-related genes that were super-induced following MOG-CFA/
PTX immunization in either of the two CP compartments (those genes graphed in Figures 3, 4A and B). Of these 23 genes, 13 genes in the CP
stromal capillary and 4 genes in the CP epithelial tissue exhibited significant positive interaction between treatment and time post-immunization,
and are denoted with their corresponding p values. The remaining genes that showed no significant interaction are labeled by (x). Timedependent changes in expression of CCL19 in stromal capillary tissue and CXCL10 in choroidal epithelial tissue are graphed as representative
examples * p < 0.05, ** p < 0.005.

endothelium to elicit initial auto reactive T cell extravasation from the circulation into the stromal compartment. This hypothesis is consistent with the recent
observation that administration of PTX to transgenic
mice over-expressing CCL2 in the CNS causes disruption of the BBB and promotes leukocyte migration into
the brain parenchyma [63].
Notwithstanding the effects of CFA/PTX treatment on
CP capillary morphology and gene expression, immunization with MOG-CFA/PTX further induced the expression of additional genes – some or all of which might
specifically reflect the autoimmune response and associated
development of EAE. While perhaps necessary for disease
to develop, the CP conditions set in place by PTX and CFA
are insufficient for inducing EAE in wild-type C57BL/6
mice. For disease to occur, supernumerary induction of
some genes, and de novo induction of others must take
place. The findings by Goverman et al. and Brabb et al.

[61,64], that injection of PTX alone can “trigger” EAE in
TCR-transgenic mice specific for myelin basic protein, by
fostering T cell access to the CNS, comports with our
results and the view that PTX enables mice to reach the
disease threshold. And helping pull this trigger may be additional effects of PTX on T cell behavior. Our observation
of increased mRNA for genes CD8a, CD80, CD86, Gzmb
(granzyme) and Ptprc (CD45) in the CP capillary stromal
tissue of both MOG-CFA/PTX and CFA/PTX cohorts may
reflect capture of PTX-activated CD8 T cells in transit
across the CP and into the CSF. This interpretation is consistent with the recent finding by Murphey et al. [65], that
PTX stimulation of cultured spleen cells results in CD 8 T
cell activation via CD80/86 co-stimulation.
As to signals responsible for the extravasation of T cells
from the circulation into the CP stroma during MOGinduced EAE, a combination of chemokines may fill this
role, as these immune mediators do in guiding
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Figure 6 Schematic summary of the induction of immune-related genes in the choroid plexus compartments following MOG-CFA/PTX
versus CFA-PTX immunization. Depicted are qualitative ‘heat maps’ of overall modulation in immune-related gene expression patterns over
time, within the separate CP stromal capillary (left) and CP choroidal epithelial (right) tissues after the two type immunization regimens. While
CFA/PTX immunization alone induces expression of immune-related genes in both tissues, MOG-CFA/PTX immunization causes supernumerary
stimulation above this level. The differences in gene expression between the immunization regimens highlight what might reflect gene changes
specifically due to MOG-associated autoimmunity. The effects due solely to CFA/PTX immunization might reveal priming of the immune response
that is necessary for the development of EAE.

parenchymal leukocyte infiltration. In particular, CCL5
level was increased significantly in CP stromal capillary
tissue at day 15 p.i., which coincides with high CCL5 protein level reported in whole brain extract of EAE mice at a
similar time-point, and argued to mediate leukocyte adherence to the CNS microvasculature [32]. And CCL19 –
a CCR7 ligand known to play a crucial role in EAE development through IL-23 producing Th17 cells [66] – was
likewise up-regulated dramatically in the CP stromal capillaries of MOG immunized mice at day 15 p.i.
With specific regard to those mechanism(s) further
driving T cell migration from the CP stroma into the
CSF, recent evidence points toward expression of another chemokine - CCL20 - by the CP choroidal epithelium as directing CCR6+ T cells across this layer and
into ventricular fluid during MS/EAE [8]. However, as
this chemokine:cognate receptor pair was not represented on the commercial TLDA card used in these
experiments, confirmation of this pathway was not performed. Aside from CCL20 providing a driving force for
T cell migration into CP epithelium, CCL2 might also
serve in this capacity, as Chodobska et al. [67] noted the
latter chemokine was rapidly stimulated in this tissue
in vivo and then released into the CSF, following traumatic brain injury. Indeed, the significant increase in
CCL2 we observed in the MOG-CFA/PTX CP choroidal
epithelium at day 9 p.i. might just reflect such a role for
this chemokine in EAE. The cognate receptor for CCL2,
CCR2 was also seen to be elevated in the choroidal epithelium at this early time-point. Presently, it is unclear if
the high levels of CCR2 mRNA indicate activation of the
epithelium, which, in the periphery, has been shown to
express CCR2 [68,69], or the accumulation of infiltrating
CCR2+ T cells.

In what might suggest multi-level control of leukocyte
extravasation into the CSF, still other chemokines were also
significantly up-regulated by the CP during EAE – namely
CXCL10 and CCL19. As CXCL10 has been reported to be
up-regulated in the sub-ventricular zone (SVZ) during
EAE, and postulated to stimulate migration of activated T
cells into the SVZ [70], its spike in expression by CP choroidal epithelial tissue at day 9 p.i. and more robust elevation
by day 15 p.i., might imply this chemokine is obligate for T
cell entry into the ventricles. In analogous manner, CCL19
was also elevated at this site at day 9 p.i. In fact, the timing
of the CP epithelial spikes in this chemokine during early
stages of EAE noted here, coincides well with that reported
by Reboldi et al. [8] for initial T cell entry into the uninflamed CNS through the CP. Recently, Marques et al.
[22,71] used hybridization-based microarray to assess the
global transcriptome of the whole CP following chronic
peripheral LPS stimulation. When compared to our study,
there were some common and unique findings. Among the
common findings, complement protein C3, and chemokines CCL2 and CCL5 were elevated following either acute
or chronic peripheral LPS stimulation, as well as during
MOG-induced EAE (complement C3 in both CP capillary
tissue and epithelium; CCL2 in CP epithelium; and CCL5
in CP capillary tissue). And Selectin (Sele and Selp) expression was also elevated both following acute peripheral LPS
stimulation [22], and in the CP epithelium after MOGinduced EAE. These common gene modulations may thus
reflect more generic CP inflammatory response genes.
As for unique findings, these too involved chemokines.
Marques et al. [71] reported stimulation of CCL7 and
CXCL1 in the CP following chronic LPS stimulation, while
we detected stimulation of CCL19 and CXCL10 in the CP
epithelium and CCL19 in the CP endothelium during
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MOG-induced EAE. A priori, up-regulation of these latter
two chemokine genes may more distinguish an EAE signature for the respective CP tissue compartments.
Of further note was our observation of a MOG-sensitive
increase in expression of B2m at day 15 p.i. in CP stromal
capillary tissue, and at both time-points in the choroidal
epithelial tissue. Aside from perhaps reinforcing a more
ubiquitous role for B2m in inflammation [37], this result
complements previous reports of increased B2m mRNA
and protein levels in both neuronal and non neuronal cell
types during EAE [72,73], a response thought to be due to
induction of synaptic plasticity by infiltrating autoreactive
immune cells. The sharp induction of complement C3,
also noted in both CP compartments of MOG-CFA/PTX
mice at the later time point (day 15 p.i), further supports
previous studies highlighting C3 deficiency inhibits development of EAE [74].
As to the specific approach used here, i.e., LCM coupled
to TLDA, it offered extraordinary opportunity to probe, in
extensive detail, the focused immune response within the
distinct CP compartments. Earlier reports, using immunohistochemistry and in situ hybridization, had shown that
the respective CP stromal capillary endothelial cells and
the CP choroidal epithelial cells displayed different expression patterns of a small nucleus of adhesion molecules
during EAE [4,20]. Specifically, VCAM-1 and ICAM-1
were found to be expressed constitutively by CP choroidal
epithelial cells of healthy SJL/N mice, and then further
induced following active immunization with spinal cord
homogenate. MAdCAM-1 was only seen in these cells
after induction of EAE. However, none of these adhesion
molecules, nor E- or P-selectin, was detected in CP stromal capillary endothelial cells [75].
We too noted constitutive VCAM-1 expression in the
CP choroidal epithelial tissue of healthy naïve mice. Likewise, VCAM-1 trended toward elevation within this CP
compartment of MOG-CFA/PTX cohorts at both days 9
and 15 p.i., though it showed no up-regulation in CFAPTX-immunized mice at either time-point. In further
agreement with previous observations [75], our analysis
demonstrated induction of E-selectin and P-selectin in the
CP choroidal epithelial tissue from MOG-CFA/PTXimmunized mice at day 9. Our results nevertheless displayed some stark differences with earlier reports. Specifically, we also noted a trend of increased VCAM-1
expression by day 15 in CP stromal capillary tissue with
MOG immunization, paralleling what has been described
in MS brain tissue [6]. And both E- and P-selectin mRNA
were also observed to be induced in CP stromal capillary
tissue of both MOG-CFA/PTX- and CFA/PTX-immunized mice compared to that of naïve mice at day 9 p.i. Eselectin increased expression in the two immunized
groups by >100-fold, while P-selectin was stimulated >10fold.
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A priori, differences in results between these EAE
studies could result from several factors, among them
being 1) the EAE model employed (e.g., immunization of
SJL/6 mice with spinal cord homogenate versus
immunization of C57BL/6 mice with MOG35-55 peptide),
the time of analysis post-immunization (e.g, before or
after disease onset), and 3) the sensitivity of the analytic
techniques (e.g., in situ hybridization versus qrt-PCR).
As neither MAdCAM-1 nor ICAM-1 were represented
on the TLDA card used in these experiments, confirmation of expression or lack thereof was not possible for
these genes.
Most recently, Liddelow et al. [76] employed LCM to
collect mouse lateral ventricular CP tissue CP for transcriptome analysis of transporter gene expression during
normal development. Here, we extended this application,
utilizing LCM to resolve – for the first time – the CP capillary stromal tissue from the CP choroidal tissue, and
then separately analyzing each for their unique immune
responses to MOG immunization.

Conclusions
Induction of EAE in C57BL/6 mice by active immunization with MOG35-55 peptide results in the respective
CP stromal capillary and choroidal epithelial compartments each mounting vigorous, yet distinct, immune
responses, underscoring the active role of the CP in instigating CNS inflammatory disease. Furthermore, our
results make clear that a significant component of the
total CP response is due to effects elicited by adjuvants
PTX and/or CFA used in the immunization protocol –
which might serve to prime the CP to support autoimmune activity necessary for developing MS/EAE.
These results are summarized schematically in Figure 6.
Additional files
Additional file 1: Mouse Immune Panel TLDA. The card map for the
96 genes (93 immune-related genes and 3 control genes) on the
commercially available mouse Immune panel TLDA is shown, with gene
names and corresponding accession numbers.
Additional file 2: Housekeeping control genes. Ct (Threshold cycle)
values for the three housekeeping genes – GAPDH, β-Actin and 18 S
represented on the mouse Immune-panel TLDA are shown. The
housekeeping genes were almost unchanged across treatments (shown
in A and B) with < 1 cycle difference between samples. C, Six genes were
normalized to each of the three housekeeping gene and expression
patterns plotted, indicating identical patterns of expression across
housekeeping control gene used.
Additional file 3: Genes that trended towards elevated expression
in MOG-CFA/PTX- immunized CP stromal capillary tissue compared
to CFA-PTX-immunized mice, at day 15 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP stromal capillary tissue from immunized and naïve mice at
day 15 p.i. A total of 14 genes trended towards greater induction in the
MOG-CFA/PTX group compared to the CFA-PTX group; these genes are
listed with their corresponding p values. Analysis was by Student’s twotailed t-test.
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Additional file 4: Genes similarly up-regulated in CP stromal
capillary tissue from both MOG-CFA/PTX- and CFA-PTX-immunized
mice at day 15 p.i. Relative mRNA expression values of 93 immunerelated genes were determined by immuno-LCM/TLDA in CP stromal
capillary tissue from immunized and naïve mice at day 15 p.i. At this later
time-point, 25 immunization-induced genes were similarly stimulated in
both MOG-CFA/PTX- and CFA-PTX-immunized mice compared to naïve
animals, and only these are listed.

3.

Additional file 5: Genes that trended towards elevated expression
in MOG-CFA/PTX immunized CP epithelium tissue compared to
CFA-PTX-immunized mice, at day 9 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP epithelium from immunized and naïve mice at day 9 p.i. A
total of 15 genes trended towards greater induction in the MOG-CFA/
PTX group compared to the CFA-PTX group; these genes are listed with
their corresponding p values. Analysis was by Student’s two-tailed t-test.

6.

Additional file 6: Genes that trended towards elevated expression
in MOG-CFA/PTX immunized CP epithelium tissue compared to
CFA-PTX-immunized mice, at day 15 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/
TLDA in CP epithelium from immunized and naïve mice at day 15 p.i. A
total of 19 genes trended towards greater induction in the MOG-CFA/
PTX group compared to the CFA-PTX group; these genes are listed with
their corresponding p values. Analysis was by Student’s two-tailed t-test.
Additional file 7: Genes similarly up-regulated in CP epithelium
from both MOG-CFA/PTX- and CFA-PTX-immunized mice at day 9
p.i. Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP epithelium from immunized
and naïve mice at day 9 p.i. At this early time-point, 10 immunizationinduced genes were similarly stimulated in both MOG-CFA/PTX- and
CFA-PTX-immunized mice compared to naïve animals, and only these are
listed.
Additional file 8: Genes similarly up-regulated in CP epithelium
from both MOG-CFA/PTX- and CFA-PTX-immunized mice at day 15
p.i. Relative mRNA expression values of 93 immune-related genes were
determined by immuno-LCM/TLDA in CP epithelium from immunized
and naïve mice at day 15 p.i. At this later time-point, 8 immunizationinduced genes were similarly stimulated in both MOG-CFA/PTX- and
CFA-PTX-immunized mice compared to naïve animals, and only these are
listed.
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